

Synthesis of Chalcones for Analysis as Anti-microbial Agents

DISSERTATION

Submitted in partial fulfilment of the requirements of the
University for the degree of Masters by Research



By

Georgina Durowoju

Faculty of Science, Engineering & Computing
Kingston University

November 2018

Acknowledgments

I would like to thank Dr Sianne Schwikkard for being the best supervisor of all time. I truly appreciate all she has done for me, for her encouragement during my difficult times and her unceasing enthusiasm and support throughout this degree. Everyone needs that one person to ignite a passion within them and that is Dr Schwikkard for me. She made me realise how exciting and gratifying the world of research can be.

Many thanks to my second supervisor, Dr Alison Kelly for all her help during the microbiology section of this project. Her enthusiasm was contagious and her guidance is much appreciated.

Thanks to Dr Jean-Marie Peron for his help with the complexities of NMR spectroscopy.

I would like to thank my family for being the best support system, for being so understanding and always, loving.

Lastly, to my amazing friends, for always encouraging me with their words of affirmation and for always believing I could do it.

Table of Contents

Acknowledgments	i
List of Figures, Schemes & Tables	iv
List of Abbreviations	vi
Abstract	vii
1. Introduction	
1.1 Literature Review	4
1.1.1 Biosynthesis of Naturally Occurring Chalcones.....	5
1.1.2 Synthesis.....	7
1.1.3 Effects of Substituents on Activity & Pharmacophore.....	9
1.1.4 Antimicrobial Activity of Phosphorous-Containing Compounds.....	14
1.1.5 Antimicrobial Resistance.....	16
1.2 Aim	19
2. Methodology	
2.1 Materials	20
2.2 Chemistry – Experimental Procedures	22
2.2.1 Synthesis of 1-(pyrrole)-3-(4-chlorophenyl)-prop-2-ene-1-one.....	22
2.2.2 Synthesis of 1-(3,4-dichlorophenyl)-3-(2,4,6-trimethoxyphenyl)-prop-2-ene-1-one.....	22
2.2.3 Synthesis of 1-(2,4-dichlorophenyl)-3-(4-methoxyphenyl)-prop-2-ene-1-one.....	23
2.2.4 Synthesis of 1-(3,4-dichlorophenyl)-3-(4-hydroxyphenyl)-prop-2-ene-1-one.....	23
2.2.5 Synthesis of 1-(2-acetylfuran)-3-(4-chlorophenyl)-prop-2-ene-1-one.....	24
2.2.6 Synthesis of 1-(4-aminophenyl)-3-(4-chlorophenyl)-prop-2-ene-1-one.....	24
2.2.7 Synthesis of 1-(4-bromophenyl)-3-(4-chlorophenyl)-prop-2-ene-1-one.....	25
2.2.8 Synthesis of 1-(4-fluorophenyl)-3-(4-chlorophenyl)-prop-2-ene-1-one.....	25
2.2.9 Synthesis of 1-(4-aminophenyl)-3-(4-bromophenyl)-prop-2-ene-1-one.....	25
2.2.10 Synthesis of 1-(2,3-dichlorophenyl)-3-(2,4,6-trimethoxyphenyl)-prop-2-ene-1-one.....	26
2.2.11 Synthesis of 1-(4-fluorophenyl)-3-(4-chlorophenyl)-prop-2-ene-1-thione.....	26
2.2.12 Synthesis of 1-(2,3-dichlorophenyl)-3-(4-methoxyphenyl)-prop-2-ene-1-thione.....	26
2.2.13 Synthesis of 1-(4-bromophenyl)-3-(4-chlorophenyl)-prop-2-ene-1-thione.....	27
2.2.14 Synthesis of 1-(4-aminophenyl)-3-(4-bromophenyl)-prop-2-ene-1-thione.....	28
2.2.15 Synthesis of 1-(tert-butoxycarboxylleucine)-3-(4-chlorophenyl)-prop-2-ene-1-one.....	28
2.3 Microbiology – Experimental	29
2.3.1 Establishing antimicrobial activity.....	29
2.3.2 Minimum Inhibitory Concentration (MIC).....	30
2.3.3 Minimum Bactericidal Concentration (MBC).....	30

3. Results	31
4. Discussion	53
4.1 Data Analysis	53
4.2 Thiochalcones	60
4.3 Effect of Substituent Positions on Aromatic Rings on the Reaction	62
4.4 Antimicrobial Activity	65
5. Conclusion	72
6. Future Works	73
7. References	74
Appendix	82

List of Figures, Schemes and Tables

Figures

Figure 1 – Daptomycin

Figure 2 – Arsphenamine

Figure 3 – Chalcone

Figure 4 – Lawesson's Reagent

Figure 5 – 1-(2, 3, 4-trimethoxyphenyl)-3-prop-2-ene-1-one

Figure 6 – 4-Hydroxyderricin

Figure 7 – 1-phenyl-3-(2-hydroxyphenyl)-prop-2-ene-1-one

Figure 8 – Substituted hydroxychalcone

Figure 9 – 3-aryl-1-(2, 4-dichloro-5-fluorophenyl)-2-propen-1-one

Figure 10 - 3 β -mercaptospiro(androstane-17, 4-dithiaphosphetan)thione

Figure 11 – 1-(2-aminophenyl)-3-(4-methylphenyl)-3-(phenylsulfonyl) propan-1-one

Figure 12 – Substituted styryl 2, 5-dimethyl-3-thienyl ketone

Figure 13 – Moenomycin A

Figure 14 – 2-(20-chloroethyl)-2, 3-dihydro-5-benzoyl-1H-1, 3, 2-benzodiazaphosphole-2-oxide

Figure 15 – Polyphosphate

Figure 16 – Differences in cell envelope structure – Gram-positive vs. Gram-negative bacteria

Figure 17 – Shape of Compound 9

Figure 18 – DOSY spectrum of compound 10 (concentrated)

Figure 19 – DOSY spectrum of compound 10 (dilute)

Figure 20 – DOSY spectrum of compound 10 (dilute in chloroform)

Figure 21 – DOSY spectrum of compound 10 (dilute in DMSO)

Figure 22 – Oxa-thio-phosphorane

Figure 23 – Non-hydrogen positioning on aromatic ring relative to ketone moiety

Schemes

Scheme 1 – Biosynthesis of naringenin chalcone

Scheme 2 – Claisen-Schmidt Condensation Reaction

Scheme 3 – Chalcone Synthesis Mechanism

Scheme 4 – Conversion of Chalcone to Thiochalcone using Lawesson's Reagent

Scheme 5 – Mechanism of Reaction between 4-aminoacetophenone & 4-bromobenzaldehyde

Scheme 6 – Mechanism for Conversion of Chalcone to Thiochalcone using Lawesson's Reagent

Scheme 7 – DCC/HOBt amino acid-chalcone coupling mechanism

Tables

Table 1 – IUPAC names and chemical structures of proposed compounds

Table 2 – List of reagents available for synthesis of chalcones & thiochalcones

Table 3 – List of solvents used in synthesis of chalcones & thiochalcones

Table 4 – List of materials used during microbiology testing

Table 5 – Masses, melting points & percentage yields of the synthesised compounds

Table 6 – Molecular formula, molecular weight & mass spectral data of the synthesised compounds

Table 7 – Infra-Red Spectroscopy Data of the synthesised compounds

Table 8 – ^1H NMR Data of the synthesised compounds

Table 9 – ^{13}C NMR Data of the synthesised compounds

Table 10 – ^1H - ^1H COSY Correlations of the synthesised compounds

Table 11 – ^1H - ^{13}C HMBC Correlations of the synthesised compounds

Table 12 – ^1H , ^{13}C and ^1H - ^1H data for oxa-thio-phosphorane using spectra of compound **14**

Table 13 – ^1H , ^{13}C and ^1H - ^1H COSY NMR Data for compound **9**

Table 14 – ^1H , ^{13}C and ^1H - ^1H data for compound **15**

Table 15 – In-vitro antimicrobial activity of the synthesised compounds

Table 16 – Minimum Inhibitory Concentration (MIC) of the biologically active compounds

Table 17 – Minimum Bactericidal Concentration (MBC) of the biologically active compounds

List of Abbreviations

- ATP – adenosine triphosphate
- *B. subtilis* – *Bacillus subtilis*
- CFU – colony-forming unit
- COSY – correlation spectroscopy
- DCC – dicyclohexylcarbodiimide
- DCM – dichloromethane
- DDD – defined daily dose
- DMF - N,N-dimethylformamide
- DNA – deoxyribose nucleic acid
- DOSY – diffusion-ordered spectroscopy
- *E.coli* – *Escherichia coli*
- EHEC – Enterohaemorrhagic *Escherichia coli*
- EU – European Union
- EUCAST – European Committee on Antimicrobial Susceptibility Testing
- FDA – Food and Drug Administration
- GCMS – gas chromatography mass spectrometry
- HMBC – heteronuclear multiple bond correlation spectroscopy
- HOBt – 1-hydroxybenzotriazole
- IUPAC – International Union of Pure and Applied Chemistry
- MBC - minimum bactericidal concentration
- MIC – minimum inhibitory concentration
- MRSA – Methicillin-resistant *Staphylococcus aureus*
- MS – Mass Spectroscopy
- NMR – Nuclear Magnetic Resonance
- NOESY – nuclear Overhauser effect spectroscopy
- *P. aeruginosa* – *Pseudomonas aeruginosa*
- PBPs – penicillin binding proteins
- PKS – polyketide synthase
- ppm – parts per million
- *S. epidermidis* – *Staphylococcus epidermidis*
- THF – tetrahydrofuran
- TLC – thin layer chromatography
- UV – ultraviolet
- VTEC – Verocytotoxin-producing *Escherichia coli*

Abstract

Chalcones are diphenyl α - β -unsaturated compounds that are present in a wide variety of plants. Naturally occurring chalcones as well as synthetic chalcones have demonstrated an assortment of biological activity, including anti-inflammatory, anti-viral and antimicrobial activity. The need for new antimicrobially active agents is becoming more imperative as antimicrobial resistance continues to present a large threat. In this project, a series of chalcones were synthesised via a Claisen-Schmidt condensation reaction. The compounds were analysed using NMR spectroscopy and Gas-Chromatography Mass Spectrometry. An attempt was made to convert four of the chalcones to thiochalcones using Lawesson's Reagent. The compounds were tested against *E. coli*, *P. aeruginosa* and *S. epidermidis*. None of the synthesised chalcones displayed any antimicrobial activity but the thiochalcones showed activity against all bacterial strains. Upon further analysis, the thiochalcones appeared to have decomposed in situ, with the major product being the oxa-thio-phosphorane compound. This compound could have been the cause behind the activity seen in compound **11** against *S. epidermidis* and compound **14** against all bacterial strains studied. Compound **11** produced a zone of inhibition of 10mm against *S. epidermidis* whilst compound **14** produced zones of inhibition against *S. epidermidis*, *P. aeruginosa* and *E. coli* of 16mm, 10.3mm and 15.3mm respectively. The MICs and MBCs of the compounds were not greater than Ciprofloxacin, the antibiotic used in this project as the positive control, as shown by the results.

1. Introduction

Antimicrobial resistance is defined as the ability of a microorganism such as bacteria to grow in the presence of antimicrobial agents designed to hinder or halt their growth and reproduction. This resistance usually develops as a result of continuous exposure to said agents leading to selective pressure: either the population dies from contact or a mutation arises in a population, allowing for resistance (Amábile-Cuevas, 2010). It should be noted that some microbes that have never come into contact with antibiotics can also be resistant depending on the extremity of the environments in which they are found (D'Costa et al, 2011). This has become more of a problem in recent times due to the rise of not only more antibiotic-resistant bacteria but also multi-drug resistance. The efficacy of available antibiotics is becoming increasingly less effective. Dr Margaret Chan, former Director-General of the World Health Organisation, believes the world is moving to a “post-antibiotic era”, in which “things as common as strep throat or a child’s scratched knee could once again kill” (Public Health England, 2016).

Economist Jim O’Neill chaired the 2016 Review of Antimicrobial Resistance. Within his report, he stated that not only does this phenomenon present a risk to the quality and longevity of life but there is also an economic impact. He stated that not acting could cost the global economy \$100 trillion. Out of a ten-point intervention plan, he pointed out four of high importance: the need to develop a global public awareness campaign, development of new antibiotics to replace those that are no longer effective, reduction of the unnecessary prescription of antibiotics for both humans and animals and a decrease in the extensive antibiotic use in agriculture (AMR, 2016). Antibiotic consumption in England had increased by 6.5% from 2011-2014, with the defined daily dose (DDD) per 1000 people rising from 21.6 to 23 in that time frame (Public Health England, 2015).

There has been a sharp decline in the development of new antibiotics in recent years and a large contributing factor is the departure of large pharmaceutical companies from antibiotic development, supposedly due to the lack of incentive. Antibiotics are expensive to discover and develop, require an overly complex but necessary regulatory procedure and return less revenue compared to medication for chronic conditions such as cancer and diabetes (Sabtu et al, 2015). Nowadays, due to antibiotic resistance, they are used as a last resort medication, meaning the companies often lose patency of the antibiotic before the cost incurred to develop

the drug can be recovered. The last class of antibiotics to be discovered was lipopeptides by Eli Lilly and Company in the early 1980s, with daptomycin (figure 1), a Gram-positive bactericidal, approved by the Food and Drug Administration (FDA) in 2003 (Pirri et al, 2009).




Figure 1: **Daptomycin**

Image source: Micklefield (2004)

The need to develop new classes of antibiotics that are able to act against both Gram-positive and Gram-negative bacteria is becoming increasingly important. This need coincides with an increase in the occurrence of multi-drug resistance bacterial strains. In Europe, an estimated 25,000 people die every year as a result of nosocomial infections caused by the following bacteria: *Escherichia coli*, *Klebsiella pneumoniae*, *Enterococcus faecium*, *Pseudomonas aeruginosa* and Methicillin-resistant *Staphylococcus aureus* (Public Health England, 2015). However, the issue lies particularly with Gram-negative bacteria as reports of multi-drug resistance are occurring at a faster rate in these bacteria, especially *Enterobacteriaceae* and *P. aeruginosa* (Sabtu et al, 2015). Efforts are being made to increase awareness of the issue as well as implementation of programmes like Infectious Disease Society of America's 10x'20 initiative, aimed at developing ten antibacterial agents by 2020, effective against the "ESKAPE" group of microbes: *Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter* species (IDSA, 2010). In addition, grants such as the Longitude Prize, where a public vote determined the outcome of

directed research, was dedicated to overcoming antimicrobial resistance (Longitude Prize, N.D).

Historically, infections have been treated using natural products such as bark and leaves from trees with reports of ancient civilizations such as the Greeks and Egyptians using mixtures containing milk, honey and plant resins as wound dressings (Shah, 2011). Natural products have been the inspiration behind many antibiotics. Arsphenamine (figure 2), the first synthetic antibiotic, was produced by Paul Ehrlich and Sahachiro Hata in 1909 but it was derived from arsenic, a chemical element and a naturally occurring metalloid (Frith, 2013).




Figure 2: **Arsphenamine**
Image source: author's own

Nature is once again becoming the source of inspiration behind the development of new medication, including novel antibacterial agents. In recent times, chalcones have been the subject of increasing interest in the realm of medicinal chemistry as they have been discovered to display a plethora of biological potential including antimicrobial activity. Chalcones are well-known molecules in natural product chemistry as they have been repeatedly isolated and examined in a bid to understand the chemical basis for herb-based medication. Their synthesis has been proven to be relatively straightforward and able to produce a range of biologically active molecules that can be modified, furthering the understanding of the pharmacophore of the compound.

Chalcones are molecules consisting of two phenyl rings held together by a 3-carbon ketone moiety bearing an α - β unsaturated bond (figure 3).




Figure 3: **Chalcone** (IUPAC: 1,3-diphenylprop-2-en-1-one)

Image Source: author's own

They were first discovered by Albert-Szent-Gyorgyi after he discovered “vitamin P”, a term formally used to describe flavonoids (Grzybowski et al, 2013). Flavonoids are a family of polyphenolic compounds that are responsible for a number of plant-based activities such as regulating cell growth (Higdon, 2016). Chalcones are interesting compounds due to their highly conjugated electron system and the presence of the unsaturated ketone moiety, which is believed to be the sole provider of a chalcone's biological activity.

In this project, various parts of the chalcone were modified in order to establish what exact substituent the compound must bear in order to be biologically active. Varying functional groups were added to the chalcone's structure in order to ascertain whether electron density has a part in its efficacy. The seemingly essential ketone was also altered to bear a sulphur instead of an oxygen. Sulphonamides are already an established class of antibiotics and so the effectiveness of the sulphonamide functional group is well known but this does not apply directly to the possible functionality of a thiochalcone or more specifically, the thione functional group. The findings of these alterations will be discussed further in this dissertation.


1.1 Literature Review

This review aims to shed light on the two subject areas this research project examines: the synthesis of biologically active chalcones and the need for the development of new antimicrobial agents to combat antimicrobial resistance. The literature discusses varying techniques to synthesise chalcones as well as the effect of different substituents on the compounds' antimicrobial activity. In this research project, modification attempts were made to the pharmacophore of the chalcone. The oxygen atom of the ketone moiety was converted to a sulphur atom by way of

thionation using Lawesson's Reagent. This review also briefly discusses Lawesson's Reagent and its previous use in the conversion of chalcones to thiochalcones. There is a limited array of literature available in regards to the synthesis of thiochalcones but there is little to no data available regarding the biological activity of these compounds. However, in a bid to help understand the possible activity of these compounds, sulphur-containing compounds that are of a similar structure to thiochalcones have been studied. Also, by-products of the use of Lawesson's Reagent are usually phosphorus-containing compounds. Such compounds have been reviewed for the purpose of this literature review.

1.1.1 Biosynthesis of Naturally Occurring Chalcones

Chalcones are the biosynthetic precursors of flavonoids, a family of polyphenolic compounds involved in a number of cell-signalling cascades in plants. The biosynthesis of chalcones is conducted via the polyketide pathway. This begins with the condensation of one molecule of 4-coumaroyl-CoA and three molecules of malonyl-CoA to form an intermediate. This intermediate undergoes a Claisen-like cyclization to give naringenin chalcone (scheme 1) (Zhuang et al, 2017). This reaction is catalysed by chalcone synthase (Dao et al, 2011). Chalcone synthase is classed as a polyketide synthase enzyme (PKS).



Scheme 1: **Biosynthesis of naringenin chalcone**


Image source: Springbob et al, 2003

PKSs are classed into three different groups based on their sequences, primary structures and catalytic mechanisms (Yu et al, 2012). Chalcone synthase belongs to the superfamily PKS III. This enzyme is omnipresent in the plant kingdom, proving

the importance of its products to the functionality of plants. Chalcones are normally distributed within various fruits and vegetables especially apples, citrus fruits, potatoes, tomatoes and bean sprouts (Orlikova, 2011), providing insight for the success of herbal medicine in the treatments of various ailments including infections. Chalcones have also been linked to providing the yellow pigment in flowers from the genera *Dahlia*, *Coreopsis* and *Cosmos* (Iwashina, 2000) and the families *Asteraceae*, *Moraceae*, *Fabaceae* and *Aristolochiaceae* (Díaz-Tielas et al, 2016).

1.1.2 Synthesis


Chalcone synthesis can be achieved using a variety of techniques including Suzuki coupling, Friedal-Crafts acylation and Claisen-Schmidt condensation. Claisen-Schmidt condensation is the most commonly used method. This reaction is well-known in organic chemistry. It involves a suitable benzaldehyde and acetophenone using a strong acid or base catalyst in a polar solvent, typically methanol (scheme 2).



Scheme 2: **Claisen-Schmidt Condensation Reaction of Chalcones**

Image Source: author's own

This reaction is known to produce a mixture of the desired product, by-products and starting material, causing variations in the yields of the reactions. However, it is the most popular method for chalcone synthesis due to its straightforward procedure and relatively efficient formation of the carbon-carbon double bond. The mechanism for the base-catalysed reaction is as follows: an enolate ion is formed from the removal of an α -hydrogen by a base. This enolate, formed from the reacting ketone, reacts with the aldehyde as ketones are less reactive toward nucleophilic addition. This intermediate will undergo dehydration which results in the chalcone (scheme 3).



Scheme 3: Chalcone Synthesis Mechanism

Image Source: author's own

Reaction conditions are usually room temperature and 1 atmosphere but the reaction can also be conducted under warmer conditions such as 40-60°C. There have been many reports of synthesis using microwave irradiation. Ahmad et al reported the synthesis of a series of 2-acetyl hetero chalcones using microwave radiation under 180 watts (Ahmad et al, 2016).

In terms of the conversion of chalcones to thiochalcones, the most commonly used methodology to date requires the use of Lawesson's Reagent (figure 4). This reagent was developed in 1978 by Lawesson and his co-workers (Krstić et al, 2010).




Figure 4: **Lawesson's Reagent** (IUPAC: 2,4-Bis(4-methoxyphenyl)-2,4-dithioxo-1,3,2,4-dithiadiphosphetane).

Image Source: author's own

The reaction is typically carried out under nitrogen and refluxed or in open air without using reflux but at warm temperatures in anhydrous toluene or tetrahydrofuran (THF) (scheme 4). Its use in the conversion of chalcones to thiochalcones is underreported and available data varies greatly in their reports of yield and purity. However, it is often seen that the reaction produces a mixture of the desired product, sulphur and phosphorous-containing by-products as well as starting material (Krstić et al, 2010).



Scheme 4: **Conversion of Chalcone to Thiochalcone using Lawesson's Reagent**

Image source: author's own

Previous procedures to thionate organic compounds utilised phosphorous pentasulfide (P_4S_{10}), first reported in 1869 by Henry and Wislicenus (Cava, 1985) but its procedure required very large amounts of this reagent and long reaction times to produce low yields. Lawesson's Reagent is a more favourable converting reagent due to its availability, ease of use and a relatively straightforward reaction.

1.1.3 Effects of Substituents on Activity & Pharmacophore

It has been suggested that adding substituents on either the A or B ring of the chalcone may influence its biological activity. However, the α,β unsaturated ketone moiety is regarded to be the main pharmacophore of a chalcone as its removal has resulted in either a major reduction or complete loss of antimicrobial activity (Batovska et al, 2010). In regards to antimicrobial activity, certain substituents are favoured more than others. As seen in the Tran et al study, chalcones with two or three methoxy groups on the B ring are inactive regardless of substituents on the A ring (refer to figure 3 for labelling and positioning) (Tran et al, 2012). It is suggested that more than two methoxy groups on the B ring eradicate the hydrophilic property of a chalcone which allows for penetration through the bacterial cell wall (Tran et al, 2012). This was reflected in results obtained by Baba et al, who reported

synthesising a series of trimethoxy-substituted chalcones but when tested, no antimicrobial activity was shown (Baba et al, 2013) (figure 5).




Figure 5: **1-(3', 4', 5'-trimethoxyphenyl)-3-(3, 4, 5-trimethoxyphenyl)-prop-2-ene-1-one**
Image source: Baba et al (2013)

Electron-donating groups such as a hydroxyl group have been seen to increase the antimicrobial activity of a chalcone, but hydroxyl groups are also hydrophilic. A free hydroxyl group on the B ring at position 4 or 6 is important for methicillin-resistant *Staphylococcus aureus* (MRSA) activity (Ávila et al, 2008) (figure 6).




Figure 6: **4-Hydroxyderricin**
Image source: Ávila et al (2008)

A degree of importance is attached to the positioning of the hydroxyl group: the meta position brought about a diminished level of activity (100µg/ml against *B.subtilis*) when compared to the ortho position (50µg/ml against *B.subtilis*) (Silva et al, 2013) (figure 7).




Figure 7: **1-phenyl-3-(3-hydroxyphenyl)-prop-2-ene-1-one** (hydroxyl group shown in ortho position)
Image source: Silva et al (2013)

Avila et al concluded from their study that a free hydroxyl group on the B ring is necessary for any antimicrobial activity as this activity is lost once it is substituted (Ávila et al, 2008). Weakly electron-donating groups such as halogens (chlorine, fluorine, bromine) have been seen to positively contribute to the antimicrobial activity of a chalcone as well. Halogens are naturally electron-withdrawing by way of induction but can also be electron-donating due to the lone pair of electrons they all bear.

Nielsen et al synthesised a series of compounds, including a pair of chalcones bearing a (3, 5)-dibromo substituent and (2, 4, 6)-trifluoromethyl substituents on the B rings of their respective compounds, shown below (Nielsen et al, 2004) (figure 8).




Figure 8: **substituted hydroxychalcone (R representing dibromo or trifluoromethyl substituents)**
Image source: Yazdan et al (2015)

These compounds showed promising activity as did a chalcone synthesised by Karthikeyan et al (2007), which had (4, 6)-dichloro and (3)-fluoro substituents on the A ring (figure 9).




Figure 9: **3-aryl-1-(2',4'-dichloro-5'-fluorophenyl)-2-propen-1-one**

Image source: Khadar-Yazdan et al (2015)

Mohamed et al (2003) converted a series of steroidal ketones to their thioxo equivalents using Lawesson's Reagent and tested the compounds for antimicrobial and antifungal activity (figure 10). They followed a standard procedure of using anhydrous toluene under reflux and isolated the compound using column chromatography. Four of the compounds displayed activity against both Gram-positive and Gram-negative bacteria including *B. subtilis*, *P. aeruginosa* and *E.coli* at 200µg/ml.




Figure 10: **3β-mercaptospiro(androstan-17, 4-dithiophosphetan)thione**

Image source: Mohamed et al

Ahmed et al (2015) reported the synthesis of a series of sulfides, their corresponding bis-sulfides and sulfones. They were tested for their antimicrobial activity and they all displayed activity against a variety of Gram-negative and Gram-positive bacteria including *B. subtilis* and *S. aureus* at varying concentrations of 3.9-31.25µg/ml. A particular sulfone with a 3-NH₂ position on the A ring (figure 11) displayed a higher level of activity compared to chalcones with chloro, methyl and trimethoxy substituents against *S. aureus*.




Figure 11: **1-(2'-aminophenyl)-3-(4-methylphenyl)-3-(phenylsulfonyl)propan-1-one**
Image source: Ahmed et al (2015)

However, the study failed to state whether this higher level of activity was due to the presence of the sulphur-containing groups or substituents on the rings of the compounds.

Vanangamudi et al (2013) synthesised a series of 2,5-dimethyl-3-thienyl chalcones via a Claisen-Schmidt condensation reaction. All the compounds showed activity against the bacteria tested including *P. aeruginosa*, *B. subtilis* and *E. coli*. In this study, they attributed the improved activity of the compounds to the methoxy, methyl and nitro substituents in the 3rd position on the B ring (figure 12).




Figure 12: **substituted styryl 2',5'-dimethyl-3-thienyl ketone (R representing methoxy, methyl and nitro substituents)**
Image source: Vanangamudi et al (2017)

In all this, structure-activity relationships still fail to adequately identify what exact part of a chalcone is responsible for its biological activity and the notion that the α - β unsaturated ketone system is the sole proprietor of this activity is challenged in this research project by the exchange of the ketone's oxygen with a sulphur atom.

1.1.4 Antimicrobial Activity of Phosphorous-Containing Compounds

As mentioned before, the use of Lawesson's reagent to convert chalcones to thiochalcones produces a mixture of compounds including phosphorous-containing by-products. It is important to understand the effect these compounds may have on antimicrobial activity as they may alter that of the synthesised compounds.

Moenomycins are a family of phosphorous-containing antibiotics (Ostash et al, 2010). They are produced by *Streptomyces*, a genus of bacteria that produces a majority of antibiotics of natural origin such as chloramphenicol and neomycin (Aínsa et al, 2000). They are classed as phosphoglycolipids due to their chemical composition and have been known to have a very complex structure with an even more complex synthesis (Ostash et al, 2010). The class was first discovered in the 1960s (figure 13) and was shown to have high levels of activity against Gram-positive bacteria (Halliday et al, 2006) but interest in its potential as antibiotics dwindled due to its poor pharmacokinetic properties – it was found to be cytotoxic at concentrations of 10 μ g/ml and higher (Ostash et al, 2010). Instead, it was commercialised as an antimicrobial growth promoter in animal feeds (Halliday et al, 2006). However, a European Union (EU)-wide ban on antimicrobial growth promoters came into effect on 1 January 2006 (European Commission, 2005).




Figure 13: **Moenomycin A**
Image Source: Ostash et al, 2010

Reddy et al synthesised a series of phosphorous heterocycles with an exocyclic P-C link. 2-(20-Chloroethyl)-2,3-dihydro-5-benzoyl-1H-1,3,2-benzodiazaphosphole-2-Oxide (figure 14) was found to be active against both *S. aureus* and *E. coli* at 250µg and 500µg, producing zones of inhibition of 6-9mm and 4-8mm respectively (Reddy et al, 2004).




Figure 14: **2-(20-Chloroethyl)-2,3-dihydro-5-benzoyl-1H-1,3,2-benzodiazaphosphole-2-Oxide**
Image Source: Reddy et al, 2004

Polyphosphates are salts formed from repeating units of phosphate units. They are utilised as a food additive by the FDA to prevent food spoilage (Moon et al, 2011). Inorganic polyphosphate is found widespread in all organisms as it can serve as an adenosine triphosphate (ATP) source. However, an external source of polyphosphate has shown antimicrobial activity against many Gram-positive bacteria including *S.aureus*. Its mode of action is thought to include the inhibition of certain stages of cell wall synthesis (Moon et al, 2011).




Figure 15: **Polyphosphate**
Image source: Morrisey et al, 2012

1.1.5 Antimicrobial Resistance

Microorganisms can either be inherently resistant to an antibiotic or develop resistance after persistent exposure, this is known as acquired resistance. This acquired resistance could arise by either mutation or a transfer of a resistance mechanism programmed on genes (Sabtu et al, 2015). This horizontal gene transfer can occur through three different mechanisms: conjugation, transformation or bacteriophage-mediated transduction (Arber, 2014). Antimicrobial resistance could be viewed as an inevitable result of antibiotic use but the issue has been exacerbated due to the systematic abuse of this medication both in and outside healthcare settings (Sabtu et al, 2015). Also, in this era of modern travel and the inevitability of human contact, an antimicrobial-resistant strain could be easily spread in a very short amount of time. For example, the New Delhi metallo- β -lactamase-1 (NDM-1) carbapenemase enzyme found in some species of *Enterobacteriaceae* was first detected in Sweden after a patient from India had been transferred for medical reasons (Kumarasamy et al, 2010).

As mentioned earlier, the ESKAPE pathogens are the leading cause of nosocomial infections such as blood infections, urinary tract infections and wound infections (Higuera et al, 2014) and largely contribute to the issue of antimicrobial resistance due to the scale of their combined multi-drug resistance. The organisms include both Gram-negative and Gram-positive whose main structural difference is the makeup of their cell envelopes. They both possess peptidoglycans in their cell walls which provide their characteristic cell shape; Gram-positive bacteria has a thick cell wall whilst Gram-negative bacteria has a thin cell wall. Despite having lower levels of peptidoglycan, Gram-negative bacteria possess a more complex cell envelope structure (Salton et al, 1996). This complexity makes Gram-negative bacteria harder to penetrate, thus more difficult to target using antimicrobial agents.




Figure 16: **Differences in Cell Envelope Structure – Gram-negative vs Gram-positive bacteria**

Image Source: Brown et al, 2015

The outer membrane of Gram-negative bacteria contains a high lipopolysaccharide complex content (Rietschel et al, 1994). This lipopolysaccharide complex is multifunctional: it acts as a barrier to lysosomes and to certain antimicrobial agents as well as acting as an adhesive agent in some Gram-negative bacteria to ensure colonization of its host (Wang et al, 2010). When a bacterial cell is lysed by the immune system through phagocytosis, the polysaccharide fragments. These sections bear Lipid A, a moiety that acts as an endotoxin, initiates an inflammatory response in animals that could result in fatal endotoxic shock, also known as septic shock (Tzeng et al, 2002). Therefore, besides the initial difficulty of attacking the cell wall of Gram-negative bacteria, attacking the cell may result in the release of the endotoxin whose action could be fatal.

In this project, the bacteria *Escherichia coli* (*E. coli*), *Pseudomonas aeruginosa* (*P. aeruginosa*) and *Staphylococcus epidermidis* (*S. epidermidis*) were utilised to test the synthesised compounds' activity against both Gram-negative and Gram-positive bacteria.

E. coli is a rod-shaped, Gram-negative bacterium of the *Enterobacteriaceae* family. It is a facultative anaerobic bacteria, meaning it produces ATP for respiration in the presence of oxygen but has the ability to respire anaerobically in the absence of oxygen (Stieglmeier et al, 2009). This bacteria is typically found in the lower intestine of warm-blooded organisms but some strains such as Verocytotoxin-producing *E. coli* (VTEC) or enterohaemorrhagic *E. coli* (EHEC) are pathogenic, causing illnesses

associated with food and water contamination (Karmali et al, 2010). In Germany of 2011, there was an outbreak of a food-borne infection caused by EHEC, leading to large numbers of people falling ill with cases of bloody diarrhoea and haemolytic-uremic syndrome (Burger, 2012), a disease that causes severe inflammation of blood vessels and formation of blood clots throughout the body (NHS England, 2017). During the 5-month long outbreak, approximately 3000 cases of EHEC-associated infections were seen with 855 of these cases developing to haemolytic-uremic syndrome. Prior to this outbreak, there were approximately 1000 cases of EHEC-associated infections per year with 70 of these cases developing to haemolytic-uremic syndrome (Burger, 2012). Upon investigation by the German authority for food safety, it was found that the origin of this outbreak was in a contaminated batch of sprouts, with EHEC isolated in the stool of infected patients (Burger, 2012).





P. aeruginosa is a Gram-negative, rod-shaped bacterium of the *Pseudomonadaceae* family. It is also a facultative anaerobe with the ability to survive in an array of environmental conditions (Wu et al, 2015). It is an opportunistic pathogen as it tends to exploit a host that is in a weakened state i.e. immune-deficient, wounded and ageing (Brown et al, 2015). *P. aeruginosa* is known to cause chronic lung infections in patients with cystic fibrosis and skin infections in severely burned patients (Colmer-Hamood et al, 2016). In the summer of 2018, a human milk bank in Northern Ireland had to be suspended as *P. aeruginosa* was found in the water supply of the milk bank's hospital (BBC, 2018). Previously, four premature babies died in the Royal Maternity Hospital in Belfast due to an infection caused by the bacteria that was later found to be borne in the hospital's water supply as well (BBC, 2012).








S. epidermidis is a Gram-positive, spherical bacterium of the *Staphylococcaceae* family. It is also facultatively anaerobic and is a member of human skin flora but still has the ability to become pathogenic, being the cause of a significant number of nosocomial infections (Namvar et al, 2014). It is known that infections caused by this bacterium begin with its introduction during device insertion such as needles breaking the surface of the skin (Otto, 2009). In the United States, *S. epidermidis* is the cause of 22% of blood infections (NNIS, 2004). Even though *S. epidermidis* causes infections that are not easy to treat, they do not cause life-threateningly dangerous infections (Otto, 2009) such as the aforementioned bacteria.





1.2 Aim

The aim of this project was to synthesise a series of chalcones from a combination of substituted acetophenones and benzaldehydes using a reliable methodology, including the use of Lawesson's Reagent to convert these chalcones to thiochalcones, in an attempt to alter the pharmacophore of the compound. The aim also includes establishing any antimicrobial activity of the compounds and investigating said activity further. The synthesis and biological activity of thiochalcones is not heavily reported. The following table itemises the structures of the compounds this project aimed to synthesise:

Table 1: IUPAC Names and Chemical Structures of Proposed Compounds

IUPAC Name/Code	Chemical Structure
1 - 1-(2'-acylpyrrole)-3-(4-chlorophenyl)-prop-2-ene-1-one	
2 - 1-(3',4'-dichlorophenyl)-3-(2,4,6-trimethoxyphenyl)-prop-2-ene-1-one	
3 - 1-(2',4'-dichlorophenyl)-3-(4-methoxyphenyl)-prop-2-ene-1-one	
4 - 1-(2',4'-dichlorophenyl)-3-(4-hydroxyphenyl)-prop-2-ene-1-one	

<p>5 - 1-(2'-acetylfuran)-3-(4-chlorophenyl)-prop-2-ene-1-one</p>	 <p>The structure shows a furan ring with an acetyl group (-C(=O)CH₃) at the 2-position. This acetyl group is part of a prop-2-en-1-one chain (an alpha,beta-unsaturated ketone) that is substituted at the beta-carbon with a 4-chlorophenyl ring.</p>
<p>6 - 1-(4'-aminophenyl)-3-(4-chlorophenyl)-prop-2-ene-1-one</p>	 <p>The structure shows a prop-2-en-1-one chain substituted at the alpha-carbon with a 4-aminophenyl ring and at the beta-carbon with a 4-chlorophenyl ring.</p>
<p>7 - 1-(4'-bromophenyl)-3-(4-chlorophenyl)-prop-2-ene-1-one</p>	 <p>The structure shows a prop-2-en-1-one chain substituted at the alpha-carbon with a 4-bromophenyl ring and at the beta-carbon with a 4-chlorophenyl ring.</p>
<p>8 - 1-(4'-fluorophenyl)-3-(4-chlorophenyl)-prop-2-ene-1-one</p>	 <p>The structure shows a prop-2-en-1-one chain substituted at the alpha-carbon with a 4-fluorophenyl ring and at the beta-carbon with a 4-chlorophenyl ring.</p>
<p>9 - N-(4-bromobenzylidene)-4'-acetoaniline</p>	 <p>The structure shows a benzene ring with an acetamido group (-NHCOCH₃) at the 4-position and a benzylidene group (-CH=N-CH₂-C₆H₄-Br) at the 1-position. The benzylidene group is attached to a 4-bromophenyl ring.</p>
<p>10 - 1-(2',4'-dichlorophenyl)-3-(2,4,6-trimethoxyphenyl)-prop-2-ene-1-one</p>	 <p>The structure shows a prop-2-en-1-one chain substituted at the alpha-carbon with a 2,4-dichlorophenyl ring and at the beta-carbon with a 2,4,6-trimethoxyphenyl ring.</p>
<p>11 - 1-(4'-fluorophenyl)-3-(4-chlorophenyl)-prop-2-ene-1-thione</p>	 <p>The structure shows a prop-2-ene-1-thione chain (an alpha,beta-unsaturated thione) substituted at the alpha-carbon with a 4-fluorophenyl ring and at the beta-carbon with a 4-chlorophenyl ring.</p>

<p>12 - 1-(2',4'-dichlorophenyl)-3-(4-methoxyphenyl)-prop-2-ene-1-thione</p>	
<p>13 - 1-(4'-bromophenyl)-3-(4-chlorophenyl)-prop-2-ene-1-thione</p>	
<p>14 - N-(4-bromobenzylidene)-4'-thioaniline</p>	
<p>15 - 1-(tert-butoxycarboxylleucine)-3-(4-chlorophenyl)-prop-2-ene-1-one</p>	

2. Methodology

2.1 Materials

All chemical reagents and solvents utilised were sourced from both Sigma-Aldrich and Alfa-Aesar unless otherwise stated. All agar powders and antibiotics used during the microbiology section of this project were sourced from Thermo Fischer Scientific.

Table 2: List of reagents available for synthesis of chalcones and thiochalcones

Reagents	
2-hydroxy-4-methoxybenzaldehyde	4-chloroacetophenone
2,4,6-trimethoxybenzaldehyde	3,4-dichloroacetophenone
Salicylaldehyde	2,4-dichloroacetophenone
4-bromobenzaldehyde	Gallacetophenone
4-hydroxybenzaldehyde	2-acetylfuran
4-chlorobenzaldehyde	2-acetylpyrrole
5-bromo-3-nitrobenzaldehyde	2-hydroxy-3-nitrobenzaldehyde
3,4-dihydroxybenzaldehyde	5-bromo-3-fluorosalicylaldehyde
3,4-dihydroxybenzaldehyde	4-methoxybenzaldehyde
Sodium/lithium/potassium hydroxide	Lawesson's reagent

Table 3: List of solvents used during synthesis of chalcones and thiochalcones

Solvents	
Dichloromethane (DCM)	Methanol
Anhydrous N,N-dimethylformamide (DMF)	Deuterated dimethyl sulfoxide (DMSO)
Ethyl acetate	Deuterated chloroform

Anhydrous tetrahydrofuran (THF)	Deuterated methanol
Anhydrous toluene	Distilled water
Hexane	

Table 4: List of materials used in microbiology testing


Materials	
Nutrient agar (Oxoid, CM0003)	Distilled water
Mueller-Hinton agar (Oxoid, CM0337)	Ciprofloxacin discs (10µg) (Oxoid, CT1615)
Mueller-Hinton broth (Oxoid, CM0405)	Ringer's Solution Tablets (Oxoid, BR0052)
Dimethyl sulfoxide (DMSO) (molecular biology grade) (Sigma-Aldrich, D8418)	

Chemical reagents were used without purification. A 1 M solution of sodium hydroxide was made by dissolving 4g of sodium hydroxide pellets in 100ml of distilled water. ¹H and ¹⁵P Nuclear Magnetic Resonance (NMR) were recorded at 400MHz and 162 MHz respectively and ¹³C at 100MHz on a Varian 400MHz system with Oxford NMR As400 Magnet in deuterated chloroform, DMSO or methanol at room temperature. Infra-red (IR) spectroscopy data was recorded on a Thermo-Scientific Nicolet iS5 FTIR Spectrometer. Gas Chromatography Mass Spectrometry (GCMS) data was recorded on an Agilent 5975C Series GC/MSD System. Reactions were monitored by thin layer chromatography (TLC) using EMD Millipore TLC Silica gel 60 plates and a solvent system consisting of various ratios of hexane, dichloromethane and ethyl acetate. The plates were visualised under an ultraviolet (UV) lamp at 254nm. Column chromatography was carried out using either silica, Sephadex™ or alumina. Mobile phase systems were mixtures of laboratory grade solvents utilised during TLC. All agars, solutions and broths used were prepared according to the manufacturer's instructions and autoclaved before their use. Petri

dishes and 96-well plates sourced from Thermo-Scientific were sterile upon purchase.


2.2 Chemistry – Experimental procedures

2.2.1 Synthesis of 1-(2'-acylpyrrole)-3-(4-chlorophenyl)-prop-2-ene-1-one (1)



4-chlorobenzaldehyde (0.54 g, 3. mmol) and 2-acetylpyrrole (0.74 g, 6.8 mmol) were dissolved in methanol (10 ml) in a round-bottomed flask and stirred at 65°C until the dissolution of the reagents. A solution of sodium hydroxide (1 M, 2-3 ml) was added and the solution slowly became bright yellow. This was left to stir for 40 minutes. The colour of the solution was yellow. The solution was left to cool before water was added (approx. 5 ml), resulting in the precipitation of the compound. This precipitate was washed with water and filtered under vacuum. Pale yellow crystals were isolated. The crystals were dried in a vacuum oven at 60°C.


2.2.2 Synthesis of 1-(3', 4'-dichlorophenyl)-3-(2, 4, 6-trimethoxyphenyl)-prop-2-ene-1-one (2)



2, 4, 6-trimethoxybenzaldehyde (1.04 g, 5.3 mmol) and 3,4-dichloroacetophenone (0.95g, 5.04 mmol) were dissolved in methanol (10 ml) in a round-bottomed flask and stirred at 65°C until the dissolution of the reagents. A solution of sodium hydroxide (1 M, 2-3 ml) was added and an instantaneous colour change was noticed, with the solution becoming bright yellow. The solution was left to stir for 30 minutes. A precipitate had already formed upon returning. The mixture was taken off heat and left to cool. Water (approx. 5 ml) was added into the mixture and it was noted that more precipitate seemed to form. The precipitate was filtered under


vacuum, resulting crystals were neon yellow. They were dried in a vacuum oven at 60°C for 30 minutes.

2.2.3 Synthesis of 1-(2', 3'-dichlorophenyl)-3-(4-methoxyphenyl)-prop-2-ene-1-one (3)



4-methoxybenzaldehyde (0.74 g, 5.3 mmol) and 2, 4-dichloroacetophenone (0.95g, 5.0 mmol) were dissolved in methanol (10 ml) in a round-bottomed flask and stirred at 65°C until the dissolution of the reagents. A solution of sodium hydroxide (1 M, 2-3 ml) was added and the solution turned yellow. It was left to stir for 30 minutes. A precipitate had already formed without the addition of water and no more formed when approximately 5 ml was added. The resulting precipitate was filtered under vacuum and dried in a vacuum oven at 60°C. The crystals were yellow in colour.


2.2.4 Synthesis of 1-(3',4'-dichlorophenyl)-3-(4-hydroxyphenyl)-prop-2-ene-1-one (4)



4-hydroxybenzaldehyde (0.64 g, 5.3 mmol) and 3, 4-dichloroacetophenone (0.95 g, 4.9 mmol) were dissolved in methanol (10 ml) in a round-bottomed flask and stirred at 65°C until the dissolution of the reagents. A solution of sodium hydroxide (1 M, 2-3 ml) was added but no colour change was noticed at this point. The solution was left to stir for 30 minutes. Upon returning, the solution remained unchanged and was left to stir for an extra 30 minutes. At this point, the solution appeared yellow but translucent. It was taken off the heat and left to cool. Concentrated sulphuric acid was added (2-3 ml) which resulted in the solution turning red but after continuous stirring, it returned to its yellow colour. The product was extracted with dichloromethane (10 ml) and the solvent was removed under reduced pressure. Not all the solvent was removed but a precipitate had begun to form. This mixture was cooled on ice and a very deep yellow precipitate formed. The mixture was placed


on the vacuum line to be dried for a total of 5 hours. The precipitate was analysed using ^1H NMR and was seen to be starting material. However, the aqueous layer had been retained and upon removal of the solvent, a dark yellow solid was obtained. This solid was dried in a vacuum oven for 3 hours at 30°C .

2.2.5 Synthesis of 1-(2'-acetylfuran)-3-(4-chlorophenyl)-prop-2-ene-1-one (5)




4-chlorobenzaldehyde (0.57g, 4.1 mmol) and acetylfuran (0.43g, 3.9 mmol) were dissolved in methanol (10 ml) in a round-bottomed flask and stirred at 45°C until the dissolution of the reagents. A solution of sodium hydroxide (1 M, 2-3 ml) was added and the solution turned pale red. It was left to stir for 15 minutes and a precipitate formed. The resulting precipitate was washed with water, filtered under vacuum left to air dry in a locker overnight. The crystals were off-white and flaky.

2.2.6 Synthesis of 1-(4'-aminophenyl)-3-(4-chlorophenyl)-prop-2-ene-1-one (6)




4-chlorobenzaldehyde (0.71g, 5.1 mmol) and 4-aminoacetophenone (0.72 g, 5.3 mmol) were dissolved in methanol (10 ml) in a round-bottomed flask and stirred at 65°C until the dissolution of the reagents. A solution of sodium hydroxide (1 M, 2-3 ml) was added and an immediate colour change was noticed with the solution turning deep orange before slowly becoming bright yellow. It was left to stir for 30 minutes and a precipitate crashed out without the addition of water. Water (10 ml) was added but it did not appear to affect the precipitate nor encourage more of its formation. This was filtered under vacuum. The crystals formed were bright yellow. They were dried in a vacuum oven at 60°C .

2.2.7 Synthesis of 1-(4'-bromophenyl)-3-(4-fluorophenyl)-prop-2-ene-1-one (7)




4-fluorobenzaldehyde (0.8 ml, 6.4 mmol) and 4-bromoacetophenone (0.99 g, 4.9 mmol) were dissolved in methanol (10ml) in a round-bottomed flask and stirred at 50°C until the dissolution of the reagents. A solution of sodium hydroxide (1 M, 2-3 ml) was added and a slight colour change was noticed, the solution became a very pale yellow. A few moments later, a precipitate had formed without the addition of water. This was filtered under vacuum. The resulting crystals were pale yellow. They were dried in a vacuum oven at 50°C.

2.2.8 Synthesis of 1-(4'-fluorophenyl)-3-(4-chlorophenyl)-prop-2-ene-1-one (8)



4-chlorobenzaldehyde (0.75 g, 5.3 mmol) and 4-fluoroacetophenone (0.78 ml, 5.6 mmol) were dissolved in methanol (10 ml) in a round-bottomed flask and stirred at 50°C until the dissolution of the reagents. A solution of sodium hydroxide (1 M, 2-3 ml) was added and the solution became pale yellow. A few moments later, a precipitate formed without the addition of water. This was filtered under vacuum and the white crystals were dried in a vacuum oven at 50°C.


2.2.9 Synthesis of N-(4-bromobenzylidene)-4'-acetoaniline (9)



4-bromobenzaldehyde (2.8 g, 15.1 mmol) and 4-aminoacetophenone (2.1 g, 15.5 mmol) were dissolved in methanol (10 ml) in a round-bottomed flask and stirred at


60°C until the dissolution of the reagents. Without the addition of the sodium hydroxide solution, the precipitate began to form. The reaction mixture was left to stir for 30 minutes. Water (10 ml) was added to see if this would alter anything but no change was noticed. The precipitate was filtered under vacuum. Resulting crystals were pale yellow and powdery. Instead of drying them in a vacuum oven, they were left to air dry in a dark locker.

2.2.10 Synthesis of 1-(2',4'-dichlorophenyl)-3-(2,4,6-trimethoxyphenyl)-prop-2-ene-1-one (10)



2, 4, 6-trimethoxybenzaldehyde (0.73g, 3.7 mmol) and 2, 4-dichloroacetophenone (1.01g, 5.3 mmol) were dissolved in methanol (10 ml) in a round-bottomed flask and stirred at 65°C until the dissolution of the reagents. A solution of sodium hydroxide (1 M, 2-3 ml) was added and a precipitate began to form immediately. This was filtered under vacuum. The crystals were left to air dry in a dark locker.


2.2.11 Synthesis of 1-(4'-fluorophenyl)-3-(4-chlorophenyl)-prop-2-ene-1-thione (11)



Compound **8** (0.78g, 0.50 mmol) and Lawesson's Reagent (0.23g, 0.56 mmol) were dissolved in anhydrous THF (30 ml, 0.4 mol) in a round-bottomed flask and stirred under nitrogen whilst heated at 45°C. The reaction was monitored using TLC until the reaction was complete, after approximately 2 hours. The solution became orange upon stirring. The solvent was evaporated off using a rotary evaporator, resulting in an orange, thick substance. Column chromatography was performed using Sephadex™ and a mobile phase of DCM and methanol in a 1:1 ratio. The product, a thick orange liquid was left to air dry in a dark locker overnight. This


resulted in flaky orange crystals forming. These crystals were stored in a sealed glass tube in a cool and dark area until needed.

2.2.12 Synthesis of 1-(2',3'-dichlorophenyl)-3-(4-methoxyphenyl)-prop-2-ene-1-thione (12)



Compound **3** (0.16 g, 0.52 mmol) and Lawesson's Reagent (0.24 g, 0.059 mmol) were dissolved in anhydrous THF (30 ml) in a round-bottomed flask and stirred under nitrogen whilst heated at 60°C and left to stir at 30 minutes. The remaining THF was evaporated off using a rotary evaporator, resulting in a dark yellow, thick oil-like substance. Column chromatography was performed using Sephadex™ and a mobile phase of DCM and methanol in a 1:1 ratio. The product, a thick yellow liquid was left to air dry in a dark locker overnight. No change was noticed but the sample was stored in a glass tube and kept in a dark and cool area until needed.


2.2.13 Synthesis of 1-(4'-bromophenyl)-3-(4-chlorophenyl)-prop-2-ene-1-thione (13)



Compound **7** (0.24 g, 0.81 mmol) and Lawesson's Reagent (0.24 g, 0.059 mmol) were dissolved in anhydrous THF (30 ml) in a round-bottomed flask and stirred under nitrogen whilst heated at 40°C. This was left to stir for 2 hours and the solution appeared slightly yellow. This was taken off the heat and the remaining solvent was evaporated using a rotary evaporator. This resulted in a pale yellow solid. This was left to dry overnight. The next day, it was noticed the solid had become a yellow thick liquid. This was washed with water (10 ml) and extracted using ethyl acetate (10 ml). The organic layer was kept and the solvent was evaporated. This step produced a yellow thick liquid. Column chromatography was performed using Sephadex™ and a mobile phase of 30% dichloromethane, 65% hexane and 5% ethyl acetate. The product, also a thick yellow liquid was left to air dry in a dark


locker overnight. This was stored in a sealed glass tube in a cool and dark area until needed.

2.2.14 Synthesis of N-(4-bromobenzylidene)-4'-acetothioaniline (14)



Compound **9** (0.15 g, 0.49 mmol) and Lawesson's Reagent (0.20 g, 0.049 mmol) were dissolved in anhydrous toluene (30 ml) in a round-bottomed flask and stirred under nitrogen whilst heated at 55°C. The solution became red upon stirring and was left stirring for a total of 8 hours. Every hour, a TLC was done to monitor the progress of the reaction. After 8 hours, there were 2 spots on the TLC meaning starting material was still present. The reaction was left to stir overnight. After an additional 12 hours, the TLC showed one spot. Remaining solvent was removed on the rotary evaporator resulting in a deep purple thick liquid. Column chromatography was performed using alumina and a mobile phase of 30% dichloromethane, 65% hexane and 5% ethyl acetate. The product, a thick purple liquid was left to air dry in a dark locker overnight. This was stored in a sealed glass tube in a cool and dark area until needed.

2.2.15 Synthesis of 1-(tert-butoxycarboxylleucine)-3-(4-chlorophenyl)-prop-2-ene-1-one (15)



An attempt to carry out a DCC/HOBt-mediated coupling of a chalcone with an amino acid was made.

Compound **6** (1.0 g, 3.9 mmol) and HOBt (0.54 g, 4.0 mmol) were added to chilled DCM (30 ml) and stirred on ice for 30 minutes. To this, Boc-Leu-OH (0.93 g, 4.0 mmol) and DCC (1 ml, 4.4 mmol) were added and the reaction mixture was taken off the ice. At room temperature, this mixture was left to stir for 2 hours. This was decanted into glass tubes and stored in a freezer overnight. 4% hydrochloric acid (30 ml), saturated sodium carbonate solution (25 ml) and brine (30 ml) were added consecutively to the reaction mixture. Bubbles evolved at each addition. Calcium sulphate, a desiccating agent (approx. 20 g) was added to this mixture and this formed clumps at the bottom of the round-bottomed flask. Once the clump forming had stopped, it was filtered off from the mixture, leaving a clear solvent with a yellow solid at the bottom of the conical flask. The solvent and the solid were separated and the solid was oven-dried at 50°C for 30 minutes. This produced a yellow sticky solid. Column chromatography was performed using Sephadex™ and a mobile phase of DCM and methanol in a 1:1 ratio. The product, also a yellow sticky solid was stored in a sealed glass tube in a cool and dark area until needed.

2.3 Microbiology – Experimental

The microbial strains *Escherichia coli* (NCTC 7928), *Pseudomonas aeruginosa* (NCTC 6749) and *Staphylococcus epidermidis* (NCTC 9865) were utilised.

The initial screening of the synthesised compounds was performed according to The European Committee on Antimicrobial Susceptibility Testing (EUCAST) methodology using disk diffusion testing. The bacterial strains were obtained from the microbial bank of the Microbiology department of Kingston University. The bacteria were grown for 24 hours at 37°C on nutrient agar. The inocula for the assays were prepared by cell suspensions in Ringer's solution (Oxoid UK, Ltd.) to give a concentration of approximately 1.5×10^8 CFU/ml and used within 15 minutes of preparation.

2.3.1 Establishing antimicrobial activity

The compounds were dissolved in DMSO at a concentration of 10 mg/ml. From the prepared cultures, the bacteria were spread onto Mueller-Hinton agar plates (4 mm depth) using a sterile swab and the Petri dishes were divided into three sections: a positive control, a negative control and the synthesised compound. The positive control was ciprofloxacin (10 µg), the negative control was 10 µl DMSO and the

compound was used in 10 µl doses. Each test was done in duplicates and incubated at 37°C for 24 hours. The zones of inhibition produced by the compounds and the antibiotic discs were measured in millimetres (mm) and recorded. Once the active compounds had been identified, repeat tests were done in triplicate to ensure reliability of results.

2.3.2 *Minimum inhibitory concentration (MIC)*

This was determined using the microtitre broth dilution method. 96-well microtitre plates were used in this procedure. Mueller-Hinton broth was prepared at double and single strength whilst a stock solution of 10 mg/ml of the active compound was prepared. A 100 µl aliquot of the double concentration broth was dispensed to the first 3 rows of the 96-well plate, followed by 200 µl of the active compound's stock solution into the first well of the first 3 rows. The first well was mixed carefully using the pipette before 100 µl was transferred to the next well. Using a sterile tip each time, this was repeated a further four times, making a dilution series of the compound under test as follows: 5 mg/ml, 2.5 mg/ml, 1.25 mg/ml, 0.625 mg/ml and 0.3125 mg/ml. The inocula for the wells were prepared as above and a 5 µl aliquot of bacteria dispensed in each well using a sterile tip for each addition. The positive control was the double concentrated Mueller Hinton broth inoculated with 5 µl of bacteria, giving a concentration of approximately 5×10^5 CFU/ml. The negative controls were the double concentrated Mueller Hinton broth with 5 µl DMSO as well as single concentrated Mueller Hinton broth on its own. The plates were incubated at 37°C for 24 hours. The plates were read by eye and the results were recorded. Repeat tests were done in triplicates to ensure reliability.

2.3.3 *Minimum bactericidal concentration (MBC)*

Nutrient agar was used in this procedure and each plate was divided into 8 sections, section 1-5 dedicated to the wells of the plates used for determining MIC containing the active compound and bacteria whilst section 6-7 were dedicated to the positive and negative controls. A sterile swab was used to transfer a small amount from each well after the MIC incubation to its corresponding section on the agar. The plates were incubated at 37°C for 24 hours. The plates were read and the results were recorded. Repeat tests were done in triplicates to ensure reliability.

3. Results

A total of fifteen compounds were synthesised: nine chalcones, four thiochalcones, a diphenyl-imine compound and a chalcone-amino acid conjugate. Out of these fifteen compounds, two of the thiochalcones showed antimicrobial activity whilst none of the chalcones showed activity. The chalcone-amino acid conjugate was not tested for any activity. The certainty of the synthesis of the thiochalcones is addressed in the discussion.

Table 5: Masses, Melting Points & Percentage Yields of the Synthesised Compounds

Code	Mass (g)	Melting Point (°C)	Percentage yield (%)
1	1.52	158.8-163.0	100.7
2	0.96	185.7-187.2	52.3
3	0.47	84.1-88.7	30.7
4	2.01	168.2-171.9	138.4
5	0.51	139.0-143.2	40.2
6	0.67	-	51.9
7	1.04	142.9-143.5	64.9
8	1.23	137.0-141.2	89.5
9	4.23	144.1-147.6	93.3
10	0.76	146.1-148.7	55.6
11	0.45	liquid at r.t	-
12	0.47	liquid at r.t	-
13	1.0	liquid at r.t	-
14	0.33	liquid at r.t	-
15	-	-	-

Melting points were recorded on a Stuart™ Digital Melting Point Apparatus and were uncorrected.

Table 6: Molecular Formula, Molecular Weight & Mass Spectral Data of the Synthesised Compounds

Code	Molecular Formula	Molecular Weight (Mw)	Mass (m/z)
1	C ₁₃ H ₁₀ ClNO	231.67	[M ⁺] 231 (Abundance – 2400000). [M ⁺²] 233 caused by ³⁷ Cl isotope.
2	C ₁₈ H ₁₆ Cl ₂ O ₄	367.22	[M ⁺] 367 (Abundance – 100000). [M ⁺²] 369 caused by ³⁷ Cl isotope. Base peak is 335, shows the loss of a methoxy group. Other peaks seen: 366 (loss of H ⁺).
3	C ₁₆ H ₁₂ Cl ₂ O ₄	307.17	[M ⁺] 307 (Abundance – 1200000). [M ⁺²] 309 caused by ³⁷ Cl isotope. Base peak is 306 (loss of H ⁺)
4	C ₁₅ H ₁₃ Cl ₂ O ₂	292.14	Base peak is 149. 295 is closest fragment.
5	C ₁₃ H ₉ ClO ₂	232.66	[M ⁺] 232 (Abundance – 26800). Base peak is 231 (loss of H ⁺). [M ⁺²] 234 caused by ³⁷ Cl isotope.
6	C ₁₅ H ₁₂ NCIO	257.71	No MS obtained as sample had run out before testing took place.
7	C ₁₅ H ₁₀ BrFO	305.13	[M ⁺] 305 (Abundance – 190000). [M ⁺²] 307 caused by ³⁷ Cl isotope. Base peak is 225 caused by the loss of a bromine atom.
8	C ₁₅ H ₁₀ ClFO	260.68	[M ⁺] 260 (Abundance – 100000). [M ⁺²] 262 caused by ³⁷ Cl isotope. Base peak is 75.
9	C ₁₅ H ₁₂ NBrO	302.16	[M ⁺] 302 (Abundance – 76000). [M ⁺²] 304 caused by Br isotope.



			Base peak is 287/286 (loss of methyl group).
10	$C_{18}H_{16}Cl_2O_4$	367.22	366 is closest fragment with 368 seen as the peak caused by ^{81}Cl isotope. Base peak is 335, possibly caused by the loss of a chlorine atom.
11	$C_{15}H_{10}ClFS$	276.75	267 is closest fragment with 269 seen as the peak caused by ^{37}Cl isotope. Base peak is 207, also peak 209 caused by isotope.
12	$C_{16}H_{12}Cl_2OS$	323.23	320 is closest fragment, $[M^{+2}]$ peak not seen. Base peak is 306, same m/z as starting reagent (3)
13	$C_{15}H_{10}BrFS$	321.21	Base peak is 75. 260 peak seen, same m/z as starting reagent (7) with 261 seen as $[M^{+2}]$ peak.
14	$C_{15}H_{12}NBrS$	318.22	318 was seen. Base peak is 303, same m/z as starting reagent (9). $[M^{+2}]$ 304 (starting material) and 319 $[M^{+1}]$ seen.
15	$C_{26}H_{31}CN_2O_4$	470.98	MS not obtained.

Table 7: Infra-Red Spectroscopy Data of Synthesised Compounds

Code	Absorption (cm ⁻¹)	Appearance	Group
1	3268	Medium	N-H stretch
	1643	Medium	C=C stretch
	817	Strong	C-Cl stretch
2	1645	Medium	C=C stretch
	840	Strong	C-Cl stretch
3	1653	Medium	C=C stretch
	823	Strong	C-Cl stretch
4	1645	Medium	C=C stretch
	1206	Strong	C-O (OH) stretch
	819	Strong	C-Cl stretch
5	2032	Weak	C-H aromatic bend
	1653	Medium	C=C stretch
	778	Strong	C-Cl stretch
6	-	-	-
7	2032	Weak	C-H aromatic bend
	1699	Strong	C=O conjugated ketone stretch
	668	Strong	C-Br stretch
8	1662	Medium	C=C stretch
	1005	Strong	C-F stretch
	813	Strong	C-Cl stretch
9	1618	Weak	C-H aromatic bend
	1688	Strong	C=O Conjugated ketone stretch
	573	Strong	C-Br stretch
10	1650	Medium	C=C stretch
	1445	Medium	CH (methyl) bend
	821	Strong	C-Cl stretch
11	-	-	-

12	-	-	-
13	-	-	-
14	-	-	-
15	-	-	-

Table 8: ¹H NMR Data of Synthesised Compounds

 												
^ - see image 1 for reference, ' - see image 2 for reference * - thiochalcone R = H unless otherwise stated												
Code	H α	H β	R1	R2	R3	R4	R5	R6	R7	R8	R9	R10
1[^] X = NH, R6 = Cl	7.33, d, 16Hz, 1H	7.80, d, 16Hz, 1H	7.39, m, 1H	6.28, m, 1H	7.17, m, 1H	7.59, d, 8Hz, 1H	7.41, d, 8Hz, 1H	-	7.41, d, 8Hz, 1H	7.59, d, 8Hz, 1H	-	-
2['] R2 = Cl, R3 = Cl, R6, R8, R10 = OCH ₃	6.53, d, 14Hz, 1H	6.88, d, 14Hz, 1H	7.69, s, 1H	-	-	7.70, d, 8Hz, 1H	7.86, d, 8Hz, 1H	3.93, s, 3H	6.16, s, 1H	3.89, s, 3H	6.16, s, 1H	3.93, s, 3H
3['] R1 = Cl, R3 = Cl, R8 = OCH ₃	7.00, d, 16Hz, 1H	7.44, d, 16Hz, 1H	-	7.50, d, 2Hz, 1H	-	7.37, dd, 2Hz, 8Hz, 1H	7.42, d, 8Hz, 1H	7.54, d, 8Hz, 1H (overlap with R10)	6.94, d, 8Hz, 1H	3.87, s	6.94, d, 8Hz, 1H	7.54, d, 8Hz, 1H (overlap with R6)



Key: chemical shift (δ), peak splitting pattern, J coupling constant (Hz), integration
 s – singlet, d – doublet, dd – doublet of doublets, t – triplet, d of t – doublet of triplets, m – multiplet

4* R1 = Cl, R3 = Cl, R8 = OH	7.82, d, 8Hz, 1H	7.75, d, 8Hz, 1H	-	8.36, d, 2Hz, 1H	-	7.37, dd, 2Hz, 8Hz, 1H	7.43, d, 8Hz, 1H	7.54, d, 9Hz, 1H	6.94, d, 9Hz, 1H	-	6.94, d, 9Hz, 1H	7.54, d, 9Hz, 1H
5^ X = O, R6 = Cl	7.36, d, 16Hz, 1H	7.68, d, 16Hz, 1H	7.84, d, 16Hz, 1H	6.63, m, 1H	7.45, d, 4Hz, 1H	7.60, d, 8Hz, 2H	7.41, d, 9Hz, 2H	-	7.41, d, 9Hz, 1H	7.60, d, 8Hz, 2H	-	-
6* R3 = NH ₂ , R8 = Cl	7.75, d, 16Hz, 1H	7.81, d, 16Hz, 1H	-	-	NH ₂ at 8.45, s, 2H	6.73, d, 9Hz, 1H	7.89, d, 9Hz, 1H	8.11, d, 8Hz, 1H	7.30, d, 8Hz, 1H	-	7.30, d, 8Hz, 1H	8.11, d, 8Hz, 1H
7* R3 = Br, R8 = F	7.50, d, 16Hz, 1H	7.79, d, 16Hz, 1H	7.60, d, 8Hz, 1H	7.43, d, 8Hz, 1H	-	7.43, d, 8Hz, 1H	7.60, d, 8Hz, 1H	8.08, dd, 8Hz, 5Hz, 1H	7.21, t, 8Hz, 1H	-	7.21, t, 8Hz, 1H	8.08, dd, 8Hz, 5Hz, 1H
8* R3 = F, R8 = Cl	7.42, d, 16Hz, 1H	7.81, d, 16Hz, 1H	7.67, dd, 9Hz, 4Hz, 1H	7.15, t, 9Hz, 1H	-	7.15, t, 9Hz, 1H	7.67, dd, 9Hz, 4Hz, 1H	7.67, d, 9Hz, 1H	7.91, d, 9Hz, 1H	-	7.91, d, 9Hz, 2H	7.67, d, 9Hz, 1H
9*	-	-	-	-	-	-	-	-	-	-	-	-
10* R1 = Cl, R3 = Cl, R6, R8, R10 = OCH ₃	7.48, d, 16Hz, 1H	7.95, d, 16Hz, 1H	-	7.47, d, 2Hz, 1H	-	7.33, dd, 8Hz, 2Hz, 1H	7.43, 8Hz, 1H	3.87, s, 3H	6.12, s, 1H	3.87, s, 3H	6.12, s, 1H	3.87, s, 3H
11* R3 = F, R8 = Cl	-	-	-	-	-	-	-	-	-	-	-	-
12* R2 = Cl, R3 =	6.83, d, 16Hz, 1H	7.43, d, 16Hz, 1H	-	-	-	7.31, d, 8Hz, 1H	7.00, d, 8Hz, 1H	-	7.36, dd, 16Hz, 1H	3.70, s, 3H	7.25, dd, 8Hz, 1H	-

Cl, R8, = OCH ₃												
13* R3 = Br, R8 = F	-	-	-	-	-	-	-	-	-	-	-	-
14* R3 = NH ₂ , R8 = Br	-	-	-	-	-	-	-	-	-	-	-	-

Peaks for compounds **9**, **11**, **13** and **14** were not assigned in this table. Compound **9**'s spectra is explained further in table 13 and the discussion whilst compound **11**, **13** and **14**'s spectra is explained in table 12 and the discussion.

Table 9: ^{13}C NMR Data of the Synthesised Compounds

<div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;">  <p>Image 1</p> </div> <div style="text-align: center;">  <p>Image 2</p> </div> </div> <p style="text-align: center;">^ - see image 1 for reference, * - see image 2 for reference</p> <p style="text-align: center;">* - thiochalcone</p>															
Code	C1	C2	C3	C4	C5	C6	C7	C8	C9	C10	C11	C12	C13	C14	C15
1^ X = NH, R6 = Cl	129.2	111.1	116.4	136.3*	178.4	125.4	140.9	125.7 *	129.6	128.9	132.5*	128.9	129.6	-	-
2* R2 = Cl, R3 = Cl, R6, R8, R10=O CH ₃	129.6	136.1*	136.3*	126.3	131.5	155.3*	196.5	126.7	131.5	106.3*	163.-	91.5	166.9	91.5	163.0
3* R1 = Cl, R3 = Cl,	130.3*	123.7	130.1*	127.2	123.2	130.5*	187.6	131.5	146.3	141.0*	130.7	114.5	OCH ₃ at 55.4	114.5	130.5







Key: chemical shift (δ), peak splitting pattern, J coupling constant (Hz), integration
s – singlet, d – doublet, dd – doublet of doublets, t – triplet, d of t – doublet of triplets, m – multiplet

R8 = OCH ₃															
4 [*] R1 = Cl, R3 = Cl, R8 = OH	131.0	132.2*	136.1*	129.6	132.0	138.5*	187.2	128.9	146.8	126.1*	131.8	116.3	160.3	116.3	131.8
5 [^] X = O, R6 = Cl	148.5	113.3	131.0	-	178.5	121.5	142.3	-	130.0	129.0	-	129.0	130.0	-	-
6 [*] R3 = NH ₂ , R8=Cl	130.0	113.9	133.4*	113.9	130.0	134.2*	189.2	129.1	130.5	-135.6*	130.6	130.2	138.1*	130.2	130.6
7 [*] R3 = Br, R8 = F	129.6	129.4	131.1	129.4	129.6	133.5*	189.5	121.9	131.1	136.5*	130.1	116.1	134.1*	116.1	130.1
8 [*] R3 = F, R8 = Cl	130.2	116.1	165.4	116.1	130.2	131.0*	189.6	121.3	144.1	136.5*	130.1	132.2	134.1*	132.2	130.1
9 [*]	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10 [*] R1 = Cl, R3 = Cl, R6, R8,R10 =OCH ₃	132.6*	129.9	133.1*	126.9	125.6	106.1*	194.4	130.4	138.3	136.3*	OCH ₃ at 55.8	90.5	OCH ₃ at 55.4	90.5	OCH ₃ at 55.8
11 [*] R3 = F, R8 = Cl	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

12* R2 = Cl, R3 = Cl, R6, R8, R10 = OCH ₃	-	126.9	-	126.9	123.6	-	200.8				132.0	130.5	-	130.5	132.0
13* R3 = Br, R8 = F	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
14* R3 = NH ₂ , R8 = Br	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Peaks for compounds **9**, **11**, **13** and **14** were not assigned in this table. Compound **9**'s spectra is explained further in table 13 and the discussion whilst compound **11**, **13** and **14**'s spectra is explained in table 12 and the discussion.

Table 10: ^1H - ^1H COSY Correlations for Synthesised Compounds

Code	COSY Coupling
1	
2	
3	
4	
5	
6	














7	
8	
9	-
10	
11	-
12	
13	-
14	-




Table 11: ^1H - ^{13}C HMBC Correlations of Synthesised Compounds

Code	HMBC Coupling
1	
2	
3	
4	
5	
6	-

7	
8	
9	-
10	
11	-
12	
13	-
14	-



Regarding the ^1H and ^{13}C NMR of compounds **11**, **13** and **14**, refer to the table below. The spectra for compound **14** showed that the expected compound was not isolated. Instead, the oxa-thio-phosphorane compound, a breakdown product from the Lawesson's Reagent mechanism was found to be the major product isolated after column chromatography.



Table 12: ^1H , ^{13}C and ^1H - ^1H COSY NMR Data for oxa-thio-phosphorane using spectra of compound **14**

					
^1H NMR Data					
Key: chemical shift (δ), peak splitting pattern, J coupling constant (Hz), integration					
C1	C2	C3	C4	C5	C6
7.6, d, 12Hz, 1H	7.04, d, 9Hz, 1H	methoxy group: 3.8, s, 3H	7.04, d, 9Hz, 1H	7.6, d, 12Hz, 1H	-
^{13}C NMR Data					
C1	C2	C3	C4	C5	C6
132.9	113.9	163	113.9	132.9	123.8
^1H-^1H COSY Data					
					
^1H-^{13}C HMBC Data					
					

Whilst analysing the data for compound **9** and consolidating the synthetic workup of this compound, it is clear that its structure is not a chalcone but the structure below. For further explanation, see discussion (4.2).



Table 13: ^1H , ^{13}C and ^1H - ^1H COSY NMR Data for compound **9**

								
R = H								
^1H NMR Data								
Key: chemical shift (δ), peak splitting pattern, J coupling constant (Hz), integration								
R1	R3	R4	R6	R8	R9	R10	R12	R13
8.03, d, 8Hz, 1H	8.03, d, 8Hz, 1H	7.80, d, 8Hz, 1H	7.80, d, 8Hz, 1H	8.41, s, 1H	7.65, d, 8Hz, 1H	7.24, d, 7Hz, 1H	7.24, d, 7Hz, 1H	7.65, d, 8Hz, 1H
Methyl group of acetophenone: 2.64, s								
^{13}C NMR Data								
								

C1	C2	C3	C4	C5	C6	C7	C8	C9
129.9	132.4	129.9	121.0	-	121.0	156.1	134.7	130.1
C10	C11	C12	C13	Methyl group of acetophenone: 26.4, carbonyl group – 191.1				
131.9	126.6	131.9	130.1					
¹ H- ¹ H COSY NMR Data								
								
¹ H- ¹³ C HMBC								
								


Compound **15** proved difficult to isolate clean with column chromatography. The peak assignments have been done with extensive use of ¹H, ¹³C and ¹H-¹H COSY spectra.

Table 14: ^1H , ^{13}C and ^1H - ^1H COSY NMR Data for Compound 15

^1H NMR Data										
 <p style="text-align: center;">$\text{R} = \text{H}$</p>										
R1	R2	R4	R5	R6	R7	R8	R9	R11	R12	H*
7.40, d, 8Hz, 1H	7.60, d, 9Hz, 1H	7.60 , d, 9Hz, 1H	7.40, d, 8Hz, 1H	7.33, d, 8Hz, 1H	7.88 , d, 8Hz, 1H	7.72 , d, 8Hz, 1H	7.99 , d, 7Hz, 1H	7.99 , d, 7Hz, 1H	7.72 , d, 8Hz, 1H	3.89 , m, 1H
Methyl groups of amino acid – 0.81, 2 x d, 12Hz										
^{13}C NMR Data										
										
C1	C2	C3	C4	C5	C6	C7	C8	C9	C10	C11
130.9	119.05	-	119.0 5	130. 9	-	-	-	-	-	-
C13	C14	C15	Carbonyl of amino acid – 175.3, methyl groups of amino acid – 28.5, CH* – 52.4							
-	-	-								
<p>A majority of the peaks were not assigned as the resolution of the spectra did not allow for the peaks to be seen. An increased number of scans whilst recording the spectra would have alleviated the issue. Also, the Boc protecting</p>										

group appears to have been removed as its methyl peaks are missing on both ^1H and ^{13}C data.

^1H - ^1H COSY NMR Data



^1H - ^{13}C HMBC




Table 15: In-vitro Antimicrobial Activity of the Synthesised Compounds

Code	Zone of Inhibition (mm)*			
	Concentration (mg/ml)	Bacteria		
		<i>S. epidermidis</i>	<i>P. aeruginosa</i>	<i>E. coli</i>
1	10	-	-	-
2	10	-	-	-
3	10	-	-	-
4	10	-	-	-
5	10	-	-	-
6	10	-	-	-
7	10	-	-	-
8	10	-	-	-
9	10	-	-	-
10	10	-	-	-
11	10	10	-	-
12	10	-	-	-
13	10	-	-	-
14	10	16	10.3 ± 0.334	11.3 ± 0.334
Ciprofloxacin	10µg	15.3 ± 0.334	18	15.3 ± 0.334
* mean value given (n=3)				

Table 16: Minimum Inhibitory Concentration (MIC) of the biologically active compounds

Code	MIC (mg/ml)		
	<i>S. epidermidis</i>	<i>P. aeruginosa</i>	<i>E. coli</i>
11	1.25	-	-
14	0.3125	1.25	1.25
Ciprofloxacin*	1	0.5	0.25-0.5
*(mg/L), as reported by EUCAST (n=3)			

Table 17: Minimum Bactericidal Concentration (MBC) of the biologically active compounds

Code	MBC (mg/ml)		
	<i>S. epidermidis</i>	<i>P. aeruginosa</i>	<i>E. coli</i>
11	2.5	-	-
14	1.25	2.5	2.5
(n=3)			

Discrepancies between the MICs and MBCs are further discussed in the discussion (4.4). The activity of the synthesised compounds was adequately recorded and noted.

4. Discussion

4.1 Data Analysis


This project is made up of two key aspects: the synthesis of chalcones and thiochalcones followed by the determination of their activity as antimicrobial agents. In order to prove the existence of the compounds synthesised, the data procured from their analytical examination had to be studied.

As seen in tables 8, 9, 10 and 11, each synthesised compound has had their ^1H and ^{13}C NMR analysed. The spectra derived from these analytical experiments including ^1H - ^1H Correlation Spectroscopy (COSY) and ^1H - ^{13}C Heteronuclear Multiple Bond Correlation Spectroscopy (HMBC) can be found in the appendix. Diagnostically, the most important protons to be identified in a chalcone are the protons on the α - β unsaturated bond as these only arise from a successful Claisen-Schmidt condensation and complete conjugation of the electron system.

The synthesised compounds have several substituents, causing the magnetic equivalency of the protons to change. Compounds **1** and **5** had 5-membered A rings. Compound **1** showed coupling of its α - β unsaturated protons at δ 7.33 and δ 7.80 with J coupling constants of 16Hz as did compound **5** with coupling seen at δ 7.41 and δ 7.69 with J coupling constants of 16Hz. Compounds **2**, **3**, **4** and **10** have dichloro substituents on the A ring with their α - β unsaturated protons around δ 6.53-7.95 with coupling constants around 14-16.8Hz, with the exception of compound **4**, whose α - β unsaturated protons have a coupling constant of 16 Hz. Compounds **2** and **10** have trimethoxy substituents on the B ring. The remaining compounds had either a halogen (Cl or Br), methoxy or hydroxyl group in the 4th position on the B ring. Peaks were typically seen in the δ 7-8 region which is where aromatic protons usually occur (see appendix 1.1.1 for ^1H NMR spectra of compound **1**, 1.2.1 for compound **2** and so on). Infra-red spectroscopy showed weak peaks at 1645 cm^{-1} across all the derived spectra, correlating to the C=C bond stretch in the aromatic ring. The C-F and C-Cl stretch around 800 cm^{-1} and 1000 cm^{-1} were seen across all halogenated compounds such as **1**, **2**, **3**, **4**, **5**, **8**, **9** and **10**.

Compound **9**'s synthesis did not require the addition of sodium hydroxide to induce a colour change or precipitation. The amino group on the 4-aminoacetophenone bears a lone pair of electrons on the nitrogen. This could have facilitated the

nucleophilic addition of the benzaldehyde with the acetophenone in solution (scheme 5).



Scheme 5: Mechanism of Reaction between 4-aminoacetophenone & 4-bromobenzaldehyde

Image source: author's own

The TLC of the compound showed one spot (solvent system: hexane & DCM, 1:1). The ¹H spectrum supports the proposed structure. The aromatic protons formed doublets at δ 8.03, δ 7.80, δ 7.65 and δ 7.24 respectively whilst the benzyldene proton can be seen as a singlet at δ 8.41. The GCMS data of the compound produced a pair of M⁺ peaks at *m/z* 303/305 indicative of bromine being present in the molecule. HMBC correlations were used to assign the aromatic doublets as belonging to ring A or ring B.

Also, the NOESY spectra for compound **9** does not show a correlation between the protons with asterisks (see figure 17) suggesting the compound is of this shape.




Figure 17: Shape of Compound **9**
Image source: author's own

The use of Lawesson's Reagent to convert the carbonyl to a thiol in this particular compound would have been possible (see scheme 6). However, the spectra for the attempted conversion, compound **14**, was consistent with the oxa-thio-phosphorane compound which is further discussed in the next section.

Upon analysing Nuclear Overhauser Effect Spectroscopy (NOESY) data, a cross peak correlating the α - β unsaturated proton was seen across a majority of the spectra (see appendix 1.1.6 for compound **1** spectrum), which suggests the cis (Z) isomer of the chalcones was synthesised. However, the high J coupling constants of these protons, typically seen at 16Hz in this project, (see table 7) indicate the conformation of the chalcones to be trans (E) isomers as well as geometrically pure (Tran et al, 2012). These are the thermodynamically most stable form (Aksöz et al, 2011).

In any chemical reaction in which two isomers can be formed, there is always a kinetic product and a thermodynamic product. The kinetic product is usually formed when the reaction time is short, not giving the thermodynamic product time to form. The use of a strong base minimises the chances of reversibility at the intermediate step, enhancing the formation of the thermodynamic product – the trans (E) isomer (see scheme 2).

A possible explanation for the appearance of this cross peak was the interaction of a chalcone molecule with another molecule by way of pi stacking. Seeing as NOESY data aims to show signals that arise from protons that are of close proximity in space, this theory fits. The formation of aggregates in solutions is a naturally

occurring phenomena that occurs with supramolecules (Perez et al, 2013). It is likely that a trans (E) isomer was in close contact with a neighbouring trans (E) isomer aggregate, resulting in a strong signal on the NOESY data. The high coupling constants of the α - β protons still suggest that the trans (E) isomer is the abundant product. So, it became imperative to understand why this peak was being shown.

It was hypothesised that the use of an aprotic solvent as well as a dilute sample for NMR would reduce the formation of aggregates and this would result in the loss of the cross peaks in the NOESY spectrum. The ^1H NMR data of aggregates are different from those of monomeric species depending on the concentration and temperature that the data is acquired (Perez et al, 2013).

A suggestion was made to acquire new NOESY data and diffusion-ordered spectroscopy (DOSY) NMR data to make a comparison. DOSY separates the NMR signals of different compounds according to their diffusion coefficient. Ideally, signals arising from the same compound should appear in one consecutive row. By acquiring NOESY data from both a concentrated and dilute sample, this was meant to show the cross peak caused by pi stacking of trans (E) isomers due to the concentrated sample and its disappearance with a dilute sample. In terms of DOSY data, two rows of peaks were expected from the concentrated sample – one caused by the pi stacked aggregate and the by the free trans (E) isomer. In the dilute sample, only a row caused by the trans (E) isomer was expected.

Compound **10** was used to acquire this new data. The new DOSY data from both its concentrated and dilute sample showed the expected set of peaks.




Figure 19: DOSY spectrum of Compound 10 (dilute in DMSO)

Image source: author's own

Also, as a standard experiment, new ^1H proton data was derived. There was a considerable difference between the original (concentrated) data derived in chloroform compared to the new (dilute) data derived in DMSO. The peaks of the dilute sample had shifted down the ppm scale, giving the peaks new chemical shift values (see appendix 1.1.18). The shift was considerably large, too large to be caused solely by solvent alterations. This was thought to support the hypothesis that the aromatic stacking of the trans (E) aggregates and free trans (E) conformations was at play.

However, the large coupling constants of the α - β unsaturated protons highly suggest the presence of the exclusively trans (E) isomer. Further reading suggested that the cross peaks seen on the NOESY spectra could be caused by the strong COSY correlation between the protons, resulting in the false NOESY peak (Claridge, 2009). In a third attempt to confirm whether this cross peak was a result of pi stacking or a strong COSY correlation, new NOESY and DOSY data was obtained (concentrated and dilute samples in both deuterated chloroform and DMSO) and it was clear that the cross peak was false. The new data was obtained in both chloroform and DMSO to negate the differing effects across the solvents. It was also taken at 600MHz for increased sensitivity. From the DOSY data (see figures 20 and

21), it is clear that a single compound is present under both the concentrated and the dilute sample conditions.




Figure 20: **DOSY spectrum of Compound 10 (dilute in chloroform) – 600MHz**
Image source: author's own





Figure 21: **DOSY spectrum of Compound 10 (dilute in DMSO) – 600MHz**
Image source: author's own

In a former project, previous attempts to synthesise chalcones using the Claisen-Schmidt condensation method using similar reagents produced a two-step synthesis: the reaction of the benzaldehyde and acetophenone to give an aldol which was further dehydrated to form the required chalcone. It was suggested that using a stronger base such as potassium or lithium hydroxide to catalyse the benzaldehyde and acetophenone reaction would have avoided the synthesis of the aldol. During this project, sodium hydroxide was the base used and it was not changed as it facilitated the reactions without forming an aldol; it was not detected during analysis. The expected colour changes (clear-yellow) were seen in all the chalcone reactions. If this was not seen after the addition of the sodium hydroxide solution, this would have given a reason to either make use of a stronger base or allow for longer reaction times.

A typical Claisen-Schmidt condensation is carried out at room temperature but the reactions in this project were carried out at 50-65°C, maximising the chance for the thermodynamic product to be made in situ. The synthesis of exclusively cis-chalcones is underreported in literature but they are also the thermodynamically less stable isomer and so tend to decompose before their presence can be denoted (Zhuang et al, 2017). There has been a report of isomerisation of the trans (E) chalcone to the cis (Z) chalcone by exposing the methanolic solution of the chalcone to visible white light (Iwata et al, 1997). The chances of this photo-isomerisation occurring to the synthesised chalcones was small as they were kept in a dark place until required.

4.2 Thiochalcones

A mechanism of the conversion of chalcones to thiochalcones is as follows: Lawesson's reagent in solution exists in equilibrium as two molecules of dithiophosphine ylide. A single molecule of the ylide attacks the carbon of the chalcone's carbonyl bond (C=O) via the P=S bond, producing a thioxaphosphetane intermediate. This intermediate undergoes an intramolecular attack forming the P-O bond, which is the driving force of this reaction (similar to the Wittig Reaction). This produces the thiochalcone and two molecules of oxa-thio-phosphorane.



Scheme 6: Mechanism for Conversion of Chalcones to Thiochalcones Using Lawesson's Reagent

Image source: author's own

As stated in the literature review (1.1.3), the thionation reaction can produce a mixture of products. Krstić et al utilised Lawesson's Reagent to convert α - β unsaturated steroidal ketones to their thio- equivalents. They noticed that the type of products and their ratio was dependant on reaction conditions. When using anhydrous toluene for 8 hours at refluxing temperature, the reaction produced a mixture of the steroidal ketones' corresponding dimer-sulfides and the starting

ketone. The desired product was not seen after the 8-hour reaction but was isolated when the reaction time was 25-45 minutes (Krstić et al, 2010). Even though reaction times did not reach 8 hours (excluding compound **14** that had a reaction time of 12 hours), they did exceed 25-45 minutes, so it is assumed this was the case with compounds **11**, **13** and **14**. Upon analysing their analytical data, it is clear that the eliminated oxa-thio-phosphorane is the abundant product (see table 10). Compound **12** is the exception as a mixture of the thiochalcone, starting chalcone and oxa-thio-phosphorane compound is present upon analysis of ^1H , ^{13}C and ^{31}P NMR data (see tables 7, 8 and 9).




Figure 22: **oxa-thio-phosphorane**

Image source: author's own

The ^1H and ^{13}C NMR of **11**, **13** and **14** (see appendices 1.11, 1.12 and 1.13) resembles that of the predicted NMR of the oxa-thio-phosphorane compound (see appendices 1.1.16 and 1.1.17). The spectra share the following factors in common: the presence of a doublet of doublets at both $\delta 7.6 - \delta 7.8$ and $\delta 7 - \delta 6.7$ as well as a singlet at $\delta 3.8$ corresponding with the methoxy group on the ring. The protons are also coupled on their respective ^1H - ^1H COSY spectra. The C=S bond that should appear around 200ppm, is missing on the ^{13}C NMR of all the compounds as well as the C=O bond that should appear around 180ppm, but a number of aromatic carbons appear in the region of 110-130ppm. The α - β unsaturated carbon peaks, that should appear around 130ppm and 110ppm respectively, are also not seen on ^{13}C data. It should also be noted that a peak seen at 193.2ppm on the ^{13}C of **12** could correspond with the C=O bond whilst a peak at 200.8ppm could be the C=S peak (see appendix 1.12.7). No I.R data was obtained as it was clear from the NMR data that the expected products were not formed.

The GCMS data of some of the thionated compounds shows that their most abundant peak corresponds to the M^+ peak of their corresponding starting chalcones (see table 6). Compound **12**'s M^+ peak is the same M^+ peak as its starting chalcone, compound **3** ($m/z - 306$) as is the case with compound **14**'s M^+ peak and compound **9** ($m/z - 303$). This evidence suggests that the thiochalcones

were made but possibly decomposed, as its monomeric species is unstable (Krstić et al, 2010).

Another method of ascertaining the presence of thionated products is a colour change. A purple colour is associated with the presence of a thionated product and this was reflected in the synthesis of compound **14**, which retained this colour after the completion of the reaction whilst the remaining compounds had a colour change of bright orange to yellow. Compound **11** maintained a bright orange colour.

¹⁵P NMR was conducted to ascertain the presence of phosphorous in all the thiochalcone samples. The peaks seen on their respective spectra (see appendix 1.11.8 for ¹⁵P spectrum of compound **11**) also support the presence of oxa-thio-phosphorane.

4.3 Effect of Substituents Positions on Aromatic Rings on the Reaction

Aldehydes bearing electron-withdrawing groups favour base-catalysed condensations whilst aldehydes bearing electron-donating groups favour acid-catalysed condensations (Zhuang et al, 2017). The below average yields of the compounds could be explained by this fact. 2, 4, 6-trimethoxybenzaldehyde was used to synthesise compounds **2**, **3** and **10**. The methoxy group is electron-donating. The use of sodium hydroxide to catalyse its reaction suggests the aldehyde combining with the acetophenone was the rate-determining step of this reaction, resulting in the average yields of 52.37%, 30.72% and 55.65% respectively.

Halogen groups are strongly electronegative and withdraw electron density from the ring via induction. They are ortho/para-directors when it comes to electrophilic substitution, due to the ability of the lone pairs to stabilise the carbocation formed during the substitution process when in the ortho and para positions. The overriding effect on the aromatic ring in the chalcones studied here, would be one of electron-withdrawing induction as we are not looking at electrophilic substitution (see figure 23).




Figure 23: **Non-hydrogen positioning on aromatic ring relative to ketone moiety**
 Image source: author's own

4-chlorobenzaldehyde, 4-fluorobenzaldehyde and 4-bromobenzaldehyde were used in the synthesis of compounds **1**, **5**, **6**, **7**, **8** and **9** that produced yields of 100.7%, 40.28%, 51.97%, 64.92%, 89.51% and 93.32% respectively. These compounds produced a mixture of good and average yields.

The electron-withdrawing effects of the halogens in the para position means the reactions would have produced good yields under basic conditions. The below-average yields of compound **6** could be due to an inadequate reaction time whilst the higher yields of compounds **1** and **9** could mean the products were a mixture of starting material and desired product.

Compound **4** was synthesised using sodium hydroxide, but the precipitate did not form until the use of concentrated sulphuric acid followed by a liquid-liquid extraction. Its uncharacteristically high yield of 138% is most likely due to the presence of water. Further drying would be needed for an accurate yield.

4.4 Antimicrobial Activity

Out of all the synthesised products, only two supposed thiochalcones displayed any antimicrobial activity. The remaining compounds, chalcones especially, did not display any activity. The reasons for this could be due to a number of factors but it is most likely the substituents on the A and B rings.

A free hydroxyl group on the B ring of a chalcone is necessary for biological activity, regardless of the substituents on the A ring (Ávila et al, 2008). Compound **4** bears a free hydroxyl group on the B ring, but no antimicrobial activity was noticed when the compound was tested. A hydroxyl group in the meta position has been noted to bring about a diminished level of antimicrobial activity previously (Silva et al, 2013) but compound **4**'s hydroxyl group was in the para position.

More than 2 methoxy groups on the B ring have been seen to eradicate any biological activity of a chalcone regardless of the substituents on the A ring (Baba et al, 2013) as is reflected in the results of compounds **2** and **10**, which are structural isomers. Compound **3** has a methoxy group in the para position. Such a group in the meta position proved useful in the Ávila et al study but the success of their compounds was attributed to hydrophobic groups such as prenyl or geranyl groups on the A ring (Ávila et al, 2008).

The lack of activity from the synthesised halogen-bearing chalcones was unexpected. Halogens such as chlorine, bromine and fluorine are universally known to increase the biological activity of chalcones. The most prominent presumption to explain this feat is the negation of the halogens, present on both the A and B rings of the chalcone. Chalcones with halogens present on only one ring of the structure are seen to be antimicrobially active, as documented in studies conducted by Osório et al (2010), Burmaoglu et al (2017) and Karthikeyan et al (2007).

Fundamentally, there are two pathways by which antibiotics can enter a bacterial cell: via a lipid-mediated pathway for hydrophobic antibiotics or through diffusion porins for hydrophilic antibiotics (Delcour, 2009).

Bacterial membranes have a high phospholipid content which is negatively charged (Osório et al, 2010). Lipophilicity is an important factor of antimicrobial agents as they have to infiltrate the cell wall envelope of bacteria. Chlorine and bromine are rather lipophilic, but their electronegativity does not differ much compared to carbon. However, fluorine is more hydrophilic than other halogens so the presence of fluorine on the aromatic rings could have caused this lack of activity.

There is a difference between the MIC and MBC values of compound **11** and **14**. The compounds were very brightly coloured in nature, causing the determination of inhibition or otherwise difficult to distinguish. The determination of MBC requires the MIC results. When recording the MBC, the section with the smallest amount of growth prior to the section with zero growth was used to confirm the MIC. For instance, with compound **11**, the MBC was recorded as 2.5 mg/ml but there was turbidity across all the wells during the MIC experiment. The section of the petri dish prior to 2.5 mg/ml had a very small amount of growth, meaning this correlates with the MIC of compound **11**.

Existing antibiotics are split into classes: Beta-Lactams, Sulfonamides, Aminoglycosides, Tetracyclines, Chloramphenicol, Macrolides, Glycopeptides, Oxazolidinones, Ansamycins, Quinolones, Streptogramins and Lipopeptides. The groups classify available antibiotics based on their target bacteria (Gram-negative or Gram-positive), mode of action (bactericidal or bacteriostatic) and chemical structure (Brunning, 2014).

Antibiotics have five basic mechanisms of action against bacteria (Rollins and Joseph, 2000):

1. Inhibition of cell wall synthesis
2. Inhibition of protein synthesis
3. Alteration of cell membranes
4. Inhibition of nucleic acid synthesis
5. Antimetabolite activity

Peptidoglycan, a component of the cell walls of both Gram-positive and Gram-negative bacteria, is made up of long, cross-linked polymers of B-N-acetyl-D-glucosamine and N-acetylmuramic acid (Volmer et al, 2008).

It is the D-alanyl-D-alanine portion of a peptide chain that is cross-linked in the presence of penicillin binding proteins (PBP). Beta-lactam and glycopeptide antibiotics target PBPs. Beta-lactam rings are thought to mimic the D-alanyl-D-alanine portion of the peptide chain. They bind strongly with PBPs, thus weakening the peptidoglycan layer, resulting in the lysis of the bacterial cell (Tipper, 1985). Glycopeptides bind to the D-alanyl-D-alanine portion of the peptide chain, which disallows PBPs from binding, leading to the inhibition of cell wall synthesis (Nagarajan, 1991).

Protein synthesis requires the action of DNA being used to synthesise mRNA via transcription. The bacterial 70S ribosome, a macromolecule required to translate mRNA to amino acids is made up of two subunits: 30S and 50S subunits. Aminoglycosides, chloramphenicol, tetracycline, oxazolidinones and macrolides work by affecting the process of translation by inhibiting certain parts of the ribosomal subunits. The inhibition of protein synthesis leads to a disruption of a

number of bacterial processes required for life, resulting in the death of the bacterial cell (Sigma-Aldrich, 2006).

Quinolones inhibit the bacterial enzyme (deoxyribose nucleic acid) DNA gyrase, which is responsible for the ATP-dependent negative super-coiling of double-stranded DNA. This is necessary to prevent the excessive positive supercoiling of the DNA strands when they separate for the commencement of replication or transcription. DNA gyrase is also made up of subunits, two A subunits and two B subunits. Quinolones bind to the A subunits, disallowing the cutting and resealing of the DNA strands (Aldred et al, 2014).

In terms of antimetabolite activity, sulfonamides, the “cousin” of the synthesised thiochalcones, inhibit bacterial folic acid production. They inhibit dihydropteroate synthase competitively, thus blocking the enzyme’s regular substrate, *p*-aminobenzoic acid from binding. This prevents the production of folic acid in the bacterial cell. All living cells require folic acid for growth but it cannot cross bacterial cell walls via diffusion, so it is synthesised from *p*-aminobenzoic acid within the bacterial cell (Walzer et al, 1988).

The varying antibiotic mechanisms of action shed light on the importance of enzymes in their activity. No concrete link has been made to define how chalcones work as antimicrobial agents. More studies would need to be carried out to determine the mode of action of chalcones and ascertain whether enzymes are involved in this process.

At present, there are two theories that describe how enzymes bind to substrates: Lock and Key Theory and Induced Fit Theory. The conventional Lock and Key theory was introduced by Emil Fisher in 1894, postulating that a substrate was a key and the enzyme was the lock and that only the correctly shaped substrate would fit into the active site of the enzyme, thus activating it (Ophardt, 2003). The Induced Fit theory was suggested by Daniel Koshland in 1958 as experimental evidence of enzymatic activity could not be fully explained by the Lock and Key theory. Koshland suggested that it was the substrate that determined the final shape of the enzyme, meaning an enzyme’s active site is flexible in nature (Koshland, 1958). This means, a substrate would need to be recognisable to the active site in terms of functional groups, side chains or structure. This partially explains how enzymes can bind to competitive molecules that permanently block its active site.

A hypothesis developed in this study is that chalcones may follow a similar mode of action to generate antimicrobial activity. Chalcones could irreversibly block the active site of some bacterial enzymes, thus preventing its necessary action from being carried out, causing either bactericidal or bacteriostatic consequences.

Sivakumar et al synthesised a series of substituted chalcones and tested their activity against *S. aureus* and *E. coli*. The study found that the active compound, with a methoxy group in the para position on the A ring and a hydroxyl group in the ortho position on the B ring, damaged the cell walls of the bacteria, reminiscent of the mechanism of action of glycopeptide antibiotics (Sivakumar et al, 2009). This mechanism involves blocking the active site of the enzyme D-alanyl-D-alanine carboxypeptidase/transpeptidase (Goodsell, 2002). This provides evidence that the mode of action chalcones undertake to behave as antimicrobial agents could possibly involve enzymatic inhibition.

Relating back to the lipophilicity of the compounds, compounds **11** and **14** were the only biologically active compounds. To an extent, their activity could be caused by the presence of oxa-thio-phosphorane (see figure 22). If the activity shown was entirely due to this compound, activity would have been seen in compounds **12** and **13** as well. Compound **11** does bear a fluorine atom on its B ring but it showed activity against the Gram-positive *S. epidermidis*. Gram-positive bacteria have a large peptidoglycan content in their cell wall (see figure 25). It may have been easier for this compound to cross the cell wall of *S. epidermidis*, supposedly boosted by the lipophilic sulphur atom on the thione moiety. With compound **14**, it showed activity against both Gram-positive and Gram-negative bacteria: *S. epidermidis*, *P. aeruginosa* and *E. coli*. The compound contains nitrogen, sulphur and bromine. Nitrogen is lipophobic whilst sulphur and bromine are more lipophilic. The presence of these atoms in the compound may be the reason for the compound's dual activity, allowing for passage across both cell walls, via a lipid-mediated pathway and through porins (Delcour, 2009), increasing the likelihood of the compound infiltrating the bacteria.

The solubility of chalcones proved problematic during the bacterial screening of this project. An ideal solvent to work with in microbiology is either water or a physiological diluent as this would eliminate the possible effect of solvent interaction on any seen antimicrobial activity. DMSO was used as a compromise: it was the least bacterially disruptive solvent that the chalcones were soluble in. It was noticed


that when the chalcone solutions were introduced to the inoculated agar plates, there was a degree of precipitation of the chalcones. The most likely cause for this is the presence of water in the agar. Water is used during chalcone synthesis to initiate its precipitation. Antimicrobial susceptibility is usually tested using broth dilution, disk diffusion or gradient method (Reller et al, 2009). All these methods still utilise either agar or broth which requires water for its preparation. This antagonism between the chalcones and agar could have affected any activity or lack thereof.

The synthesis of compound **15** was attempted in a bid to increase the solubility of chalcones in water, in turn, improving its bioavailability. Peptide couplings are usually facilitated by coupling reagents such as DCC and 4-Dimethylaminopyridine (DMAP). This synthesis made use of DCC and HOBt. DCC activates the carboxyl group of the amino acid by forming an O-acylisourea intermediate that forms a complex with HOBt. This complex couples with the amino end of compound **6**, forming the desired product, the reformed catalyst HOBt and the by-product dicyclohexylurea (scheme 7). The reaction is usually carried out at low temperatures, facilitated by a mixture of dry ice and ether, to minimise the formation of this by-product. Freezing it overnight prompts its precipitation which can be filtered off before the work-up stage of the reaction. The strong smell of urea was used as an indicator of its presence throughout the reaction.

It appears the Boc protecting group had been removed during the synthesis of compound **15** as the expected peak around δ 3.5 on the ^1H spectra correlating with the group's methyl substituents is missing. Usually, this removal is facilitated by the use of a strong acid such as trifluoroacetic acid. The workup section of the synthesis utilised 4% hydrochloric acid which would seem too weak to remove the protecting group but there was no other acid use in the synthesis.

Compound **6** was chosen because of the presence of chlorine, with hopes of this compound being soluble in water but also antimicrobially potent due to the halogen. The ^1H NMR of **15** (see table 11) showed that there was a mixture of starting chalcone (see appendix 1.15) and compound **15**. However, starting reagent is evident on the ^1H spectrum of **6** (see appendix 1.6) so this error was carried forward.

It was difficult to clean compound **15** during column chromatography. Using a silica column still produced a very sticky compound. Its complete synthesis became secondary in a bid to continue synthesising chalcones with an increased premise of biological activity.



Scheme 7: **DCC/HOBt amino acid-chalcone coupling mechanism**

Image source: author's own

5. Conclusion

The aim of this project was to synthesise a series of chalcones from a variety of substituted benzaldehydes and acetophenones. The prospect of a biologically active chalcone with a carbon-sulphur bond prompted the use of Lawesson's Reagent in a bid to convert these chalcones to their thio-equivalents. To an extent, this was achieved upon analysis of the obtained NMR and GCMS data. The conformation of the synthesised chalcones has been confirmed as trans (E) from derived NOESY and DOSY data.

The lack of activity from the synthesised chalcones could be caused by a multitude of reasons including the substituents made to their structures and the methodology selected to test their activity.

The activity seen by thiochalcones **11** against *S. epidermidis* and **14** against *E.coli*, *P. aeruginosa* and *S. epidermidis* could be attributed to the eliminated oxa-thio-phosphorane molecule, an inevitable by-product of the use of Lawesson's Reagent. Compound **12**, shown to have a higher ratio of the desired product did not show any activity against the bacteria used. However, the compounds could still be biologically active but towards other organisms such as viruses, protozoa and fungi (Zhuang et al, 2017).

It has been repeatedly reported that modifications made to the chalcone structure enhances its biological activity. The chalcones synthesised during this study bore a variety of substituents including methoxy, hydroxyl and halogenic groups. The positioning of these groups has been linked to the biological activity and lack thereof in chalcones, as is reflected by the results of this study.

The data from this project could contribute to the ever-expanding field of chalcone synthesis and their biological activity. It could also add to what is known of their structure-activity relationships, especially the importance of substituents and their positioning on the aromatic rings.

6. Future Works

A bid to separate and isolate the products within compounds **11-14** could be undertaken to better understand the dynamics of a Lawesson's Reagent-mediated thionation and to further understand what was displaying antimicrobial activity during this project. To expand on the biological activity of the synthesised chalcones, their cytotoxicity could be determined by running bio-assays on mammalian cells both normal and cancerous, possibly to reveal any anti-tumour behaviour.

Reports of synergy between chalcones and antibiotics have been made (Belofsky et al, 2004). The possibility of this could be determined using the synthesised compounds, testing their efficacy with a variety of antibiotics and seeing whether it is worth further investigating in the use of chalcones in medicine as synergistic agents.

Also, to understand the exact mode of action chalcones use to act as antimicrobial agents, a modelling/docking study in the active sites of key enzymes could be carried out. This would indicate whether enzymatic interaction is a possible cause for a chalcone's antimicrobial activity.

The purification of compound **15** should be undertaken. Solubility tests should also be conducted to ascertain whether the addition of an amino acid improves the solubility of a chalcone and whether it has an effect on its antimicrobial activity, if it displays any.

7. References

- Ahmad, M. R., Sastry, V. G., Bano, N., & Anwar, S. (2016). Synthesis of novel chalcone derivatives by conventional and microwave irradiation methods and their pharmacological activities. *Arabian Journal of Chemistry*, 9, S931-S935.
- Ahmed, N., Konduru, N. K., & Owais, M. (2015). Design, synthesis and antimicrobial activities of novel ferrocenyl and organic chalcone based sulfones and bis-sulfones. *Arabian Journal of Chemistry*.
- Aínsa, J. A. (2000). Practical Streptomyces Genetics. T. Kieser, MJ Bibb, MJ Buttner, KF Chater, DA Hopwood. *International Microbiology*, 3(4), 260-261.
- Aksöz, B. E., & Ertan, R. (2011). Chemical and structural properties of chalcones I. *FABAD J Pharm Sci*, 36, 223-242.
- Aldred, K. J., Kerns, R. J., & Osheroff, N. (2014). Mechanism of quinolone action and resistance. *Biochemistry*, 53(10), 1565-1574.
- Amábile-Cuevas, C. F. (2010). Global perspectives of antibiotic resistance. In Antimicrobial resistance in developing countries (pp. 3-13). Springer, New York, NY.
- Arber, W. (2014). Horizontal gene transfer among bacteria and its role in biological evolution. *Life*, 4(2), 217-224.
- Ávila, H. P., Smânia, E. D. F. A., Delle Monache, F., & Júnior, A. S. (2008). Structure–activity relationship of antibacterial chalcones. *Bioorganic & Medicinal Chemistry*, 16(22), 9790-9794.
- Baba, H., Azubike, O. and Usifoh, C. (2013). Synthesis and antimicrobial evaluation of some chalcones. *Biological Research and Pharmaceutical Research*, 1(2), pp.22-29.
- Batovska, D. I., & Todorova, I. T. (2010). Trends in utilization of the pharmacological potential of chalcones. *Current Clinical Pharmacology*, 5(1), 1-29.
- BBC News (2012). *Two babies dead after infection at Belfast hospital*. [online] Available at: <http://www.bbc.co.uk/news/mobile/uk-northern-ireland-16640250> [Accessed 20 Oct. 2018].

BBC News. (2018). *Bacteria disrupts breast milk service*. [online] Available at: <https://www.bbc.co.uk/news/uk-northern-ireland-45566718> [Accessed 20 Oct. 2018].

Belofsky, G., Percivill, D., Lewis, K., Tegos, G. P., & Ekart, J. (2004). Phenolic Metabolites of *Dalea versicolor* that Enhance Antibiotic Activity against Model Pathogenic Bacteria. *Journal of natural products*, 67(3), 481-484.

Reprinted by permission from Springer Nature: Nature, Nature Reviews Microbiology. Brown, L., Wolf, J. M., Prados-Rosales, R., & Casadevall, A. (2015). Through the wall: extracellular vesicles in Gram-positive bacteria, mycobacteria and fungi. *Nature Reviews Microbiology*, 13(10), 620.

Brown, S. P., Cornforth, D. M., & Mideo, N. (2012). Evolution of virulence in opportunistic pathogens: generalism, plasticity, and control. *Trends in microbiology*, 20(7), 336-342.

Brunning, A. (2014). *An Overview of Antibiotics | Longitude Prize*. [online] Longitudeprize.org. Available at: <https://longitudeprize.org/blog-post/overview-antibiotics> [Accessed 20 Oct. 2018].

Burger, R. (2012). EHEC O104: H4 in Germany 2011: Large outbreak of bloody diarrhea and haemolytic uraemic syndrome by shiga toxin-producing *E. coli* via contaminated food.

Burmaoglu, S., Algul, O., Gobek, A., Aktas Anil, D., Ulger, M., Erturk, B. G. & Aslan, G. (2017). Design of potent fluoro-substituted chalcones as antimicrobial agents. *Journal of enzyme inhibition and medicinal chemistry*, 32(1), 490-495.

Cava, M. P., & Levinson, M. I. (1985). Thionation reactions of Lawesson's reagents. *Tetrahedron*, 41(22), 5061-5087.

Colmer-Hamood, J. A., Dzvova, N., Kruczek, C., & Hamood, A. N. (2016). In vitro analysis of *Pseudomonas aeruginosa* virulence using conditions that mimic the environment at specific infection sites. *Progress in molecular biology and translational science* (Vol. 142, pp. 151-191). Academic Press.

Claridge T.D.W. (2009). High-resolution NMR techniques in organic chemistry. *Tetrahedron Organic Chemistry*. Amsterdam: Elsevier; 2009. 383, 279-280.

- D'Costa, V. M., King, C. E., Kalan, L., Morar, M., Sung, W. W., Schwarz, C., ... & Golding, G. B. (2011). Antibiotic resistance is ancient. *Nature*, 477(7365), 457.
- Dao, T. T. H., Linthorst, H. J. M., & Verpoorte, R. (2011). Chalcone synthase and its functions in plant resistance. *Phytochemistry Reviews*, 10(3), 397.
- Delcour, A. H. (2009). Outer membrane permeability and antibiotic resistance. *Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics*, 1794(5), 808-816.
- Díaz-Tielas, C., Graña, E., Reigosa, M. J., & Sánchez-Moreiras, A. M. (2016). Biological activities and novel applications of chalcones. *Planta daninha*, 34(3), 607-616.
- Dunbar, K. L., Scharf, D. H., Litomska, A., & Hertweck, C. (2017). Enzymatic carbon–sulfur bond formation in natural product biosynthesis. *Chemical reviews*, 117(8), 5521-5577.
- European Commission (2005). Ban on antibiotics as growth promoters in animal feed enters into effect. Available from http://europa.eu/rapid/press-release_IP-05-1687_en.htm [Last Accessed 6th November 2018]
- Frith, J. (2013). Arsenic-the. *Journal of Military and Veterans Health*, 21(4), 11.
- Grzybowski et al - A. Grzybowski & K. Pietrzak (2013). Albert Szent-Györgyi (1893-1986): The scientist who discovered vitamin C. *Clinics in Dermatology*. 31 (3), 327-331.
- Goodsell, D. (2002). PDB101: Molecule of the Month: Penicillin-binding Proteins. Available from <https://pdb101.rcsb.org/motm/29> [Last Accessed 26th October 2018]
- Halliday, J., McKeveney, D., Muldoon, C., Rajaratnam, P., & Meutermans, W. (2006). Targeting the forgotten transglycosylases. *Biochemical pharmacology*, 71(7), 957-967.
- Higueta, N. I. A., & Huycke, M. M. (2014). Enterococcal disease, epidemiology, and implications for treatment.
- Infectious Diseases Society of America. (2010). The 10x'20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. *Clinical Infectious Diseases*, 50(8), 1081-1083.

- Iwashina, T. (2000). The structure and distribution of the flavonoids in plants. *Journal of Plant Research*, 113(3), 287-299.
- Iwata, S., Nishino, T., Inoue, H., NAGATA, N., SATOMI, Y., NISHINO, H., & SHIBATA, S. (1997). Antitumorigenic activities of chalcones (II). Photoisomerization of chalcones and the correlation with their biological activities. *Biological and Pharmaceutical Bulletin*, 20(12), 1266-1270.
- Higdon, J. (2016). Flavonoids. Available from: <http://lpi.oregonstate.edu/mic/dietary-factors/phytochemicals/flavonoids> [Last Accessed 8th October 2018]
- Karmali, M. A., Gannon, V., & Sargeant, J. M. (2010). Verocytotoxin-producing *Escherichia coli* (VTEC). *Veterinary microbiology*, 140(3-4), 360-370.
- Karthikeyan, M. S., Holla, B. S., & Kumari, N. S. (2007). Synthesis and antimicrobial studies on novel chloro-fluorine containing hydroxy pyrazolines. *European journal of medicinal chemistry*, 42(1), 30-36.
- Khadar-Yazdan, S., Vidya-Sagar, D., & Basha-Shaik, A. (2015). Chemical and Biological Potentials of Chalcones: A Review. *Organic & Medicinal Chemistry International Journal*, 1(1), 1-8.
- Koshland, D. E. (1958). Application of a Theory of Enzyme Specificity to Protein Synthesis. *Proceedings of the National Academy of Sciences of the United States of America*, 44(2), 98–104.
- Krstić, N. M., Bjelaković, M. S., Dabović, M. M., & Pavlović, V. D. (2010). Thionation of Some α , β -unsaturated steroidal ketones. *Molecules*, 15(5), 3462-3477.
- Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. *Lancet Infect Dis* 2010;10:597–602.
- Longitudeprize.org. (2018). *Challenge | Longitude Prize*. [online] Available at: <https://longitudeprize.org/challenge> [Accessed 20 Oct. 2018].
- Micklefield, J. (2004). Daptomycin structure and mechanism of action revealed. *Chemistry & biology*, 11(7), 887-888.
- Mohamed, N. R., Elmegeed, G. A., & Younis, M. (2003). Studies on organophosphorus compounds VII1, 2: transformation of steroidal ketones with

- Lawesson's Reagent into thioxo and heterofused steroids. Results of antimicrobial and antifungal activity. *Phosphorus, Sulfur, and Silicon*, 178(9), 2003-2017.
- Moon, J. H., Park, J. H., & Lee, J. Y. (2011). Antibacterial action of polyphosphate on *Porphyromonas gingivalis*. *Antimicrobial agents and chemotherapy*, 55(2), 806-812.
- Morrissey, J. H., Choi, S. H., & Smith, S. A. (2012). Polyphosphate: an ancient molecule that links platelets, coagulation and inflammation. *Blood*.
- Nagarajan, R. (1991). Antibacterial activities and modes of action of vancomycin and related glycopeptides. *Antimicrobial agents and chemotherapy*, 35(4), 605.
- Namvar, A. E., Bastarahang, S., Abbasi, N., Ghehi, G. S., Farhadbakhtiaran, S., Arezi, P. & Chermahin, S. G. (2014). Clinical characteristics of *Staphylococcus epidermidis*: a systematic review. *GMS hygiene and infection control*, 9(3).
- National Health Service (NHS) (2017). *Atypical haemolytic uraemic syndrome (aHUS) (all ages)*.
- Nielsen, S. F., Boesen, T., Larsen, M., Schønning, K., & Kromann, H. (2004). Antibacterial chalcones—bioisosteric replacement of the 4'-hydroxy group. *Bioorganic & medicinal chemistry*, 12(11), 3047-3054.
- NNIS - National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. *National Nosocomial Infections Surveillance System. Am J Infect Control. 2004 Dec; 32(8):470-85*.
- Ophardt, C. (2003). *Mechanism of Enzyme Action*. [online] Chemistry.elmhurst.edu. Available at: <http://chemistry.elmhurst.edu/vchembook/571lockkey.html> [Accessed 20 Oct. 2018].
- Orlikova, B., Tasdemir, D., Golais, F., Dicato, M., & Diederich, M. (2011). Dietary chalcones with chemopreventive and chemotherapeutic potential. *Genes & nutrition*, 6(2), 125.
- Osório, T. M., Delle Monache, F., Chiaradia, L. D., Mascarello, A., Stumpf, T. R., Zanetti, C. R. & Garcia, L. A. T. (2012). Antibacterial activity of chalcones,

- hydrazones and oxadiazoles against methicillin-resistant *Staphylococcus aureus*. *Bioorganic & medicinal chemistry letters*, 22(1), 225-230.
- Ostash, B., & Walker, S. (2010). Moenomycin family antibiotics: chemical synthesis, biosynthesis, and biological activity. *Natural product reports*, 27(11), 1594-1617.
- Otto, M. (2009). *Staphylococcus epidermidis*—the 'accidental' pathogen. *Nature Reviews Microbiology*, 7(8), 555.
- Pérez, A., de Saá, D., Ballesteros, A., Serrano, J. L., Sierra, T., & Romero, P. (2013). NMR Spectroscopic Study of the Self-Aggregation of 3-Hexen-1, 5-diyne Derivatives. *Chemistry—A European Journal*, 19(31), 10271-10279.
- Pirri, G., Giuliani, A., Nicoletto, S. F., Pizzuto, L., & Rinaldi, A. C. (2009). Lipopeptides as anti-infectives: a practical perspective. *Central European journal of biology*, 4(3), 258-273.
- Public Health England (2015). Health matters: antimicrobial resistance.
- Public Health England (2016). Antimicrobial Resistance Empirical and Statistical Evidence-Base: A report from the Department of Health Antimicrobial Resistance Strategy Analytical Working Group.
- Reddy, P. V. G., Kiran, Y. B. R., Reddy, C. S., & Reddy, C. D. (2004). Synthesis and Antimicrobial Activity of Novel Phosphorus Heterocycles with Exocyclic P–C Link. *Chemical and pharmaceutical bulletin*, 52(3), 307-310.
- Reller, L. B., Weinstein, M., Jorgensen, J. H., & Ferraro, M. J. (2009). Antimicrobial susceptibility testing: a review of general principles and contemporary practices. *Clinical infectious diseases*, 49(11), 1749-1755.
- Review on Antimicrobial Resistance (AMR). (2016). Tackling drug-resistant infections globally: final report and recommendations. Review on Antimicrobial Resistance.
- Rietschel, E. T., Kirikae, T., Schade, F. U., Mamat, U., Schmidt, G., Loppnow, H. & Di Padova, F. (1994). Bacterial endotoxin: molecular relationships of structure to activity and function. *The FASEB Journal*, 8(2), 217-225.
- Rollins, D. and Joseph, S. (2000). *BSCI 424 Pathogenic Microbiology -- Mechanisms of Antibiotic Action and Resistance*. [online] Life.umd.edu. Available at:

<https://www.life.umd.edu/classroom/bsci424/Chemotherapy/AntibioticMechanisms.htm> [Accessed 20 Oct. 2018].

Sabtu, N., Enoch, D. A., & Brown, N. M. (2015). Antibiotic resistance: what, why, where, when and how? *British medical bulletin*, 116(1).

Salton MRJ, Kim KS. Structure. In: Baron S, editor. *Medical Microbiology*. 4th edition. Galveston (TX): University of Texas Medical Branch at Galveston; 1996. Chapter 2.

Shah, J. B. (2011). The history of wound care. *The Journal of the American College of Certified Wound Specialists*, 3(3), 65-66.

Sivakumar, P. M., Priya, S., & Doble, M. (2009). Synthesis, biological evaluation, mechanism of action and quantitative structure–activity relationship studies of chalcones as antibacterial agents. *Chemical biology & drug design*, 73(4), 403-415.

Silva, W. A., Andrade, C. K. Z., Napolitano, H. B., Vencato, I., Lariucci, C., Castro, M., & Camargo, A. J. (2013). Biological and structure-activity evaluation of chalcone derivatives against bacteria and fungi. *Journal of the Brazilian Chemical Society*, 24(1), 133-144.

Sigma-Aldrich (2006) Inhibition of Protein Synthesis by Antibiotics. *BioFiles*, 1 (4), 17.

Springob, K., Nakajima, J. I., Yamazaki, M., & Saito, K. (2003). Recent advances in the biosynthesis and accumulation of anthocyanins. *Natural product reports*, 20(3), 288-303.

Stieglmeier, M., Wirth, R., Kminek, G., & Moissl-Eichinger, C. (2009). Cultivation of anaerobic and facultatively anaerobic bacteria from spacecraft-associated clean rooms. *Applied and environmental microbiology*, 75(11), 3484-3491.

Tipper, D. J. (1985). Mode of action of β -lactam antibiotics. *Pharmacology & therapeutics*, 27(1), 1-35.

Tran, T. D., Nguyen, T. T. N., Do, T. H., Huynh, T. N. P., Tran, C. D., & Thai, K. M. (2012). Synthesis and antibacterial activity of some heterocyclic chalcone analogues alone and in combination with antibiotics. *Molecules*, 17(6), 6684-6696.

Tzeng, Y. L., Datta, A., Kolli, V. K., Carlson, R. W., & Stephens, D. S. (2002). Endotoxin of *Neisseria meningitidis* composed only of intact lipid A: inactivation of

the meningococcal 3-deoxy-D-manno-octulosonic acid transferase. *Journal of bacteriology*, 184(9), 2379-2388.

Vanangamudi, G., Subramanian, M., & Thirunarayanan, G. (2017). Synthesis, spectral linearity, antimicrobial, antioxidant and insect antifeedant activities of some 2, 5-dimethyl-3-thienyl chalcones. *Arabian Journal of Chemistry*, 10, S1254-S1266.

Vollmer, W., Blanot, D., & De Pedro, M. A. (2008). Peptidoglycan structure and architecture. *FEMS microbiology reviews*, 32(2), 149-167.

Walzer, P. D., Kim, C. K., Foy, J. M., Linke, M. J., & Cushion, M. T. (1988). Inhibitors of folic acid synthesis in the treatment of experimental *Pneumocystis carinii* pneumonia. *Antimicrobial agents and chemotherapy*, 32(1), 96-103.

Wang, X., & Quinn, P. J. (2010). Endotoxins: lipopolysaccharides of gram-negative bacteria. In *Endotoxins: Structure, Function and Recognition* (pp. 3-25). Springer, Dordrecht.

Wu, W., Jin, Y., Bai, F., & Jin, S. (2015). *Pseudomonas aeruginosa*. In *Molecular Medical Microbiology* (Second Edition) (pp. 753-767).


Yu, D., Xu, F., Zeng, J., & Zhan, J. (2012). Type III polyketide synthases in natural product biosynthesis. *IUBMB life*, 64(4), 285-295.

Zhuang, C., Zhang, W., Sheng, C., Zhang, W., Xing, C., & Miao, Z. (2017). Chalcone: a privileged structure in medicinal chemistry. *Chemical reviews*, 117(12), 7762-7810.

Appendix

1. Compound 1

1.1 ¹H NMR



Current Data Parameters
NAME GDAPC
EXPNO 10
PROCNO 1

F2 - Acquisition Parameters
Date_ 20180115
Time 16:35 h
INSTRUM KJ_Avance_111_400
PROBHD Z108818_0245 (1
PULPROG zg30
TD 65536
SOLVENT DMF0
NS 16
DS 2
SWH 6228.685 Hz
FIDRES 0.250967 Hz
AQ 3.9845689 sec
RG 228
DX 60.800 usec
DF 16.30 usec
TE 296.0 K
D1 1.00000000 sec
TDC 1
SFO1 399.7304685 MHz
NUC1 1H
P1 12.75 usec
PIW1 16.47899928 W

F2 - Processing parameters
SI 65536
SF 399.7300000 MHz
WDW EM
SSE 0
LB 0.20 Hz
GB 0
PC 1.00


1.1.1 Expansion of aromatic region of ^1H




```
Current Data Parameters
NAME          CDAPC
EXPNO         10
PROCNO        1

F2 - Acquisition Parameters
Date_         20160113
Time          16.35 h
INSTRUM       XLAmazc_400
PROBHD        z108618_0245 f1
PULPROG       zg30
TD            65536
SOLVENT       DMSO
NS            16
DS            2
SWH            8223.688 Hz
FIDRES        0.250963 Hz
AQ            3.9845869 sec
RG            228
RW            60.800 usec
DE            16.30 usec
TE            296.0 K
D1            1.0000000 sec
TD0           1
SFO1          399.7324885 MHz
NUC1           1H
FL            12.75 usec
PLW1          18.47889928 W

F2 - Processing parameters
SI            65536
SF            399.7300000 MHz
WDW           EM
SSB           0
LB            0.20 Hz
GB            0
PC            1.00
```



1.1.2 ¹³C NMR





```

Current Data Parameters
NAME          CDMPC
EXPNO         20
PROCNO        1

F2 - Acquisition Parameters
Date_         20180111
Time          18.49 s
INSTRUM       XJ_Avance_III_400
PROBHD        Z1C8618 0245 (
PULPROG       zgpg30
TD            65536
SOLVENT       CDCl3
NS            256
DS            4
SWH           24038.461 Hz
FIDRES        0.733596 Hz
AQ            1.5631288 sec
RG            2050
DW            20.800 usec
DE           22.74 usec
TE           296.0 K
D1            2.0000000 sec
D11           0.0300000 sec
DEC           1
SFO1          100.6222401 MHz
NUC1           13C
P1            9.20 usec
PLW1          49.5000000 W
SFO2          399.7215389 MHz
NUC2           1H
CPDPRG12     wa.tz*6
EPCED2       30.00 usec
PLW2          16.47699928 W
PLW12         0.35068901 W
PLW13         0.26785901 W

F2 - Processing parameters
SI            65536
SF            100.5121884 MHz
WDW           EM
SSB           0
LB            1.00 Hz
GB            0
PC            1.40
    
```

1.1.3 ^1H - ^1H COSY



```

Current Data Parameters
NAME      S0400
EXNO     12
PROCNO   1


F2 - Acquisition Parameters
Date      20180115
Time      16.31 h
INSTRUM   XI_AvanceIII_400
PROBHD    Z10669_0240_1
PULPROG   zgpg30
SOLVENT   DMSO
NS         2
DS         8
SWH        4273.624 Hz
FIDRES     4.173347 Hz
AQ         0.2396163 sec
RG         2530
SQ         117.000 usec
RF         6.50 usec
CP         298.14
DD         0.0000300 sec
D1         1.98207703 sec
D12        0.0000400 sec
F16        0.0020000 sec
RG         0.0002000 sec
CDEPR     1
SFO1      399.733082 MHz
NUC1       1H
F1         12.75 usec
P1A1      15.47699928 w
GPM1[1]   SINE,1.00
GPA1      16.00 %
GPM1[2]   SINE,1.00
GPA2      12.00 %
GPM1[3]   SINE,1.00
GPA3      40.00 %
E16       1000.00 usec

F1 - Acquisition parameters
TD         128
SFO1      399.733082 MHz
FIDRES     66.73306 Hz
SQ         10.691 ppw
RG         0

F2 - Processing parameters
SI         1224
SF         399.7330820 MHz
WDW        S
SSB        0
LB         0 Hz
GB         0
PC         1.40

F1 - Processing parameters
SI         1224
SF         399.7330820 MHz
WDW        S
SSB        0
LB         0 Hz
GB         0
PC         0
    
```

1.1.4 ^1H - ^{13}C HMBC



```

Current Data Parameters
NAME          GDAPC
EXPNO        14
PROCNO       1



F2 - Acquisition Parameters
Date_        20180620
Time         20:52 h
INSTRUM      KU_Avance_III_400
PROBHD       2108618_0245 [
PULPROG      hmcetgp13hd
TD           4096
SOLVENT      CDCl3
NS           16
DS           16
SWH          3996.250 Hz
FIDRES       1.907349 Hz
AQ           0.5242880 sec
RG           2050
DW           128.000 usec
DE           6.50 usec
TE           298.5 K
CNST6        120.0000000
CNST7        165.0000000
CNST13       10.0000000
D0           0.0000300 sec
D1           1.36892796 sec
D6           0.05000000 sec
D16          0.00020000 sec
INO          1
TD0AV        1
SFO1         399.7322566 MHz
NUC1         1H
P1           12.75 usec
P2           25.50 usec
PLW1         16.47699928 W
SFO2         100.5292241 MHz
NDC2         13C
P3           5.20 usec
P24          2000.00 usec
PLW2         49.50000000 W
SPNAM(7)     Crp50comp.4
SFOAL7       0.500
SPOFFS7      0 Hz
SPN7         6.40140009 W
GPNAM(1)     SINE.100
GP21         80.00 %
GPNAM(3)     SINE.100
GP23         14.00 %
GPNAM(4)     SINE.100
GP24         -8.00 %
GPNAM(5)     SINE.100
GP25         4.00 %
GPNAM(6)     SINE.100
GP26         -2.00 %
P16          1000.00 usec

F1 - Acquisition parameters
TD           128
SFO1         100.5222 MHz
FIDRES       348.772308 Hz
SW           222.055 ppm
P16MODE      Echo-Antiecho

F2 - Processing parameters
SI           2048
SF           399.7300000 MHz
WDW          SINE
SSB          2
LB           0 Hz
GB           0
PC           1.40

F1 - Processing parameters
SI           1024
MC2          echo-antiecho
SF           100.5121854 MHz
WDW          SINE
SSB          2
LB           0 Hz
GB           0
    
```


1.1.5 ¹H-¹H NOESY



```

Current Data Parameters
NAME      CDAPC
EXPER    13
PROCNO    1


F2 - Acquisition Parameters
Date      20180620
Time      22.27
INSTRUM   KL Avance 400
PROBHD    BBOBBO1H_0275 (
PULPROG   zgpg30
TD        65536
SOLVENT   CDCl3
NS         8
DS         4
SWH        3956.250 Hz
FIDRES     3.874697 Hz
AQ         0.2621440 sec
RG         287
LW         128.000 usec
DE         14.08 usec
TE         297.2 K
D0         0.0021177 sec
d1         1.8835999 sec
d8         0.0000001 sec
d15        0.0022000 sec
INC        0.00225600 sec
DELEV      .
SFO1       399.7322566 MHz
NUC1       1
P1         12.75 usec
P2         25.50 usec
PL1        16.47693928 W
GENAM1     SINE_130
CP21       40.00 %
P15        1500.00 usec

F1 - Acquisition parameters
TD         65536
SFO1       399.7323 MHz
FIDRES     39.517579 Hz
SW         3.772 ppr
EXMODE     States-TPPI

F2 - Processing parameters
SI         1024
SF         399.7300000 MHz
WDW        QSIGN2
SSB         2
LB          0 Hz
GB          0
PC          1.00

F1 - Processing parameters
SI         1024
SF         399.7300000 MHz
WDW        QSIGN2
SSB         2
LB          0 Hz
GB          0
    
```

1.1.6 ¹³C NMR



```


Current Data Parameters
NAME          CDAPC
EXPNO        20
PROCNO       1

F2 - Acquisition Parameters
Date_        20181011
Time         19.49 s
INSTRUM      KU Avance 401 400
PROBHD      Z1086 W 5Q45 4
PULPROG      zgpg30
TD           65536
SOLVENT1     CDCl3
NS           256
DS           4
AQ           24038.761 Hz
FIDRES       0.753590 Hz
AQ           1.3631488 sec
RG           2050
DW           20.800 usec
DE           22.74 usec
TE           296.6 K
T1           2.0000000 sec
d11          0.0300000 sec
TD0          1
SFO1         100.5222401 MHz
NUC1         13C
P1           9.20 usec
PTW1         43.5000000 W
SFO2         399.7315989 MHz
NUC2         1H
SFOFAC12     w11216
PCPD2        30.00 usec
PLW2         16.4769928 W
PLW12        0.33068001 W
PLW13        0.26788001 W

F2 - Processing parameters
SI           65536
SF           100.5721864 MHz
WDW          EM
SSB          0
LB           1.00 Hz
GB           0
PC           1.40
    
```

1.2 Compound 2

1.2.1 ¹H NMR




Current Data Parameters
NAME GDIMS
EXPNO 20
PROCNO 1

F2 - Acquisition Parameters
Date_ 20180622
Time 20.03 h
INSTRUM KU_Avance_DJI_400
PROBHD Z108618_0245 (1
PULPROG zg30
TD 65536
SOLVENT DMSO
NS 16
DS 2
SWH 8223.685 Hz
FIDRES 0.250967 Hz
AQ 3.9845889 sec
RG 228
DM 60.800 usec
DE 18.30 usec
TE 296.1 K
D1 1.0000000 sec
TD0 -
SFO1 399.7324685 MHz
NUC1 1H
P1 12.75 usec
PL1 16.47693928 W

F2 - Processing parameters
SI 65536
SF 399.7300000 MHz
WDW EM
SSB 0
LB 0.20 Hz
GB 0
PC 1.00

1.2.2 Expansion of aromatic region of ^1H





Current Data Parameters
NAME GDTME
EXPNO 20
PROCNO 1

F2 - Acquisition Parameters
Date_ 20180622
Time 20.05 h
INSTRUM XU_Avance_III_400
PROBHD Z108619_0245 ()
PULPROG zg30
TD 65536
SOLVENT DMSO
NS 16
DS 2
SWH 8223.685 Hz
FIDRES 0.230967 Hz
AQ 3.9845889 sec
RG 228
DA 60.800 usec
DE 16.30 usec
TE 296.1 K
D1 1.0000000 sec
TDO -
SFO1 399.7324685 MHz
NUC1 1H
P1 12.75 usec
PLW1 16.47699928 W

F2 - Processing parameters
SI 65536
SF 399.7300000 MHz
WDW EM
SSB 0
CB 0.20 Hz
GB 0
PC 1.00

1.2.3 ^1H - ^1H COSY



```

Current Data Parameters
NAME      G31MB
EXPNO    22
PROCNO    1



F2 - Acquisition Parameters
Date_     20180822
Time      20.48 h
INSTRUM   XU_AvanceIII_400
PROBHD    ZG062H_0245_1
PULPROG   zgpg30
TD        2528
SOLVENT   DMSO
NS         2
DS         8
SWH        2463.654 Hz
FIDRES     2.405395 Hz
AQ         0.4137440 sec
RG         2520
CW         203.500 usec
PC         6.50 usec
CO         235.5 Hz
D0         0.0000300 sec
D1         1.77584800 sec
D12        0.0000400 sec
T1R        0.0020000 sec
RG         0.0004000 sec
DETV       1
SFO1       399.7323211 MHz
NUC1        1H
P1         12.75 usec
P1M1       16.67699928 u
GAMMA1[1] 513.100
CP21       16.00 %
CPHASE2[1] SINE,100
GP22       12.00 %
GPHASE[2]  SINE,100
GAMMA2[2] 513.100 %
GAMMA3[3]  40.00 %
PL2        1000.00 usec

F1 - Acquisition parameters
TD        128
SFO1       399.7323 MHz
FIDRES     38.498222 Hz
SW         8.162 ppm
RG         512


F2 - Processing parameters
SI         128
SF         399.7300000 MHz
WDW        5 Hz
SSB        0
LB         0 Hz
GB         0
PC         1.40

F1 - Processing parameters
SI         128
MC2        512
SF         399.7300000 MHz
WDW        5 Hz
SSB        0
LB         0 Hz
GB         0
  
```

1.2.4 Expansion of COSY



1.2.5 Expansion of COSY



```

Current Data Parameters
NAME      QCTM3
EXPNO     22
PROCNO    1


F2 - Acquisition Parameters
Date_     20180622
Time     20:48:11
INSTRUM   XC Avance III 400
PROBHD    Z13BPA 0.215 (
PULPROG   zgpg30
TD         65536
SOLVENT   DMSO
NS         2
DS         4
SWH        2483.697 Hz
FIDRES     2.760328 Hz
AQ         0.4157440 sec
RG         662.9
AQ         203.000 usec
DE         8.33 usec
TE         300.2 K
D0         0.0000000 sec
D1         1.7599999 sec
D13       0.0000000 sec
D16       0.0000000 sec
D19       0.0000000 sec
TD0       1
SFO1      399.732323 MHz
NUC1       13
P1         12.79 usec
PL1       18.47599928 W
SFO11     518.130
SFO2      18.00 MHz
SFO12     518.130
SFO3      12.00 MHz
SFO13     518.130
SFO4      49.00 MHz
P1a       1000.00 usec

F1 - Acquisition parameters
TD         65536
SFO1      399.7323 MHz
F1RES     38.485222 Hz
SA         6.142 ppm
SFO1a     518.130

F2 - Processing parameters
SI         1324
SF         399.7300000 MHz
WDW        SINE
SSB        0
LB         0.30 Hz
GB         0
PC         1.40

F1 - Processing parameters
SI         1024
SF         518.1300000 MHz
WDW        SINE
SSB        0
LB         0.30 Hz
GB         0
  
```

1.2.6 ^1H - ^{13}C HMBC



```

Current Data Parameters
NAME          GD1MB
EXPNO         25
PROCNO        1


F2 - Acquisition Parameters
Date_         20180622
Time          22:52 h
INSTRUM       KU_Avance_III_400
PROBHD        1108618_0245 (
PULPROG       hbbeetop13nd
TD            4096
SOLVENT       DMSO
NS            16
DS            16
SWH           2463.054 Hz
FIDRES        1.202663 Hz
AQ            0.8314880 sec
RG            2050
SW            203.000 usec
DE            6.50 usec
TE            296.0 K
CNS16         120.0000000
CNS17         165.0000000
CNS113        10.0000000
DQ            0.00000300 sec
D1            1.06172800 sec
D6            0.00000000 sec
D16           0.00020000 sec
INO           0.00002240 sec
TD0AV         1
SF01          399.7323231 MHz
NUC1           1H
P1            12.75 usec
P2            25.50 usec
P1M1          16.47699928 W
SF02          100.5222241 MHz
NUC2           13C
P3            9.20 usec
P24           2000.00 usec
P1M2          49.50000000 W
GPNAM(7)      Csp3comp_4
SPCAL7        0.500
SPFFS7        0 Hz
SF07          6.40140009 W
GPNAM(1)      SINE,100
GPE1          80.00 %
GPNAM(3)      SINE,100
GPE3          14.00 %
GPNAM(4)      SINE,100
GPE4          -8.00 %
GPNAM(5)      SINE,100
GPE5          -4.00 %
GPNAM(6)      SINE,100
GPE6          -2.00 %
P16           1000.00 usec

F1 - Acquisition parameters
TD            128
SF01          100.5222 MHz
FIDRES        346.772358 Hz
SW            222.055 ppm
FnMODE        Echo-Antiecho

F2 - Processing parameters
SI            2048
SF            399.7300000 MHz
WDW           SINE
SSB           2
LB            0 Hz
GB            0
PC            1.40

F1 - Processing parameters
SI            1024
MC2           echo-antiecho
SF            100.5121804 MHz
WDW           SINE
SSB           2
LB            0 Hz
GB            0
    
```


1.2.7 ^1H - ^1H NOESY



```

Current Data Parameters
NAME      GRDMR
EXNO     25
PROCNO   1


F2 - Acquisition Parameters
Date_    20180622
Time     21.23 h
INSTRUM  RL_Avance_1
PROBHD   z1c3x18 5mm 1
PULPROG  roesygpph
TD        65536
SOLVENT  DMSO
NS        8
DS        4
SWH       2463.354 Hz
FIDRES    2.405326 Hz
AQ        0.4157440 sec
RG        128
Ww        203.000 usec
TE        30.26 usec
TD        296.0 K
SFO       300.628777 sec
SI        33793.02 sec
DS        3.30000001 usec
d16       3.30000000 sec
AQ        0.50000000 sec
TD0       1
TAcq      399.732323 MHz
SFO1      11
NUC1      12.75 usec
F2        25.00 usec
P141      8.47699928 W
SFO1      399.732323 MHz
GPRM[1]   STX7.00
GPR1      10.00 s
P15       1000.00 usec

F1 - Acquisition parameters
LD        256
SFO1      399.7323 MHz
FIDRES    19.242611 Hz
SK        6.162 ppm
PULPROG   stx7-TEPC

P2 - Processing parameters
SI        1024
SF        399.7300000 MHz
WDW       EM
SSB       2
LB        3 Hz
GB        0
PC        1.00

F1 - Processing parameters
SI        1024
MC2       stx7-TEPC
SF        399.7300000 MHz
WDW       EM
SSB       2
LB        3 Hz
GB        0
    
```

1.2.8 ¹³C NMR




Current Data Parameters
 NAME: CD19E
 EXPNO: 40
 PROCNO: 1

F2 - Acquisition Parameters
 Date_ Time: 20161015 22:18 h
 INSTRUM: KU Avance III 400
 PROBLD: 2108618 0245 f
 PULPROG: zgpg30
 ID: 6536
 SOLVENT: CDCl3
 NS: 2500
 DS: 4
 SWH: 24038.461 Hz
 FIDRES: 0.733596 Hz
 AQ: 1.3631488 sec
 RG: 2050
 DQ: 20.800 usec
 DE: 22.74 usec
 LL: 296.0 K
 E1: 2.0000000 sec
 D11: 0.2500000 sec
 TRO: 1
 SFO1: 100.6222401 MHz
 NUQ1: 130
 P1: 9.20 usec
 PLW1: 49.5000000 W
 SFO2: 399.7318389 MHz
 NUQ2: 14
 P2: 1.00 usec
 PLW2: 16.4769928 W
 PFM2: 0.5306800 W
 PLW3: 0.2678500 W

F2 - Processing parameters
 SI: 6536
 SF: 100.612884 MHz
 WDW: EM
 SSB: 0
 LB: 1.00 Hz
 GB: 0
 PC: 1.40

1.3 Compound 3

1.3.1 ¹H NMR





Current Data Parameters
NAME GUMDC
EXPNO 10
PROCNO 1

F2 - Acquisition Parameters
Date_ 20180128
Time 21.46 h
INSTRUM KU_Avance_III_400
PROBHD z1c6618_0248 /
PULPROG zg30
TD 65536
SOLVENT CDCl3
NS 16
DS 2
SWH 8229.685 Hz
FIDRES 0.250867 Hz
AQ 3.9845869 sec
RG 362
DW 60.809 usec
DE 18.30 usec
TE 296.1 K
D1 1.0000000 sec
DD 1
SFO1 399.7324685 MHz
NUC1 1H
P1 12.73 usec
PLN1 16.47699528 W

F2 - Processing parameters
SI 65536
SF 399.7320000 MHz
WDW EM
SSB 0
LB 0.20 Hz
GB 0
FC 1.00

1.3.2 ^1H - ^1H COSY



```

Current Data Parameters
NAME      50900
EXPNO    12
PROCNO    1

F2 - Acquisition Parameters
Date_     20180820
Time      14.04 h
INSTRUM   XI_Avance_III_400
PROBHD    zgpg30_0260_1
PULPROG   cosygprgf7
TD        65536
SOLVENT   CDCl3
NS         2
DS         8
SWH        2941.177 Hz
FIDRES    2.272243 Hz
AQ         0.3481600 sec
RG         2030
CW         170.000 usec
ZG         6.00 usec
RG2        295.5 k
DQ         0.0000300 sec
D1         1.84353004 sec
D12        0.0000400 sec
ZFL        0.0020000 sec
RG3        0.0000000 sec
CDEPR     1
SFO1      399.7318218 MHz
NUC1       1H
P1         12.75 usec
F1F1      15.47699978 Hz
GAMMA1(1) 543.100
GPR1       16.00 %
CPHASE1(1) SINE.100
GPR2       12.00 %
GAMMA1(2) 543.100
GPR3       40.00 %
R1G        1000.00 usec


F1 - Acquisition parameters
SI         128
SF         509.7318 MHz
FIDRES    40.850883 Hz
SW         7.358 ppm
RGPRDS    0

F2 - Processing parameters
SI         1024
SF         399.7350000 MHz
RGPRDS    5 Hz
SSE        0
LB         0 Hz
GB         0
PC         1.40

F1 - Processing parameters
SI         1024
SF         509.7350000 MHz
RGPRDS    5 Hz
SSE        0
LB         0 Hz
GB         0

```

1.3.3 ^1H - ^{13}C HMBC



```

Current Data Parameters
NAME          GDMC2
EXPNO        14
PROCNO       1



F2 - Acquisition Parameters
Date_         20180719
Time_        19:37 h
INSTRUM      KU_Avance_III_400
PROBHD       2108618_0245 (
PULPROG      hmbcetgp13nd
TD           4096
SOLVENT      CDCl3
NS           16
DS           16
SWH          3144.654 Hz
FIDRES       1.535476 Hz
AQ           0.4512440 sec
RG           2050
DW           159.000 usec
DE           6.50 usec
TE           296.1 K
CNS16        120.0000000
CNS17        165.0000000
CNS13        10.0000000
D0           0.0000000 sec
D1           1.24195194 sec
D6           0.05000000 sec
D16          0.00000000 sec
IN0          0.00002240 sec
TD0          1
TDAV        399.7319039 MHz
NUC1         1H
P1           12.75 usec
P2           25.50 usec
PLW1         16.47699928 W
SFO2         100.522241 MHz
NUC2         13C
P3           9.20 usec
P24          2000.00 usec
PLW2         49.50000000 W
SFO1         100.522241 MHz
SFO3         0 Hz
SFO4         0 Hz
SFO5         6.40140009 W
GENAM[1]     SINE.100
GE01         80.00 %
GENAM[3]     SINE.100
GE03         14.00 %
GENAM[4]     SINE.100
GE04         -8.00 %
GENAM[5]     SINE.100
GE05         -4.00 %
GENAM[6]     SINE.100
GE06         -2.00 %
P16          1000.00 usec

F1 - Acquisition parameters
ID           128
SFO1         100.5222 MHz
FIDRES       348.772308 Hz
AQ           222.955 ppm
F0MODE       Echo-Antiecho

F2 - Processing parameters
SI           2048
SF           399.7300000 MHz
WDW          SINE
SSB          2
LB           0 Hz
GB           0
PC           1.40

F1 - Processing parameters
SI           1024
MC2          echo-antiecho
SF           100.5121884 MHz
WDW          SINE
SSB          2
LB           0 Hz
GB           0
    
```

1.3.4 ^1H - ^1H NOESY



```

Current Data Parameters
NAME      QMDC
EXPNO    13
PROCNO   1

F2 - Acquisition Parameters
Date_    20120520
Time     16.30 h
INSTRUM  ssi-avance 400
PROBHD   zggqbc1h_024E (
PULPROG  noesygpgp
CD       2048
SOLVENT  DMSO-d6
NS       6
DS       4
SWH      2941.179 Hz
FIDRES   0.372273 Hz
AQ       0.7481600 sec
RG       400
AQ       170.000 usec
TE       29.97 usec
TE       29.9 K
CO       0.00015377 sec
CI       1.9025 503 sec
DS       0.30000001 sec
D16      0.00020000 sec
RC       0.00030000 sec
TDav     1
SFO1     399.7318215 MHz
NUC1     13
F1       12.75 usec
F2       25.50 usec
PL1      15.47639928 w
GPNAM[1] 8 NR.100
CP21     43.00 %
PI6      1000.00 usec


F1 - Acquisition parameters
CD       256
SFO1     399.7318 MHz
FIDRES   22.877642 Hz
SN       7.358 ppm
RMSCD6   States-DEPI

F2 - Processing parameters
SI       1024
SF       399.7300000 MHz
WDW      GSTRN
SSB      2
GB       0 Hz
GC       0
FC       1.00

F1 - Processing parameters
SI       1024
SFO2     States-DEPI
SF       399.7300000 MHz
WDW      GSTRN
SSB      2
GB       0 Hz
GC       0

```

1.3.5 ¹³C NMR




Current Data Parameters
 NAME GDMDC
 EXPNO 20
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20180311
 Time 18.18 h
 INSTRUM KJ Avance III 400
 PROBHD Z1C8618 0215 (4
 PULPROG zgpg30
 TD 65536
 SOLVENT CDCl3
 NS 256
 DS 4
 SWH 24038.461 Hz
 FIDRES 0.733596 Hz
 AQ 1.3631488 sec
 RG 2050
 DW 20.800 usec
 DE 22.74 usec
 TE 296.2 K
 D1 2.0300000 sec
 D11 0.0300000 sec
 TDE 1
 SFO1 100.5222401 MHz
 NUC1 13C
 P1 9.20 usec
 PLW1 49.5000000 W
 SFO2 399.921888 MHz
 NUC2 1H
 CPDPRG12 wa lz 6
 PCPD2 30.00 usec
 PLW2 16.4769928 W
 PLW12 0.35068001 W
 PLW13 0.26785001 W

F2 - Processing parameters
 ST 65536
 SF 100.5121884 MHz
 WDW EM
 SSB 0
 LB 1.00 Hz
 GB C
 RC 1.40

1.4 Compound 4
1.4.1 ¹H NMR





Current Data Parameters
NAME GDVAC2
EXPNO 10
PROCNO 1

F2 - Acquisition Parameters
Date_ 20130308
Time 8.09 h
INSTRUM KJ_Avance_III_400
PROBHD Z108618_0243 (4
PULPROG zg30
TD 65536
SOLVENT DMSO
NS 16
DS 2
SWH 8223.685 Hz
FIDRES 0.250967 Hz
AQ 3.9843889 sec
RG 228
DW 60.800 usec
DE 16.30 usec
TE 296.1 K
U_ 1.0000000 sec
SFC 1
SFO1 399.7324685 MHz
NUC1 1H
P1 12.75 usec
PL1 16.47699926 W

F2 - Processing parameters
SI 65536
SF 399.7300000 MHz
WDW EM
SSB 0
LB 0.20 Hz
GB 0
PC 1.00

1.4.2 ^1H - ^1H COSY



```

Current Data Parameters
NAME      GDVAC2
EXNO     12
PROCNO   1



F2 - Acquisition Parameters
Date_    20180629
Time     19.25 h
INSTRUM  XU_Avance_III_400
PROCNO   2108610246 (
PULPROG  zgpg30mfqf
OP       2268
SOLVENT  DMSO
NS       2
DS       8
SWH      2439.077 Hz
FIDRES   2.361860 Hz
AQ       0.4139460 sec
RG       2000
CW       250.000 usec
DE       6.50 usec
TE       298.2 K
DQ       0.0000300 sec
D1       1.7113237 sec
D12      0.0000240 sec
D18      0.0020000 sec
RO       0.00047000 sec
CDelay   1
SFO1     399.7323540 MHz
NUC1     1H
PT       12.05 usec
P1.M1    18.47699928 w
GPMAP[1] SINE.100
G2P1     16.00 %
GPMAP[2] SINE.100
G2P2     12.00 %
GPMAP[3] SINE.100
G2P3     40.00 %
RG2      1000.00 usec

F1 - Acquisition parameters
RG      156
SFO1    399.7324 MHz
FIDRES  38.109756 Hz
SW      6.102 ppm
PMPROG  QP


F2 - Processing parameters
SI      1024
SF      399.7330000 MHz
WDW     SFR
SSB     0
LB      0 Hz
GB      0
PC      1.10

F1 - Processing parameters
SI      1024
SF      399.7330000 MHz
WDW     SFR
SSB     0
LB      0 Hz
GB      0
    
```

1.4.3 Expansion of COSY



1.4.4 ¹H-¹³C HMBC



```

Current Data Parameters
NAME          GDVACC2
EXPNO        14
PROCNO       1



F2 - Acquisition Parameters
Date_        20180620
Time         23:53 h
INSTRUM     KU_Avance_III_400
PROBHD     108610_0245 (
PULPROG     hbhccetgpl3ind
TD          4096
SOLVENT     DMSO
NS          16
DS          16
SWH         2439.024 Hz
FIDRES     1.190930 Hz
AQ         0.8396800 sec
RG         2050
FW         205.000 usec
DE         6.50 usec
TE         296.0 K
CNST6      120.0000000
CNST7      165.0000000
CNST13     10.0000000
DQ         0.0000030 sec
D1         1.05353606 sec
D6         0.05000000 sec
D16        0.00020000 sec
INO        0.00002240 sec
TDav       1
SFO1       399.7323540 MHz
NUC1       1H
P1         12.75 usec
P2         25.50 usec
PLW1       16.47699928 W
SFO2       100.5222241 MHz
NUC2       13C
P3         9.20 usec
P24        2000.00 usec
PLW2       49.50000000 W
SPNAM(7)   Cip60comp.4
SFOAL7     0.500
SPOFFS7    0 Hz
SPN7       6.40140009 W
GPNAM(1)   SINE,100
GP1        80.00 %
GPNAM(3)   SINE,100
GP3        14.00 %
GPNAM(4)   SINE,100
GP4        -8.00 %
GPNAM(5)   SINE,100
GP5        -4.00 %
GPNAM(6)   SINE,100
GP6        -2.00 %
P16        1000.00 usec

F1 - Acquisition parameters
TD          128
SFO1       100.5222 MHz
FIDRES     348.772308 Hz
SW         222.055 ppm
FhMODE     Echo-Antiecho

F2 - Processing parameters
SI         2048
SF         399.7300000 MHz
WDW        SINE
SSB        2
LB         0 Hz
GB         0
PC         1.40

F1 - Processing parameters
SI         1024
MC2        echo-antiecho
SF         100.5121884 MHz
WDW        SINE
SSB        2
LB         0 Hz
GB         0
    
```

1.4.5 ^1H - ^1H NOESY



```

Current Data Parameters
NAME          CDVAC2
EXFREQ       15
PROCNO       1



F2 - Acquisition Parameters
Date         20.0821
Time        1.08 h
INSTRUM     KX Avance III 400
PROBHD      BTX6613 0215 4
PULPROG     zgpg30
TD          2248
SOLVENT     DMSO
NS          8
DS          4
SWH         2739.024 Hz
FIDRES     2.321960 Hz
AQ         0.4198400 sec
RG         67
LW         200.000 usec
DE         30.00 usec
TE         296.15 K
NUC1       0.00013877 sec
NUC2       1.83003498 sec
NUC3       0.30000001 sec
NUC4       0.00020000 sec
INCL       0.00041000 sec
I18V       1.84V
SFO1       399.7323540 MHz
NUC1       13
P1         12.70 usec
P2         25.50 usec
PL1        16.47699928 dB
SFO1M1     399.7323540 MHz
CPD1       0.00 sec
P18        1000.00 usec

F1 - Acquisition parameters
TD         706
SFO1       399.7324 MHz
FIDRES     19.054378 Hz
SR         5.102 ppt
EXMODE     States-TPPI

F2 - Processing parameters
SI         1024
SF         399.7300000 MHz
WDW        QSIK2
SSB        2
LB         0 Hz
GB         0
PC         1.00

F1 - Processing parameters
SI         1024
MC2        States-TPPI
SF         399.7300000 MHz
WDW        QSIK2
SSB        2
LB         0 Hz
GB         0
  
```

1.4.6 Expansion of NOESY



```

Current Data Parameters
NAME      CDVAC2
EXFID    15
PROCNO    1


F2 - Acquisition Parameters
Date      20180621
Time      1.00
INSTRUM   KL AVANCE
PROBHD    BBO-1H-1.400
PULPROG   zgpg30
TD        65536
SOLVENT   DMSO
NS        8
DS        4
SWH       2439.024 Hz
FIDRES    2.381860 Hz
AQ        0.4188400 sec
RG        67
DQ        205.500 usec
DE        30.63 usec
TE        296.1 K
D0        0.00018877 sec
D1        1.8303498 sec
J0        0.3000000 sec
D15       0.00020000 sec
IR        0.0004000 sec
F2F5      399.7325540 MHz
SFO1      100
NUC1       1H
P1         12.75 usec
P2         25.50 usec
FREQ1     16.4769928 W
GENMM1    SINE130
CP21      40.00 %
F16       1000.00 usec

F1 - Acquisition parameters
TD        256
SFO1      399.7324 MHz
FIDRES    19.054978 Hz
SW        5.102 ppm
EXMODE    zgpg30-TPII

F2 - Processing parameters
SI        1024
SF        399.7300000 MHz
WDW       QSI
SSB       2
LB        0 Hz
GB        0
PC        1.00

F1 - Processing parameters
SI        1024
SF        399.7300000 MHz
WDW       QSI
SSB       2
LB        0 Hz
GB        0
  
```

1.4.7 ¹³C NMR




Current Data Parameters
 NAME: GVVAC2
 EXPNO: 20
 PROCNO: 1


F2 - Acquisition Parameters
 Date_: 20181011
 Time: 18.36 h
 INSTRUM: XL Avance III 400
 PROBRD: z130618_0245 (1
 PULPROG: zgpg30
 TD: 65536
 SOLVSOL: CDCL3
 NS: 256
 DS: 4
 SFO: 21328.661 MHz
 FIDRES: 0.733596 Hz
 AQ: 1.563488 sec
 RG: 2053
 JW: 20.800 Hz
 DE: 22.74 usec
 TE: 295.3 K
 J1: 2.0000000 sec
 D11: 0.0200000 sec
 TSC: 1
 SFO1: 100.6222001 MHz
 NUC1: 13C
 P1: 8.20 usec
 PLW1: 49.5000000 W
 SFO2: 399.7315989 MHz
 NUC2: 1H
 CPDPRG2: wh1x16
 PCPD2: 30.00 usec
 PLW2: 11.41539928 W
 PLW3: 0.35068001 W
 PLW4: 0.26785001 W

F2 - Processing parameters
 ST: 65536
 SF: 100.621884 MHz
 WDW: EM
 SSB: 0
 LB: 1.00 Hz
 GB: 0
 PC: 1.40


1.5 Compound 5
1.5.1 ^1H NMR




1.5.2 Expansion of aromatic region




1.5.3 ^1H - ^1H COSY




1.5.4 Expansion of COSY




1.5.5 ^1H - ^{13}C HMBC



1.5.6 ^{13}C NMR



1.7 Compound 6
1.6.1 ¹H NMR




Current Data Parameters
NAME GDCAM
EXPNO 10
PROCNO 1



F2 - Acquisition Parameters
Date_ 20180308
Time 13.48 h
INSTRUM KU_Avance_III_400
PROBHD Z108618_0245 {
PULPROG zg30
TD 65536
SOLVENT CDCl3
NS 16
DS 2
SWH 8223.685 Hz
FIDRES 0.250967 Hz
AQ 3.9845889 sec
RG 228
DW 60.800 usec
DE 16.30 usec
TE 295.9 K
D1 1.00000000 sec
TDO 1
SFO1 399.7324635 MHz
NUC1 1H
P1 12.75 usec
PLW1 16.47699928 W

F2 - Processing parameters
SI 65536
SF 399.7300000 MHz
WDW EM
SSB 0
LB 0.20 Hz
GB 0
PC 1.00


1.6.2 Expansion of aromatic region



1.6.3 ^1H - ^1H COSY



1.6.4 ¹³C NMR



```


Experiment Data Parameters
NAME          G00303
EXPNO         33
PROCNO        1

F2 - Acquisition Parameters
Date_         20190914
Time          12:49 h
INSTRUM      NI_AvanceIII_400
PROBHD       Z1P302.3042 (
PULPROG      zgpg30p2
TD           65536
SOLVENT      DMS-D6
NS           256
DS           4
SWH          24038.461 MHz
FIDRES       0.133396 Hz
AQ           1.3691488 sec
RG           2020
DE           20.00 usec
TE           296.8 K
TEST2       130.6500000
D1           2.0000000 sec
D2           0.03398898 sec
D12          0.00020500 sec
D16          0.00020500 sec
D38          1.50000000 sec
RG           1
SFO1         100.622401 MHz
NUC1          13C
P1           9.20 usec
PL1          0.00000000
PL12         0.00000000
PL16         0.00000000
PL38         0.00000000
SFO2         100.622401 MHz
NUC2          13C
P2           12.75 usec
PL2          0.00000000
PL22         0.00000000
PL26         0.00000000
PL38         0.00000000
SFO3         100.622401 MHz
NUC3          13C
P3           31.00 usec
PL3          0.00000000
PL32         0.00000000
PL36         0.00000000
PL38         0.00000000
SFO4         100.622401 MHz
NUC4          13C
P4           31.00 usec
PL4          0.00000000
PL42         0.00000000
PL46         0.00000000
PL48         0.00000000

F2 Processing parameters
SI           32768
SF           100.621894 MHz
WDW          EM
SSB          0
LB           1.00 Hz
GB           0
PC           1.40
    
```


1.7 Compound 7

1.7.1 ¹H NMR




Current Data Parameters
NAME GD4BF
EXPNO 10
PROCNO 1

F2 - Acquisition Parameters
Date_ 20180427
Time 14.04 h
INSTRUM KC_Avance_III_400
PROBHD Z108618_0245 {
PULPROG zg30
TD 65536
SOLVENT CDCl3
NS 16
DS 2
SWH 8223.688 Hz
FIDRES 0.250967 Hz
AQ 3.9845889 sec
RG 512
DW 60.800 usec
DE 16.30 usec
TE 295.8 K
D1 1.0000000 sec
TD0 1
SFO1 399.7324685 MHz
NUC1 1H
P1 12.75 usec
PLW1 16.47699928 W

F2 - Processing parameters
SI 65536
SF 399.7300000 MHz
WDW EN
SSB 0
LB 0.20 Hz
GB 0
PC 1.00

1.7.2 Expansion of aromatic region





```

Current Data Parameters
NAME          GD4BF
EXPNO         10
PROCNO        1

F2 - Acquisition Parameters
Date_         20180427
Time          14.34 h
INSTRUM       KU_Avance_III_400
PROBHD        Z108618_0245 (
PULPROG       zg30
ID            65536
SOLVENT       CDCl3
NS            16
DS            2
SWH           8223.683 Hz
FIDRES        0.250967 Hz
AQ            3.9845889 sec
RG            512
DW            60.800 usec
DE            16.30 usec
TE            295.8 K
D1            1.0000000 sec
TD0           1
SFO1          399.7324685 MHz
NUC1          1H
P1            12.75 usec
PLW1          16.47699928 W

F2 - Processing parameters
SI            65536
SF            399.7300000 MHz
WDW           EM
SSB           0
LB            0.20 Hz
GB            0
PC            1.00
    
```

1.7.3 ^1H - ^1H COSY



```

Current Data Parameters
NAME      GMM8F
EXPNO    12
PROCNO   1


F2 - Acquisition Parameters
Date_    20180427
Time     14.20 A
INSTRUM  XU_AvanceIII_400
PROBHD   Z10669L024s_1
PULPROG  zgpg30mf
TD        65536
SOLVENT  CDCl3
NS        2
DS        8
SWH       3205.128 Hz
FIDRES    3.730008 Hz
AQ        0.3184880 sec
RG         2560
DW        106.500 usec
DE        6.50 usec
TE        303.2 K
D0        0.0000300 sec
D1        1.8722092 usec
D13       0.0000400 sec
T1R       0.0002000 sec
RG2       0.0003200 sec
DELTA     1
SFO1      399.731939 MHz
NUC1      1H
P1        12.75 usec
P141      15.47699928 usec
GAMMA1    513.100
CP21      16.00 %
CP22      SINE.100
CP23      12.00 %
GAMMA1S1  513.100
GAMMA1S2  40.00 %
RG3       1000.00 usec

F1 - Acquisition parameters
TD        65536
SFO1      399.7319 MHz
FIDRES    3.730028 Hz
SWH       3205.128 Hz
PULPROG  zgpg30
RG         2560

F2 - Processing parameters
SI        32768
SF        399.7300000 MHz
WDW       EM
SSB       0
LB        0 Hz
GB        0
PC        1.40

F1 - Processing parameters
SI        32768
SF        399.7300000 MHz
WDW       EM
SSB       0
LB        0 Hz
GB        0
PC        1.40
    
```

1.7.4 ^1H - ^{13}C HMBC



```

Current Data Parameters
NAME          GD4HF
EXPNO        14
PROCNO       1



F2 - Acquisition Parameters
Date_        20180427
Time         15.33 h
INSTRUM     PU_Avance_III_400
PROBHD      1106418_0245_1
PULPROG     hmcsetgp13nd
TD          1096
SOLVENT     CDCl3
NS          8
DS          16
SWH         3205.128 Hz
FIDRES     1.565004 Hz
AQ         0.6389760 sec
RG         7050
DW         156.000 usec
DE         6.50 usec
TE         296.3 K
CNST6      120.0000000
CNST7      165.0000000
CNST13     10.0000000
D0         0.00000300 sec
D1         1.25424004 sec
D6         0.05000000 sec
D16        0.00020000 sec
IN0        0.00002240 sec
TDav
SFO1       399.7319336 MHz
NUC1       1H
P1         12.75 usec
P2         25.50 usec
PLW1      16.47699928 W
SFO2       100.5222241 MHz
NUC2       13C
P3         9.20 usec
P24        2000.00 usec
PLW2      49.50000000 W
SPNAM[7]   Crp60comp.4
SFOCAL7    0 Hz
SFOCF7     0 Hz
SPW7       6.40140009 W
GPNAM[1]   SINE.100
GP11       80.00 kHz
GPNAM[3]   SINE.100
GP23       14.00 kHz
GPNAM[4]   SINE.100
GP24       -8.00 kHz
GPNAM[5]   SINE.100
GP25       -4.00 kHz
GPNAM[6]   SINE.100
GP26       -2.00 kHz
P16        1000.00 usec

F1 - Acquisition parameters
TD         128
SFO1       100.5222 MHz
FIDRES     348.772398 Hz
SW         222.055 ppm
F1MODE     Echo-Antiecho

F2 - Processing parameters
SI         2048
SF         399.7300000 MHz
WDW        SINE
SSB        2
LB         0 Hz
GB         0
PC         1.40

F1 - Processing parameters
SI         1024
MC2        echo-antiecho
SF         100.5121884 MHz
WDW        SINE
SSB        2
LB         0 Hz
GB         0
  
```

1.7.5 ^1H - ^1H NOESY



```

Current Data Parameters
NAME      CD4BF
EXPNO    13
PROCNO   1


F2 - Acquisition Parameters
Date_    20180423
Time     09:43 h
INSTRUM  KC AVANCE_11_400
PROBHD   5138619_0275 (
PULPROG  "noesy3pt"
TD       2546
SOLVENT  DMS-D6
NS       8
DS       4
SWH      3225.728 Hz
FIDRES   3.132038 Hz
AQ       0.3194680 sec
RG       362
DQ       158.503 usec
DE       21.34 usec
TE       295.3 K
D0       0.00013577 sec
D1       1.93118703 sec
J0       0.35000001 sec
D15      0.00020000 sec
IRI      0.00031200 sec
TD0      1
SFO1     399.7319336 MHz
NUC1     13
P1       12.75 usec
P2       25.50 usec
F1e1     16.47699928 W
GENAM[1] 81N2.130
CPD1     40.00 %
F1e      1200.00 usec

F1 - Acquisition parameters
TE       295
SFO1     399.7319 MHz
FIDRES   25.040064 Hz
RG       362
F2MODE   States-TPPI

F2 - Processing parameters
SI       1024
SF       399.7300000 MHz
WDW      QSINE
SSB      2
LB       0 Hz
GB       0
PC       1.00

F1 - Processing parameters
SI       1024
RG2      States-TPPI
SF       399.7300000 MHz
WDW      QSINE
SSB      2
LB       0 Hz
GB       0
    
```

1.7.6 ¹³C NMR




```

Current Data Parameters
NAME      004DF
EXPNO    20
PROCNO   1

F2 - Acquisition Parameters
Date_    2018101
Time     13.13 h
INSTRUM  KULAvance_III_400
PROBHD   Z138618 0215 1
PULPROG  zgpg30
TD       65536
SOLVENT  CDCl3
NS       256
DS       4
SWH      24036.401 Hz
FIDRES   0.733596 Hz
AQ       1.3631488 sec
RG       2550
DW       20.800 usec
DE       22.74 usec
TE       298.2 K
D1       2.0000000 sec
d11      0.0300000 sec
DDO      -
SFO      100.622401 MHz
NUC1     13C
NUC2     13C
P1       9.20 usec
PL1      0.5000000 W
SFO2     399.7810989 MHz
NUC3     1H
CPDPRG2  wa1z18
PCPD2    30.00 usec
PLW2     16.47699528 W
PLW12    0.33066001 W
PLW13    0.26785001 W

F2 - Processing parameters
SI       65536
SF       100.6121986 MHz
WDW      EM
SSB      0
LB       1.00 Hz
GB       0
PC       1.40
    
```

1.8 Compound 8
1.8.1 ¹H NMR




Current Data Parameters
NAME gd4cf
EXPNO 10
PROCNO 1



F2 - Acquisition Parameters
Date_ 20180427
Time 12.36 h
INSTRUM KC_Avance III_400
PROBHD z108618_0248 (1
PULPROG zg30
ID 65536
SOLVENT CDCl3
NS 18
DS 2
SWH 8223.689 Hz
FIDRES 0.250967 Hz
AQ 3.9845889 sec
RG 436
DW 60.800 usec
DE 18.30 usec
TE 295.0 K
D1 1.0000000 sec
TDC -
SFO1 399.7324685 MHz
NUC1 1H
P1 12.75 usec
PLW1 16.47689828 W

F2 - Processing parameters
SI 65536
SF 399.7300000 MHz
WDW EM
SSB 0
LB 0.20 Hz
GB 0
PC 1.00

1.8.2 Expansion of aromatic region



1.8.3 ^1H - ^1H COSY



```

Current Data Parameters
NAME      G04CP
EXPNO     12
PROCNO    1


F2 - Acquisition Parameters
Date_     20180427
Time     12.31 h
INSTRUM   XUL_Avanceo_1H_400
PROBHD    ZS0621LZ2Co 1
PULPROG   coayprgfqf
AQ        2048
SOLVENT   CDCl3
NS        2
DS        8
SWH       3105.590 Hz
FIDRES    3.032803 Hz
AQ        0.3297280 sec
RG        2000
SK        161.000 usec
SI        6.00 usec
CF        208.0 x
DD        0.0000300 sec
DL        1.86186634 usec
DLS       0.0000400 usec
T1S       0.0000000 sec
RO        0.00052200 sec
CDEPR     1
SFO1      399.7318010 MHz
NUC1       1H
P1         12.05 usec
F2_A1     16.07609928 w
GPRM(1)   SINE,100
GPRM(2)   SINE,100
GPRM(3)   12.00 s
GPRM(4)   SINE,100
GPRM(5)   40.00 s
RG        1000.00 usec

F1 - Acquisition parameters
SI        128
SWH       309.7319 MHz
FIDRES    68.826848 Hz
SR        7.783 ppr
RGPRM     0F

F2 - Processing parameters
SI        1024
SF        399.7300000 MHz
WDW       0
SSB       0 Hz
GB        0
PC        1.40

F1 - Processing parameters
SI        1024
SF        399.7300000 MHz
WDW       0
SSB       0 Hz
GB        0
PC        0
    
```

1.8.4 ^1H - ^{13}C HMBC



```

Current Data Parameters
NAME          GD4CF
EXPNO        14
PROCNO       1



F2 - Acquisition Parameters
Date_        20180427
Time         13.26 h
INSTRUM     MZ_Avance III_400
PROBHD      2108618_0245 (
PULPROG     hmbocetcp13rd
TD           4096
SOLVENT     CDCl3
NS           8
DS           16
SWH          3105.590 Hz
FIDRES      1.516401 Hz
AQ           0.4594560 sec
RG           2050
DM           161.000 usec
DE           6.50 usec
TE           296.2 K
CNS16       120.000000
CNS17       165.000000
CNS113      10.000000
D0           0.00000300 sec
D1           1.2376000 sec
D6           0.00000000 sec
D15         0.00020000 sec
IN0         0.00002240 sec
TD0         1
SFO1        399.7319010 MHz
NUC1        1H
P1           12.75 usec
P2           25.50 usec
PL01        16.47699928 W
SFO2        100.5222241 MHz
NUC2        13C
P3           8.20 usec
P24         2000.00 usec
PL02        49.50000000 W
SPNAM[7]    Crp60comp.4
SFOAL7      0 Hz
SFOF57      0 Hz
SPW7        6.40140009 W
GPNAM[1]    SINE.100
GPE1        80.00 %
GPNAM[3]    SINE.100
GPE3        14.00 %
GPNAM[4]    SINE.100
GPE4        -8.00 %
GPNAM[5]    SINE.100
GPE5        -4.00 %
GPNAM[6]    SINE.100
GPE6        -2.00 %
P16         1000.00 usec

F1 - Acquisition parameters
TD           128
SFO1        100.5222 MHz
FIDRES      348.772308 Hz
SW          222.055 ppm
F0MODE      Echo-Antiecho

F2 - Processing parameters
SI           2048
SF           399.7300000 MHz
WDW          SINE
SSB          2
LB           0 Hz
GB           0
PC           1.40

F1 - Processing parameters
SI           1024
MC2         echo-antiecho
SF           100.5121884 MHz
WDW          SINE
SSB          2
LB           0 Hz
GB           0
  
```

1.8.5 ¹H-¹H NOESY



```

Current Data Parameters
NAME      CD4CF
EXPERNO  13
PROCNO    1



F2 - Acquisition Parameters
Date_     20180427
Time      8.11
INSTRUM   KL Avance 400
PROBHD    MIC8618_02/5 (
PULPROG   noesy3d
LS        2046
SOLVENT   CDCl3
NS        8
DS        4
SWH        3125.590 Hz
FIDRES     3.632803 Hz
AQ         0.3297230 sec
RG         287
CW         161.000 usec
DE         22.28 usec
TE         295.2 K
D0         0.0001477 sec
D1         1.82094696 sec
d8         0.00000001 sec
d16        0.00020000 sec
IKC        0.00032200 sec
TD0AV      1
SF01       399.7319010 MHz
NUC1       1
P1         12.75 usec
P2         25.00 usec
PL01       16.47699928 W
GENAM1    SINE.100
CP21       40.00 %
P16        1000.00 usec

F1 - Acquisition parameters
TS         736
SF01       399.7319 MHz
FIDRES     24.262423 Hz
SR         7.769 ppr
EMODE      States-TPPI


F2 - Processing parameters
SI         1024
SF         399.7300000 MHz
WDW        QSINE
SSB        2
LB         0 Hz
GB         0
PC         1.00

F1 - Processing parameters
SI         1024
MC2        States-TPPI
SF         399.7300000 MHz
WDW        QSINE
SSB        2
LB         0 Hz
GB         0
    
```

1.8.6 Expansion of NOESY



1.8.7 ¹³C NMR




```

Current Data Parameters
NAME          GD4CF
EXPNO        20
PROCNO       1

F2 - Acquisition Parameters
Date_        20180311
Time        21.04 s
INSTRUM     KU Avance III 400
PROBHD      Z108618 0245 (
PULPROG     zgpg30
TD          65536
SOLVENT     CDCL3
NS          256
DS          4
SWH         24058.461 Hz
FIDRES     0.733596 Hz
AQ         0.5631488 sec
RG         2050
DW         20.800 usec
DE         22.74 usec
TE         295.9 K
D1         2.0000000 sec
D11        0.0300000 sec
TDC        1
SFO1       100.6222401 MHz
NUC1        13C
P1         9.20 usec
PLW1       49.5600000 W
SFO2       329.7313989 MHz
NUC2        1H
CPDPRG2     wa tz 6
PCPD2       30.00 usec
PLW2       16.4769928 W
PLW12      0.35068901 W
PLW13      0.28780901 W

F2 - Processing parameters
SI          65536
SF         100.5121884 MHz
WDW         EM
SSB         0
LB         1.00 Hz
GB         0
PC         1.40
    
```

1.9 Compound 9
1.9.1 ¹H NMR




Current Data Parameters
NAME GCAMB
EXPNO 10
PROCNO 1



F2 - Acquisition Parameters
Date_ 20180612
Time 17.10 h
INSTRUM KU_Avance_III_400
PROBHD ZLC6818_C245 ()
PULPROG zg30
ID 65836
SOLVENT CDCl3
NS 16
DS 2
SWH 8223.688 Hz
FIDRES 0.250867 Hz
AQ 3.9845889 sec
RG 406
DW 60.800 usec
DE 18.30 usec
TE 296.1 K
DC 1.0000000 sec
TD 1
SFO1 399.7324685 MHz
NUC1 1H
P1 12.75 usec
PL1 16.47699928 W

F2 - Processing parameters
SI 65836
SF 399.7300000 MHz
WDW EM
SSE 0
LB 0.20 Hz
GB 0
FC 1.00

1.9.2 Expansion of aromatic region




1.9.3 ^1H - ^1H COSY





```

Current Data Parameters
NAME          GDMB
EXPNO        12
PROCNO       1
-----
F2 - Acquisition Parameters
Date_         20180812
Time          17.25 h
INSTRUM      XLAvance_III_400
PROBHD       ZL0861B_02co (
PULPROG      zgpg30
SOLVENT      CDCl3
NS           2
DS           8
SWH          3335.833 Hz
FIDRES       3.255206 Hz
AQ          0.307200 sec
RG           2300
WDW          EM
SSB          0
GB           0
PC           1.00000000
DC           0.0000300 sec
CL          1.89448299 sec
C13          0.0000400 sec
T1R         0.0020000 sec
NO          0.0000000 sec
TDav        1
SF01        399.732043 MHz
SFO1         1H
P1          12.25 usec
P1A1        18.8769928 w
GDMAX[1]    SINE,100
GP2L        16.00 %
GDMAX[2]    SINE,100
GP2Z        12.00 %
GDMAX[3]    SINE,100
GP2S        40.00 %
P1G         1000.00 usec
-----
F1 - Acquisition parameters
SI          128
SFO1        399.732 MHz
FIDRES       52.08332 Hz
SWH          8.539 ppm
P1G00h      0M
-----
F2 - Processing parameters
SI          1024
SF          399.732000 MHz
WDW         5 Hz
SSB         0
LB          0 Hz
GB          0
PC          1.40
-----
F1 - Processing parameters
SI          1024
MC2         QT
SF          399.732000 MHz
WDW         5 Hz
SSB         0
LB          0 Hz
GB          0
  
```


1.9.4 ^1H - ^{13}C HMBC



1.9.5 ^1H - ^1H NOESY



```

Current Data Parameters
NAME      CERME
EXPNO    10
PROCNO   1


F2 - Acquisition Parameters
Date_    20.0612
Time     21.08
INSTRUM  KQ Avance 1-400
PROBHD   ZLC6612_0275 (
PULPROG  'noesygpr'
IR       2046
SOLVENT  DMSD3
NS       8
DS       4
SWH      3333.333 Hz
FIDRES   0.215908 Hz
AQ       0.3272000 sec
RG       287
JC       150.000 usec
DE       20.20 usec
TE       296.1 K
DO       0.50013577 sec
DI       1.94347521 sec
SR       0.32000001 sec
AQ       0.32022000 sec
INCR     0.50030000 sec
TDAY     1
SF01     399.732048 MHz
NUC1     1H
P1       12.75 usec
P2       25.50 usec
P1P2     16.4699998 W
SFO1M11  8192.100
CPD1     40.00 %
P16      1200.00 usec

F1 - Acquisition parameters
TE       296
SF01     399.732 MHz
FIDRES   0.215908 Hz
SR       0.32000001 sec
EXMODE   G140es-TPPI

F2 - Processing parameters
SI       1024
SF       399.7300000 MHz
WDW      Q31R2
SSB      2
IS       0 Hz
GB       0
PC       1.00

F1 - Processing parameters
SI       1024
SF02     8192.1001 MHz
SF       399.7300000 MHz
WDW      Q31R2
SSB      2
IS       0 Hz
GB       0
  
```

1.9.6 ¹³C NMR



```


Current Data Parameters
NAME          GDM6
EXPNO         20
PROCNO        1

F2 - Acquisition Parameters
Date_         20180311
Time          19.31 h
INSTRUM       XJ_Avance_III_400
PROBHD        Z1C8618 0245 (
PULPROG       zgpg30
TD            65536
SOLVENT       CDCl3
NS            256
DS            4
SWH           24038.461 Hz
FIDRES        0.733596 Hz
AQ            1.5631288 sec
RG            2050
DW            20.800 usec
DE            22.74 usec
TE            296.0 K
D1            2.0000000 sec
D11           0.0300000 sec
TDC           1
SFO1          100.6222401 MHz
NUC1           13C
P1            9.20 usec
PLW1          49.5000000 W
SFO2          399.7316989 MHz
NUC2           1H
CPDPRG12     wa.tz*6
PCPD2        30.00 usec
PLW2          16.47699928 W
PLW12         9.55068931 W
PLW13         9.26785331 W

F2 - Processing parameters
SI            65536
SF            100.621884 MHz
WDW           EM
SSB           0
LB            1.00 Hz
GB            0
PC            1.40
    
```

1.10 Compound 10

1.10.1 ¹H NMR




Current Data Parameters
NAME GDM02
EXPNO 10
PROCNO 1

F2 - Acquisition Parameters
Date_ 20130719
Time 10:49 h
INSTRUM KU_Avance III_400
PROBHD ZL08618_0245 (1
PULPROG zg30
ID 65536
SOLVENT CDCl3
NS 16
DS 2
SWE 9223.685 Hz
FIDRES 0.250967 Hz
AQ 3.9845889 sec
RG 575
DW 60.800 usec
DE 16.30 usec
TE 296.2 K
D1 1.0000000 sec
TDO -
SFO 399.7324685 MHz
NUC1 1H
F1 12.75 usec
PL1 16.47699928 W

F2 - Processing parameters
SI 65536
SF 399.7300000 MHz
WDW EM
SSE 0
LB 0.20 Hz
GB 0
PC 1.00

1.10.2 Expansion of aromatic region



6.1273





```
Current Data Parameters
NAME          GDMC2
EXPNO         10
PROCNO        1

F2 - Acquisition Parameters
Date_         20180719
Time          10.49 h
INSTRUM       KU_Avance_III_400
PROBHD        z109618_0245 (
PULPROG       zg30
TD            65536
SOLVENT       CDCl3
NS            16
DS            2
SWH           8223.585 Hz
FIDRES        0.250967 Hz
AQ            3.9845889 sec
RG            575
SN            60.800 usec
DE            16.30 usec
TE            296.3 K
D1            1.0000000 sec
DPC           1
SFO1          399.7324688 MHz
NUC1           1H
P1            12.75 usec
PLW1          16.47699928 W

F2 - Processing parameters
SI            65536
SF            399.7300000 MHz
WDW           EM
SSB           0
CB            0.20 Hz
GB            0
PC            1.00
```

1.10.3 ^1H - ^1H COSY



```

Current Data Parameters
NAME      G0002
EXPOSO   12
PROCNO    1


F2 - Acquisition Parameters
Date      20180719
Time      10.49 h
INSTRUM   XQ_Avance_1H1_400
PROBHD    Z00661H_0245-1
PULPROG   coesyprgfqf
TD         2048
SOLVENT   CDCl3
NS         2
DS         8
SWH        3144.854 Hz
FIDRES    3.070951 Hz
AQ         0.3256320 sec
RG         2500
SQ         169.000 usec
RF         6.50 usec
NUC1       13C
NUC2       1H
DECO       0.02000300 sec
D1         1.86666997 sec
D12        3.0000400 sec
F1A        0.0020000 sec
RG         0.02007800 sec
CDEPR     1
SFO1      399.7319039 MHz
NUC1      13C
F1A1      16.47699928 MHz
CPDPR1[1] SINE,100
CPDPR2[2] SINE,100
CPDPR3[3] SINE,100
SFO2      400.1460000 MHz
RG2        40.00
RG3        1000.00 usec

F1 - Acquisition parameters
PC         128
SFO1      399.7319 MHz
FIDRES    49.138020 Hz
SW         7.887 MHz
PROCNO    01



F2 - Processing parameters
SI         1324
SF         399.7300000 MHz
WDW        5 Hz
SSB        0
LB         0 Hz
GB         0
PC         1.40

F1 - Processing parameters
SI         1024
SF         399.7300000 MHz
WDW        5 Hz
SSB        0
LB         0 Hz
GB         0
    
```

1.10.4 ¹H-¹³C HMBC



1.10.5 ^1H - ^1H NOESY



```

Current Data Parameters
NAME          CDMC2
EXPER        13
PROCNO       1


F2 - Acquisition Parameters
Date         20180719
Time        18.07 h
INSTRUM     KC AVANCE
PROBHD      MIC619_0775
PULPROG     noyaygpc
IR        2246
SOLVENT     CDCl3
NS          8
DS          4
SWH         3174.657 Hz
FIDRES     3.070951 Hz
AQ         0.3256320 sec
RG         362
SQ         155.000 usec
DE         22.01 usec
TE         296.2 K
DQ         0.00014277 sec
C1         -0.92504299 sec
SFO1        399.7300000 sec
SFO2        0.000000000 sec
SFO3        0.00020000 sec
INC         0.00031900 sec
TEAV        1
SFO1        399.7319039 MHz
SFO2        1
P1         12.75 usec
P2         25.50 usec
PTA01      16.47699928 W
SFO11       819.4639078 MHz
CPD1        0.00 s
P16         1000.00 usec

F1 - Acquisition parameters
TS          256
SFO1        399.7319 MHz
FIDRES     24.567610 Hz
SFO        7.867 epr
EnMODE     status-TPPI

F2 - Processing parameters
SI          1024
SF          399.7300000 MHz
WDW         Q6SINE
SSB         2
LB          0 Hz
GB          0
PC          1.00

F1 - Processing parameters
SI          1024
MC2        STATUS-TPPI
SF          399.7300000 MHz
WDW         Q6SINE
SSB         2
LB          0 Hz
GB          0
    
```


1.10.6 ¹³C NMR



```


Current Data Parameters
NAME          GDM32
EXPNO         10
PROCNO        1

F2 - Acquisition Parameters
Date_         20181016
Time          1.03 s
INSTRUM       XU Avance III 400
PROBHD        Z108618 0245 (
PULPROG       zgpg30
OB           65536
SOLVENT       CDCl3
NS            2560
DS            4
SWH           24038.461 Hz
FIDRES        0.733596 Hz
AQ            1.5631488 sec
RG            2050
DW            20.800 usec
DE            22.74 usec
TE            296.2 K
D1            2.0000000 sec
D11           0.0300000 sec
TDC           1
SFO1          100.622401 MHz
NUC1           13C
P1            3.20 usec
PLW1          48.5000000 w
SFO2          399.7315389 MHz
NUC2           1H
CFPRG12       wa lz16
PCPD2         30.00 usec
PLW2          16.47699928 w
PLW12         0.35068001 w
PLW13         0.26785001 w


F2 - Processing parameters
SI            65536
SF            100.6121884 MHz
WDW           EM
SSB           0
LB            1.00 Hz
GB            C
PC            1.40
    
```

1.11 Compound 11

1.11.1 ¹H NMR



1.11.2 Expansion of aromatic region





Current Data Parameters
 NAME QDlaw
 EXPNO 10
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20180605
 Time 13.21 h
 INSTRUM KC_Avance_III_400
 PROBHD z108618_0245 (1
 PULPROG zg30
 TD 65536
 SOLVENT DMSO
 NS 16
 DS 2
 SWH 8223.685 Hz
 FIDRES 0.250967 Hz
 AQ 3.9845889 sec
 RG 101
 DW 60.800 usec
 DE 16.30 usec
 TE 296.0 K
 D1 1.00000000 sec
 D10 1
 SFO1 399.7324695 MHz
 NUC1 1H
 P1 12.75 usec
 PLW1 16.47599928 W

F2 - Processing parameters
 SI 65536
 SF 399.7299835 MHz
 WDW EM
 SSB 0
 LB 0.20 Hz
 GB 0
 PC 1.00

1.11.3 ^1H - ^1H COSY



```

Current Data Parameters
NAME      SGLAW
EXPGNO   12
PROCNO    1



F2 - Acquisition Parameters
Date      20180605
Time      13.37 h
INSTRUM   XU_Avance_III_400
PROBHD    Z10861H_0265_1
PULPROG   zgpg30
SS        2048
SOLVENT   DMSO
NS         2
DS         8
SWH        5591.127 Hz
FIDRES     3.63660 Hz
AQ         0.22908160 sec
RG         2030
CW         142.000 usec
CT         6.50 usec
CR         295.0 %
DD         0.0000300 sec
DL         1.90087700 sec
DLS        0.0000400 sec
FIR        0.00020000 sec
RO         0.00028000 sec
DELEV      1
SEQ1       399.731713 MHz
NUC1        1H
P1         12.75 usec
P1A1       18.47699928 u
GAMMA[1]   5133.100
GZ1        16.00 %
CHRG1[2]   91NE,100
CP22       12.00 *
GAMMA[3]   5133.100
GZ2        40.00 %
F1G        1000.00 usec

F1 - Acquisition Parameters
QC         128
NUC1       399.7316 MHz
FIDRES     53.017606 Hz
SW         8.809 ppm
PRGPRG     QP

F2 - Processing parameters
SI         1024
SF         399.7299825 MHz
WDW        5 Hz
SSB        0
LB         0 Hz
GB         0
PC         1.40

F1 - Processing parameters
SI         1024
MC2        0
SF         399.7299825 MHz
WDW        5 Hz
SSB        0
LB         0 Hz
GB         0
  
```

1.11.4 Expansion of COSY



Current Data Parameters
 NAME GOLAW
 EXPNO 12
 PROCNO 1


M2 - Acquisition Parameters
 Date_ 20160805
 Time 11:37 h
 INSTRUM XL_Avance_400
 FREQID Z1000L1264
 PULPROG zgpg30
 LG 2048
 SOLVENT DMSO
 NS 2
 DS 8
 SWH 3521.127 Hz
 FIDRES 3.438600 Hz
 AQ 0.2908100 sec
 EC 2000
 CK 142.000 usec
 CY 6.50 usec
 CR 295.0 x
 DC 0.0000300 sec
 DL 1.90087700 sec
 DLR 0.0000400 usec
 FID 0.0020000 sec
 RO 0.0002800 sec
 DELAY 1
 SFO1 399.7317713 MHz
 SF02 400
 FI 12.75 usec
 F_A1 16.47699928 w
 GENAM11 SINE,100
 GEN2 16.00 %
 GENAM12 SINE,100
 GEN2 12.00 %
 GENAM13 SINE,100
 GEN2 40.00 %
 ELG 1000.00 usec

F1 - Acquisition parameters
 SI 128
 SFO1 399.7318 MHz
 FIDRES 58.017805 Hz
 SW 8.809 ppm
 FWHM 0.6

F2 - Processing parameters
 SI 1024
 MC2 GF
 SF 399.7299825 MHz
 WHW 5 Hz
 SSB 0
 LB 0 Hz
 GB 0
 PC 1.40

F1 - Processing parameters
 SI 1024
 MC2 GF
 SF 399.7299825 MHz
 WHW 5 Hz
 SSB 0
 LB 0 Hz
 GB 0

1.11.5 ^1H - ^{13}C HMBC



```

Current Data Parameters
NAME          G0Law
EXPNO        14
PROCNO       1


F2 - Acquisition Parameters
Date_         20180605
Time          20:34 h
INSTRUM      NU_Avance_1H_400
PROBHD       z10618_0245_1
PULPROG      hmbcetgp13rd
TD           4996
SOLVENT      DMSO
NS           16
DS           16
SMH          3521.127 Hz
FIDRES       1.719300 Hz
AQ           0.5816220 sec
RG           2050
SW           142.000 usec
DE           6.50 usec
TE           295.7 K
CNS16        120.0000000
CNS17        165.0000000
CNS13        10.0000000
D0           0.0000000 sec
D1           1.31186400 sec
D6           0.05000000 sec
D16          0.00020000 sec
INO          0.00002240 sec
IDAW        1
SFO1         399.7317713 MHz
NUC1         1H
P1           12.75 usec
P2           25.50 usec
PLW1         16.47699928 W
SFO2         100.522241 MHz
NUC2         13C
P3           9.20 usec
P24          2000.00 usec
PLW2         49.50000000 W
SFO3         100.6260624 MHz
SFOAL7       0 Hz
SPOFFS7      0 Hz
SFW          6.40140009 W
GPNAM(1)     SINE.100
GP1          80.00 %
GPNAM(3)     SINE.100
GP3          14.00 %
GPNAM(4)     SINE.100
GP4          -8.00 %
GPNAM(5)     SINE.100
GP5          -4.00 %
GPNAM(6)     SINE.100
GP6          -2.00 %
P16          1000.00 usec

F1 - Acquisition parameters
TD           128
SFO1         100.5222 MHz
FIDRES       346.772308 Hz
SW           222.055 ppm
FMODE        Echo-Antiecho

F2 - Processing parameters
SI           2048
SF           399.729905 MHz
WDW          SINE
SSB          2
LB           0 Hz
GB           0
PC           1.40

F1 - Processing parameters
SI           1024
MC2          echo-antiecho
SF           100.5121884 MHz
WDW          SINE
SSB          2
LB           0 Hz
GB           0
    
```

1.11.6 ^1H - ^1H NOESY



Current Data Parameters
 NAME: cLew
 EXPTNO: 15
 PROCNO: 1


F2 - Acquisition Parameters
 Date_ 20180605
 Time: 21.42 n
 INSTRUM: KL AVANCE
 PROGNO: M08619_02/5 ()
 PULPROG: zgpg30
 LE: 2045
 SOLVENT: dmso
 NS: 8
 DS: 4
 SWH: 3521.127 Hz
 FIDRES: 3.4334600 Hz
 AQ: 0.2908100 sec
 RG: 67
 CW: 142.000 usec
 DE: 18.72 usec
 TP: 296.3 N
 D0: 0.00012577 sec
 D1: 1.85915901 sec
 SFO1: 399.7299905 MHz
 C15: 0.00020000 sec
 INC: 0.00028400 sec
 DEPR: 1
 SFO1: 399.7317713 MHz
 VFO1: 17
 F1: 12.75 usec
 F2: 25.30 usec
 FWHM: 16.47699928 Hz
 GPNAM1: SINE120
 GR1: 40.00 %
 P16: 1000.00 usec

F1 - Acquisition parameters
 TS: 296
 SFO1: 399.7318 MHz
 FIDRES: 27.508802 Hz
 SW: 8.809 ppm
 ENMODE: States-TPPI

F2 - Processing parameters
 S: 1024
 SF: 399.7299905 MHz
 WDW: QSBINZ
 SSB: 2
 LB: 0 Hz
 GB: 0
 EC: 1.00

F1 - Processing parameters
 S: 1024
 GC2: States-TPPI
 SF: 399.7299905 MHz
 WDW: QSBINZ
 SSB: 2
 LB: 0 Hz
 GB: 0

1.11.8 ¹⁵P NMR




Current Data Parameters
NAME CDLaw_P
EXPNO 10
PROCNO 1

F2 - Acquisition Parameters
Date 20180730
Time 13.58 h
INSTRUM KU Avance III 400
PROBHD Z109818_0245 (zq30
PULPROG zg30
TD 65536
SOLVENT CDCl3
NS 32
DS 4
SWH 64102.563 Hz
FIDRES 1.956235 Hz
AQ 0.0111508 sec
RG 2050
DN 7.800 usec
DR 8.85 usec
DE 295.2 K
DL 2.0000000 sec
DDC 1
SFO1 161.905593 MHz
NUC1 31P
P1 7.75 usec
PLWT 36.90499878 W

F2 - Processing parameters
SI 65536
SF 161.8136700 MHz
WDW EM
SSB 0
LB 3.00 Hz
GB 0
RC 1.40

1.12 Compound 12
1.12.1 ¹H NMR




```

Current Data Parameters
NAME      gDMDC_low
EXPNO     10
PROCNO    1



F2 - Acquisition Parameters
Date_     20180618
Time      14.37 h
INSTRUM   KU_Avance III_400
PROBHD    zgpg30
PULPROG   zgpg30
TD         65536
SOLVENT   CDCl3
NS         16
DS         2
SWH        8223.685 Hz
FIDRES     0.250967 Hz
AQ         3.9845889 sec
RG         37
DW         60.800 usec
DE         16.30 usec
TE         296.3 K
D1         1.0000000 sec
TEO        1
SFO1       399.7324685 MHz
NUC1       1H
P1         12.75 usec
PLWL       16.47699928 W

F2 - Processing parameters
SI         65536
SF         399.7300324 MHz
WDW        EM
SSB        0
LB         0.20 Hz
GB         0
PC         1.00
    
```

1.12.2 Expansion of aromatic region



1.12.3 ^1H - ^1H COSY



```

Current Data Parameters
NAME      GDMC02
EXPNO    22
PROCNO    1



F2 - Acquisition Parameters
Date_     20180618
Time      17.18 h
INSTRUM   XU_AvanceIII_400
PROBHD    Z10669L0240_1
PULPROG   zgpg30mf
TD        65536
SOLVENT   CDCl3
NS         2
DS         8
SWH        8851.389 Hz
FIDRES     4.74039E-04
AQ         0.2103440 sec
RG         2030
DQ         103.000 usec
RO        6.50 usec
DE        236.134
DO         0.0000360 sec
D1         1.98074901 usec
D12        0.0000400 sec
T1R        0.00020000 sec
RG2        0.00020600 sec
DELTA     1
SFO1       399.7325524 MHz
NUC1       1H
P1         12.75 usec
PC1        15.47699928 w
GAMMA1[1] 51X1.00
CP21       16.00 s
CPHASE[2]  SINE.100
PC22       12.00 s
GAMMA[2]  51X1.00
GOLD3     40.00 s
PL2       1000.00 usec

F1 - Acquisition parameters
TD        65536
SFO1       399.7325 MHz
FIDRES     4.74039E-04
RG         2030
PROBHD     QNP

F2 - Processing parameters
SI         1024
SF         399.7300320 MHz
WDW        5 Hz
SSB        0
LB         0 Hz
GB         0
PC         1.40

F1 - Processing parameters
SI         1024
MC2        0
SF         399.7300320 MHz
WDW        5 Hz
SSB        0
LB         0 Hz
GB         0
    
```

1.12.4 Expansion of COSY



```

Current Data Parameters
NAME      GDMC_0ax
EXNO     22
PROCNO   1


F2 - Acquisition Parameters
Date      20180818
Time     17.18 s
INSTRUM  XD_Avance_1H_400
PROBHD   ZD061H126z-1
PULPROG  zgpg30mfqf
TD        65536
SOLVENT  DMSO
NS        2
DS        8
SWH       4854.369 Hz
FIDRES    4.740298 Hz
AQ        0.2103440 sec
RG        2030
SFO       100.626130 MHz
PC        6.50 usec
T1        2.96.3 s
D0        0.0000300 sec
DELTA     1.98074901 usec
DELTA2    0.0000460 sec
T1R       0.0020000 sec
NO        0.0000600 sec
CDEPR     1
SFO1      399.7325524 MHz
SFO2      1H
P1         12.75 usec
P1_AFT    16.47699928 s
GPRAMP[1] SIN(1.00)
GPRAMP[2] 16.00 %
GPRAMP[3] 0.0000000
GPRAMP[4] 12.00 s
GPRAMP[5] 511.00 %
GPRAMP[6] 40.00 %
E16       1000.00 usec

F1 - Acquisition Parameters
PC        12.8
SFO1      399.73255 MHz
FIDRES    45.848518 Hz
SWH       12.747 ppm
P1         0.0000000


F2 - Processing parameters
SI        1024
SF        399.7320322 MHz
WDW       5 Hz
SSB       0
LB        0 Hz
GB        0
PC        1.40

F1 - Processing parameters
SI        1024
SF        399.7320322 MHz
WDW       5 Hz
SSB       0
LB        0 Hz
GB        0
PC        0
    
```

1.12.5 ^1H - ^{13}C HMBC



1.12.8 ¹⁵P NMR




Current Data Parameters
NAME CDVDC_Law_P
EXPNO 10
PROCNO 1

F2 - Acquisition Parameters
Date 20180730
Time 13.44 h
INSTRUM KU Avance III 400
PROBHD Z1098618_0245 (
PULPROG zg30
TD 65536
SOLVENT CDCl3
NS 32
DS 4
SWH 64102.563 Hz
FIDRES 1.936235 Hz
AQ 0.0111508 sec
RG 2150
DN 7.800 usec
DR 8.85 usec
DE 296.0 K
DL 2.0000000 sec
DDC 1
SFO1 161.905593 MHz
NUC1 31P
P1 7.75 usec
PLWT 36.90499878 W

F2 - Processing parameters
SI 65536
SF 161.8136700 MHz
WDW EM
SSB 0
LB 3.00 Hz
GB 0
RC 1.40

1.13 Compound 13
1.13.1 ¹H NMR




Current Data Parameters
NAME GD4EP_Low
EXPNO 20
PROCNO 1

F2 - Acquisition Parameters
Date_ 20180710
Time 11.24 h
INSTRUM KU_Avance III_400
PROBHD Z108618_C245 (1
PULPROG zg30
TD 65536
SOLVENT CDCl3
NS 16
DS 2
SWH 8223.655 Hz
FIDRES 0.250967 Hz
AQ 3.9845889 sec
RG 22.8
DW 60.800 usec
DE 15.30 usec
TE 296.5 K
D1 1.0000000 sec
CDO -
SFO1 399.7324685 MHz
NUC1 1H
P1 12.75 usec
PL1 16.47639928 W

F2 - Processing parameters
SI 65536
SF 399.7300468 MHz
WDW EM
SSB 0
LB 0.20 Hz
GB 0
PC 1.00

1.13.2 Expansion of aromatic region





```

Current Data Parameters
NAME          9D4BF_Law
EXPNO         20
PROCNO        1

F2 - Acquisition Parameters
Date_         20180710
Time          11.24 h
INSTRUM      KU_Avance III_400
PROBHD       Z109613_0245 (
PULPROG      zg30
TD           65536
SOLVENT      CDCl3
NS           16
DS           2
SWH           8223.885 Hz
FIDRES       0.1250987 Hz
AQ           3.9845889 sec
RG           22.6
DW           80.800 usec
DE           16.30 usec
TE           296.5 K
D1           1.00000000 sec
CDC          -
SFO1         399.7324688 MHz
NUC1          1H
P1           12.75 usec
PLW1         16.47699928 W

F2 - Processing parameters
SI           65536
SF           399.7324688 MHz
WDW          EM
SSB          0
LB           0.120 Hz
GB           0
PC           1.00
    
```

1.13.3 ^1H - ^1H COSY



```

Current Data Parameters
NAME      G4482_1w
EXPNO    12
PROCNO    1



F2 - Acquisition Parameters
Date_    20180826
Time     17.48 h
INSTRUM  XU_Avance_III_400
PROCNO   2108010245 (
PULPROG  zgpg30mfqf
CP       2248
SOLVENT  CDCl3
NS       2
DS       8
SWH      3209.474 Hz
FIDRES   3.212377 Hz
AQ       0.3512399 sec
RG       2030
DW       1.021000 usec
DE       6.50 usec
TE       300.2 K
D0       0.0000300 sec
D1       1.29039696 usec
D12      0.00002400 usec
T1A      0.0020000 sec
RG       0.0032400 sec
CDelay   1
SFO1     399.7319345 MHz
NUC1     1H
PC       12.05 usec
P1A1     18.47699928 w
GPMAX[1] SIN2.000
G221     SIN2.000
GPMAX[2] SIN2.100
G222     SIN2.100
GPMAX[3] SIN2.000
G223     SIN2.000
ELG      1000.00 usec

F1 - Acquisition parameters
PC       12.05
SFO1     399.7316 MHz
FIDRES   31.398026 Hz
SWH      8.229 MHz
P1A1     0

F2 - Processing parameters
SI       1024
SF       399.7330478 MHz
WDW      SINC
SSB      0
LB       0 Hz
GB       0
PC       12.10

F1 - Processing parameters
SI       1024
SF       399.7330478 MHz
WDW      SINC
SSB      0
LB       0 Hz
GB       0
  
```

1.13.4 Expansion of COSY



```

Current Data Parameters
NAME      GD4BF2_Lav
EXPNO    12
PROCNO    1


F2 - Acquisition Parameters
Date_    20180806
Time     17.48 h
INSTRUM  XE_AvanceIII_600
PROBHD   Z00609_U260_1
PULPROG  cosyprgfqf
RG       2568
SOLVENT  CDCl3
NS       2
DS       4
SWH      3289.474 Hz
FIDRES   3.22377 Hz
AQ       0.3112960 sec
RG       2560
SWH      162.500 usec
RG       6.50 usec
RG       873.2 s
DO       0.0000300 sec
D1       1.8803696 sec
D13      0.0000400 sec
T1R      0.0020000 sec
RG       0.0000400 sec
DElay    1
SFO1     399.7318345 MHz
NUC1     1H
P1       12.75 usec
P1_A1    16.47699998 w
GPHASE1  SINE,100
G2P1     16.00 s
CPHASE2  SINE,100
G2P2     12.00 s
GPHASE3  SINE,100
G2P3     16.00 s
RG       1000.00 usec

F1 - Acquisition parameters
RG       128
SFO1     399.7318 MHz
FIDRES   31.38026 Hz
SWH      8.223 ppm
RG       0

F2 - Processing parameters
SI       128
SF       399.7300418 MHz
RG       5 Hz
SSE      0
LB       0 Hz
GB       0
PC       1.40

F1 - Processing parameters
SI       128
SF       399.7300418 MHz
RG       5 Hz
SSE      0
LB       0 Hz
GB       0
    
```

1.13.5 ^1H - ^{13}C HMBC



1.13.6 ^1H - ^1H NOESY



```


Current Data Parameters
NAME      CD4EF_Law
EXPTNO   25
PROCNO    1

F2 - Acquisition Parameters
Date_     20180710
Time      8:07 n
INSTRUM   AVANCE
PROBHD    MIC619_0016
PULPROG   zgpg30
IS        2046
SOLVENT   CDCl3
NS        8
DS        4
SWH       3496.503 Hz
FIDRES    3.414557 Hz
AQ        0.2928640 sec
RG         19
CW        143.000 usec
DE        19.01 usec
TE        296.2 K
DQ        0.00012677 sec
C1        1.5371100 sec
d8        0.30000001 sec
d18       0.00020000 sec
INOC      0.00028600 sec
TD        1
SF01      399.7317661 MHz
NUC1       1
P1        12.75 usec
P2        25.50 usec
PL101     16.47699928 W
GPRAM11   8192.100
CP21      40.00 %
P16       1000.00 usec


F1 - Acquisition parameters
TE        296
SF01      399.7317661 MHz
FIDRES    27.316453 Hz
SR        3.747
EPMODE    States-TPPI

F2 - Processing parameters
SI        1024
SF        399.7300468 MHz
WDW       QSIGN2
SSB       2
IS        0 Hz
GB        0
PC        1.00

F1 - Processing parameters
SI        1024
RG2       States-TPPI
SF        399.7300468 MHz
WDW       QSIGN2
SSB       2
IS        0 Hz
GB        0
    
```



1.13.8 ¹⁵P NMR



```


Current Data Parameters
NAME      CD455_Low_P
EXPNO    10
PROCNO    1

*2 - Acquisition Parameters
Date_     20180730
Time      13.49 h
INSTRUM   KV Avance III 600
PROBHD    Z138618_0245 (
PULPROG   zgpg30
TD         65536
SOLVENT   CDCl3
NS         32
DS         4
SWH        64102.563 Hz
FIDRES     1.3562e-5 Hz
AQ         0.0111808 sec
RG         2050
DW         7.800 usec
DE         8.85 usec
TE         295.2 K
D1         2.0000000 sec
DDG        1
SFO1      161.860793 MHz
NUC1       31P
P1         7.75 usec
PI1        36.90499878 W

*2 - Processing parameters
SI         65536
SF         161.8136700 MHz
WDW        EM
SSB        0
LB         3.00 Hz
GB         0
PC         1.40
    
```

1.14 Compound 14

1.14.1 ¹H NMR



Current Data Parameters
NAME GDAMA_low
EXPNO 10
PROCNO 1

F2 - Acquisition Parameters
Date_ 20160723
Time 10.18 h
INSTRUM KU_Avance_III_400
PROBHD Z106618_0245 ()
PULPROG zg30
TD 65536
SOLVENT DMF0
NS 16
DS 2
SWH 8223.685 Hz
FIDRES 0.250967 Hz
AQ 3.9845889 sec
RG 228
DW 60.800 usec
DE 15.30 usec
TE 298.2 K
D1 1.0000000 sec
DDC 1
SFO1 399.7324895 MHz
NUC1 1H
P1 12.75 usec
PLW1 16.47699828 W

F2 - Processing parameters
SI 65536
SF 399.7300000 MHz
WDW EM
SSB 0
LB 0.20 Hz
GB 0
PC 1.00

1.14.2 Expansion of aromatic region

7.6418
7.6354
7.6302
7.6186
7.6134
7.6067
7.6040
7.5989
7.5872
7.5820
7.5757

7.2730
7.2546
7.2409
7.2361
7.1926
7.1909
7.1891
7.1877
7.1862
7.1798
7.1713
7.1700
7.1684
7.1666
7.1648
7.1632
7.1523
7.1483
7.1473
7.1308


7.0219
7.0156
7.0083
7.0030
6.9987
6.9935
6.9862
6.9798





Current Data Parameters
NAME GDAME_Law
EXPNO 10
PROCNO 1

F2 - Acquisition Parameters
Date_ 20180723
Time 10.18
INSTRUM KJ_Avance_III_400
PROBHD 2100618_0243
PULPROG zg30
TD 65536
SOLVENT DMSO
NS 16
DS 2
SWH 8223.685 Hz
FIDRES 0.250967 Hz
AQ 3.9843889 sec
RG 228
DW 60.800 usec
DE 16.30 usec
IE 296.2 K
D1 1.00000000 sec
ID0 1
SFO1 399.7324685 MHz
NUC1 15
P1 12.75 usec
PLW1 16.47659928 W

F2 - Processing parameters
SI 65536
SF 399.7300000 MHz
WDW EM
SSB 0
LB 0.20 Hz
GB 0
PC 1.00



1.14.3 ^1H - ^1H COSY



```

Current Data Parameters
NAME          GDAMB.Law
EXPNO        12
PROCNO       1



F2 - Acquisition Parameters
Date_         20160723
Time          10.19 h
INSTRUM      XG_Avance_500
PROBHD      zgpg30
PULPROG      zgpg30
AQ           2.048
SOLVENT      DMSO
NS           2
DS           4
SWH          2617.60 Hz
FIDRES      2.356746 Hz
AQ          0.3911680 sec
RG          2000
SQ          181.000 usec
SI          6.00 usec
RG          296.2 K
DO          0.0000300 sec
D1          1.80002400 sec
D13         0.0000400 sec
SFO         0.0020000 sec
RG          0.0000000 sec
CDEPR       1
SFO1        399.730000 MHz
NUC1         13C
PC          12.75 usec
F1F2        16.47699928 w
GPNAM[1]    SINE.100
G2C1        16.00 %
GPNAM[2]    SINE.100
G2C2        18.00 %
GPNAM[3]    SINE.100
G2C3        40.00 %
E1G         1000.00 usec

F1 - Acquisition parameters
SI          128
SFO1        399.730 MHz
FIDRES      40.823141 Hz
SW          8.509 ppm
FREQS1      0

F2 - Processing parameters
SI          1024
SF          399.730000 MHz
WDW         5 Hz
SSB         0
LB          0 Hz
GB          0
PC          1.40

F1 - Processing parameters
SI          1024
SF          399.730000 MHz
WDW         5 Hz
SSB         0
LB          0 Hz
GB          0
    
```

1.14.4 Expansion of COSY



```

Current Data Parameters
NAME      GDAMB Law
EXNO     12
PROCNO    1


F2 - Acquisition Parameters
Date      20180723
Time      10.19 h
INSTRUM   XE_Avance III_400
PROCNO    208619_0240_1
PULPROG   zgpg30
AQ         0.391680 sec
RG         2500
OR         181.0000000
SI         6.00 usec
SF         298.2 K
DO         0.0000300 sec
D1         1.80052495 sec
D12        0.0000400 sec
PR         0.0020000 sec
RG         0.0008200 sec
AQ2        1
SFO1       399.7319863 MHz
NUC1       1H
P1         12.75 usec
PL1        18.47699998 w
GPNAM[1]   SINE,1.00
GPA1       16.00 %
GPNAM[2]   SINE,1.00
GPA2       12.00 %
GPNAM[3]   SINE,1.00
GPA3       40.00 %
E16        1000.00 usec

F1 - Acquisition parameters
SI         128
SF         399.732 MHz
FIDRES     40.823141 Hz
SR         6.149 ppp
RG         2500

F2 - Processing parameters
SI         128
SF         399.7320000 MHz
WDW        S
SSB        0
LB         0 Hz
GB         0
PC         1.40

F1 - Processing parameters
SI         128
SF         399.7320000 MHz
WDW        S
SSB        0
LB         0 Hz
GB         0
PC         1.40
    
```

1.14.5 ^1H - ^{13}C HMBC



```

Current Data Parameters
NAME          GDAMB_low
EXPNO        14
PROCNO       1



F2 - Acquisition Parameters
Date_        20180723
Time         19.33 h
INSTRUM     KU_Avance III_400
PROBHD      Z108618_0245_ [
PULPROG     hmcetgpi3ind
TD           4096
SOLVENT     DMSO
NS           16
DS           16
SWH          2617.801 Hz
FIDRES       1.278293 Hz
AQ           0.7823360 sec
RG           250
RW           191.000 usec
DE           6.50 usec
TE           296.4 K
CNST6       120.0000000
CNST7       165.0000000
CNST13      19.0000000
DD           0.0000300 sec
D1           1.11088002 sec
D6           0.05000000 sec
D16          0.00020000 sec
IND0        0.00002240 sec
TDAY        1
SFO1        399.7319865 MHz
NUC1        1H
P1           12.75 usec
P2           25.50 usec
PLW1        16.47699928 W
SFO2        100.5222241 MHz
NUC2        13C
P3           9.20 usec
P24         2000.00 usec
PLW2        49.50000000 W
SPNAM[?]    Crp60comp_4
SFO3        0 Hz
SPOFFS7     0 Hz
SPW7        6.46140009 W
GPNAM[1]    SINE.100
GP21        80.00 %
GPNAM[3]    SINE.100
GP23        14.00 %
GPNAM[4]    SINE.100
GP24        -8.00 %
GPNAM[5]    SINE.100
GP25        -4.00 %
GPNAM[6]    SINE.100
GP26        -2.00 %
P16         1000.00 usec

F1 - Acquisition parameters
TD          328
SFO1        100.5222 MHz
FIDRES      348.772308 Hz
SW          222.055 ppm
FbMCOE     Echo-Antiecho

F2 - Processing parameters
SI          2048
SF          399.7300000 MHz
WDW         SINE
SSB         2
LB          0 Hz
GB          0
PC          1.40

F1 - Processing parameters
SI          1024
MC2         echo-antiecho
SF          100.5121684 MHz
WDW         SINE
SSB         2
LB          0 Hz
GB          0
    
```

1.14.6 ^1H - ^1H NOESY



```

Current Data Parameters
NAME      CDAMB_low
EXPER    13
PROCNO    1


L2 - Acquisition Parameters
Date      20180723
Time      18.07
INSTRUM   KX Avance 11 400
PROBHD    BBOBBO1H_0275 (
PULPROG   zgpg30
TD        65536
SOLVENT   DMSO
NS        8
DS        4
SWH        2617.901 Hz
FIDRES    2.38846 Hz
AQ         0.3911690 sec
RG         117
LW         191.000 usec
DE         28.01 usec
TE         296.6 K
DQ         0.0017477 sec
C1         1.5395696 sec
C2         0.30000001 sec
C12        0.0022000 sec
INOC       0.00238200 sec
TEAV       -
SFO1       399.7319865 MHz
NUC1       13
P1         12.75 usec
P2         25.30 usec
PL1        16.47699928 W
PPL1        SINE_120
CPD1       40.00 %
P12        1500.00 usec

F1 - Acquisition parameters
TD        65536
SFO1       399.732 MHz
FIDRES    20.451571 Hz
SW        6.379 ppm
EXMODE     States-TPPI

L2 - Processing parameters
SI         1024
SF         399.7300000 MHz
WDW        QSFINE
SSB        2
LB         0 Hz
GB         0
PC         1.00

F1 - Processing parameters
SI         1024
SF         399.7300000 MHz
WDW        QSFINE
SSB        2
LB         0 Hz
GB         0
  
```

1.14.7 ¹³C NMR




```

Current Data Parameters
NAME      CDAME_low
EXPNO     40
PROCNO    1

F2 - Acquisition Parameters
Date_    200803
Time     14.59
INSTRUM  KU Avance III 400
PROBHD   Z1C8618 0245 (
PULPROG  zgpg30
TD        65536
FIDRES   0.733596 Hz
SOLVENT  CDCl3
NS        4091
DS        4
SWH       24038.461 Hz
FIDRES    0.733596 Hz
AQ        1.5631488 sec
RG        2050
DW        20.800 usec
DE        22.74 usec
TE        296.0 K
D1        2.0000000 sec
D11       0.0300000 sec
TD0       1
SFO1      100.5222401 MHz
NUC1       13C
P1         9.20 usec
PLW1      49.5000000 W
SFO2      399.7215889 MHz
NUC2       1H
CPDPRG2   wa lz16
PCPD2     30.00 usec
PLW2      16.4769928 W
PLW12     0.35068501 W
PLW13     0.25785501 W

F2 - Processing parameters
SI         65536
SF         100.5121884 MHz
WDW        EM
SSB        0
LB         1.00 Hz
GB         0
PC         1.40
    
```


1.14.8 ¹⁵P NMR



```


Current Data Parameters
NAME      CDAMB_Law_P
EXPNO    10
PROCNO    1

*2 - Acquisition Parameters
Date_     20180730
Time      18:15 h
INSTRUM   KU Avance III 400
PROBHD    Z108618_C245 (
PULPROG   zgpg30
TD         65536
SOLVENT   CDCl3
NS         32
DS         4
SWH        64102.563 Kz
FIDRES     1.906225 Hz
AQ         0.5111608 sec
RG         2050
RW         7.890 usec
DR         8.85 usec
TE         297.3 K
CL         2.0000000 sec
CL1        0.03000000 sec
TD0         1
ST01       161.8000793 MHz
NUC1        31P
P1          7.75 usec
PLW1        36.90499878 W
PLW2        399.7315989 MFz
NUC2         1H
CDEPRG 2   waltz16
PCPD2       90.00 usec
PLW2        16.47699928 W
PLW12       0.33068001 W
PLW13       0.26785001 W


*2 - Processing parameters
S        65536
SF        161.8136700 MHz
WDW        EM
SSB        0
LB         3.00 Hz
GB         0
CB         0
PC         1.40
    
```

1.15 Compound 15

1.15.1 ¹H NMR



1.15.2 Expansion of aromatic region



BRUKER TopSpin TopSpin 3.5 pl 7



K1455838
 October 19, 2016 6:32:48 PM BST
 PPREM2005024704
 GDHBT 10 1
 C:\Users\K1455838\MyNMR\data\k1455838_on_AV400nmr

Current Data Parameters
 NAME GDMCH1
 EXFNO 10
 PROCNO 1

F2 - Acquisition Parameters
 Date 20160509
 Time 16.43 h
 INSTRUM XC_Avance_III_400
 PROBHD BBO6418_0245 1
 PULPROG zgpg
 TD 65536
 SOLVENT DMF0
 NS 16
 DS 2
 SWH 8223.685 Hz
 FIDRES 0.250967 Hz
 AQ 3.9645889 sec
 RG 228
 DW 60.300 usec
 DE 14.30 usec
 TP 297.2 %
 EI 1.00000000 sec
 TEI 1
 STOT 399.7324635 MHz
 NUC1 1H
 EI 12.75 usec
 PL1 16.41699928 Hz

F2 Processing parameters
 SI 65536
 SF 399.7300000 MHz
 WDW EM
 SSB 0
 LB 0.20 Hz
 GB 0
 PC 1.00

1.15.3 ^1H - ^1H COSY



Current Data Parameters
 NAME GDF0BT
 EXPCO 12
 EROCK 1

F2 - Acquisition Parameters
 Date 20180509
 Time 16:39 h
 INSTRUM XL Avance III 400
 PROBHD ZL066H1260 1
 PULPROG odaymrfqf
 CD 2248
 SOLVENT DMSO
 DS 2
 DS a
 BPH 3597.122 Hz
 FIDRES 3.512815 Hz
 AQ 0.2846723 sec
 EC 2248
 DK 139.500 usec
 DT 6.50 usec
 TE 297.2 K
 D0 0.0000300 sec
 D1 1.90702195 sec
 D13 0.0000400 sec
 F18 0.0002000 sec
 H0 0.0007500 sec
 CDEPR 1
 SFO1 399.7317977 MHz
 XN1 1H
 F1 12.75 usec
 F1A1 18.67699928 a
 GPHAS[1] SINE100
 GP21 16.00 %
 GPHAS[2] SINE100
 GP31 16.00 %
 GPHAS[3] SINE100
 GP41 40.00 %
 E16 1000.00 usec

F1 - Acquisition Parameters
 CD 128
 SFO1 399.7318 MHz
 FIDRES 58.208336 Hz
 DS 0.999 ppm
 EPROCK QF


F2 - Processing parameters
 SC 128
 BP 399.7300000 MHz
 MDW 5 Hz
 SSB 0
 LB 0 Hz
 GB 0
 PC 1.40

F1 - Processing parameters
 SC 128
 MC2 25
 BP 399.7300000 MHz
 MDW 5 Hz
 SSB 0
 LB 0 Hz
 GB 0
 CD 0

1.15.4 ^1H - ^{13}C HMBC

 K1456638
 October 19, 2018 6:33:49 PM BST
 PPREM2005024704
 GDHOB1 14 1
 C:/Users/K1456638/MyNMRs/data/K1456638_on_AV400/nmr

 TopSpin TopSpin 3.5 pl 7



```

Current Data Parameters
NAME      GDHOB1
EXPNO    14
PROCNO   1



F2 - Acquisition Parameters
Date_    20180509
Time     17:47 h
INSTRUM  KU_Avance_III_400
PROBHD   Z108618_0245 (
PULPROG  hmbcetcp1ind
TD        4096
SOLVENT  DMG0
NS        16
DS        16
SWH       3597.122 Hz
FIDRES    1.756407 Hz
AQ        0.5693440 sec
RG        2050
DW        139.000 usec
DE        6.50 usec
TE        297.1 K
CNST6    120.0000000
CNST7    165.0000000
CNST13   10.0000000
DO        0.00000300 sec
D1        1.32387197 sec
D6        0.05000000 sec
D16       0.00020000 sec
INO       0.00002240 sec
TD0AV    1
SFO1     399.7317973 MHz
NUC1      1H
P1        12.75 usec
P2        25.50 usec
PLW1     16.47699928 W
SFO2     100.6222241 MHz
NUC2      13C
P3        9.20 usec
P24      2000.00 usec
PLW2     49.50000000 W
SFO3(7)  Ccp60comp.4
SFOCAL7  0.500
SPOFFS7  0 Hz
SFW      6.40140009 W
GPNAM[1] SINE.100
GP21     80.00 %
GPNAM[3] SINE.100
GP23     14.00 %
GPNAM[4] SINE.100
GP24     -8.00 %
GPNAM[5] SINE.100
GP25     -4.00 %
GPNAM[6] SINE.100
GP26     -2.00 %
P16      1000.00 usec

F1 - Acquisition parameters
TD        228
SFO1     100.6222 MHz
FIDRES    348.772308 Hz
SW        222.055 ppm
FHM0MODE  Echo-Antiecho

F2 - Processing parameters
SI        2048
SF        399.7300000 MHz
WDW       SINE
SSB       2
LB        0 Hz
GB        0
PC        1.40

F1 - Processing parameters
SI        1024
WC2      echo-antiecho
SF        100.5121884 MHz
WDW       SINE
SSB       2
LB        0 Hz
GB        0
    
```

1.15.5 ^1H - ^1H NOESY



Current Data Parameters
 NAME CDH051
 EXPNO 16
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20180509
 Time 18:04 h
 INSTRUM BRUKER AVANCE III 400
 PROCNO 2128618_0275 ()
 F1F2PRG2 noesypp2
 ID 2048
 SOLVENT DMS
 NS 8
 DS 4
 SWH 3597.122 Hz
 FIDRES 3.317815 Hz
 AQ 0.2846720 sec
 RG 1
 CW 139.000 usec
 DE 18.26 usec
 TP 299.1 K
 D0 0.00012277 sec
 D1 1.9660284 sec
 J0 0.0000000 sec
 J15 0.0022000 sec
 ITC 0.0027600 sec
 IPRG 1
 SFO1 399.7317978 MHz
 NUC1 1H
 P1 12.75 usec
 P2 28.50 usec
 FWH 16.47699978 W
 GPM111 81Hz-100
 CPD1 40.00 %
 F16 1000.00 usec

F1 - Acquisition parameters
 TP 296
 SFO1 399.7318 MHz
 FIDRES 29.102518 Hz
 NS 8.999 ppr
 FMODE States-TPPI


F2 - Processing parameters
 SI 1024
 SF 399.7300000 MHz
 WDM QBHz
 SSB 2
 LB 0 Hz
 GB 0
 PC 1.00

F1 - Processing parameters
 SI 1024
 SF 399.7300000 MHz
 WDM QBHz
 SSB 2
 LB 0 Hz
 GB 0

2. GCMS


2.1 Compound 1

File :E:\DATA\GD-2.D
Operator :
Acquired : 20 Feb 2018 23:10 using AcqMethod HIGHTEMPAUTO.M
Instrument : GC MS 1
Sample Name:
Misc Info :
Vial Number: 38




2.2 Compound 2

File :E:\DATA\GD-1.D
Operator :
Acquired : 20 Feb 2018 22:45 using AcqMethod HIGHTEMPAUTO.M
Instrument : GC MS 1
Sample Name :
Misc Info :
Vial Number: 37




2.3 Compound 3

File :E:\DATA\GD-3.D
Operator :
Acquired : 20 Feb 2018 23:36 using AcqMethod HIGHTEMPAUTO.M
Instrument : GC MS 1
Sample Name :
Misc Info :
Vial Number: 39





2.4 Compound 4

File :E:\DATA\GDVAC2.D
Operator :
Acquired : 19 Oct 2018 9:57 using AcqMethod HIGHTEMPAUTO.M
Instrument : GC MS 1
Sample Name :
Misc Info :
Vial Number: 80




2.5 Compound 5

File :E:\DATA\GD-4.D
Operator :
Acquired : 10 Jul 2018 11:26 using AcqMethod HIGHTEMPAUTO.M
Instrument : GC MS 1
Sample Name :
Misc Info :
Vial Number: 46




2.6 Compound 7

File :E:\DATA\GD-7.D
Operator :
Acquired : 10 Jul 2018 12:39 using AcqMethod HIGHTEMPAUTO.M
Instrument : GC MS 1
Sample Name :
Misc Info :
Vial Number: 49




2.7 Compound 8

File :E:\DATA\GD-6.D
Operator :
Acquired : 10 Jul 2018 12:14 using AcqMethod HIGHTEMPAUTO.M
Instrument : GC MS 1
Sample Name :
Misc Info :
Vial Number: 48





2.8 Compound 9

File :E:\DATA\GD-5.D
Operator :
Acquired : 10 Jul 2018 11:50 using AcqMethod HIGHTEMPAUTO.M
Instrument : GC MS 1
Sample Name :
Misc Info :
Vial Number: 47





2.9 Compound 10

File :E:\DATA\GDMC2.D
Operator :
Acquired : 27 Jul 2018 14:06 using AcqMethod HIGHTEMPAUTO.M
Instrument : GC MS 1
Sample Name :
Misc Info :
Vial Number: 82





2.10 Compound 11

File : E:\DATA\GD4CF_LAW.D
Operator :
Acquired : 27 Jul 2018 13:42 using AcqMethod HIGHTEMPAUTO.M
Instrument : GC MS 1
Sample Name :
Misc Info :
Vial Number: 81





2.11 Compound 12

File :E:\DATA\GD-8.D
Operator :
Acquired : 10 Jul 2018 13:04 using AcqMethod HIGHTEMPAUTO.M
Instrument : GC MS 1
Sample Name :
Misc Info :
Vial Number: 50





2.12 Compound 13

File :E:\DATA\GD4BF_LAW.D
Operator :
Acquired : 27 Jul 2018 14:31 using AcqMethod HIGHTEMPAUTO.M
Instrument : GC MS 1
Sample Name :
Misc Info :
Vial Number: 83




2.13 Compound 14

File :E:\DATA\GDAMB_LAW.D
Operator :
Acquired : 27 Jul 2018 15:22 using AcqMethod HIGHTEMPAUTO.M
Instrument : GC MS 1
Sample Name :
Misc Info :
Vial Number: 85




3. IR Data


3.1 Compound 1



3.2 Compound 2




3.3 Compound 3



3.4 Compound 4




3.5 Compound 5




3.6 Compound 7



3.7 Compound 8



3.8 Compound 9



3.9 Compound 10

